2023 Annual General Shareholders’ Meeting

Meeting Handbook

Wednesday, 9:30am, June 28, 2023

CHANG YUNG-FA FOUNDATION International Convention Center, 10F, No.11,
Zhongshan S. Rd., Taipei City 10048, Taiwan (R.O.C.)

DISCLAIMER:
THIS ENGLISH HANDBOOK FOR 2023 ANNUAL GENERAL SHAREHOLDERS’ MEETING IS TRANSLATED FROM THE CHINESE VERSION EXCEPT APPENDICE 2. IT IS INTENDED FOR REFERENCE ONLY. THE COMPANY HEREBY DISCLAIMS ANY AND ALL LIABILITIES FOR THE TRANSLATION. THE CHINESE MEETING HANDBOOK, EXCEPT MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY, SHALL GOVERN ANY AND ALL MATTERS RELATED TO THE INTERPRETATION OF THE SUBJECT MATTER STATED HEREIN.
TABLE OF CONTENTS

I. Meeting Procedures.................................................................................................................. 1

II. Meeting Agenda ...................................................................................................................... 3
   1. Report Matters ......................................................................................................................... 5
   2. Acknowledgement Matters ....................................................................................................... 6
   3. Proposals and Discussions ....................................................................................................... 9
   4. Extemporary Motion ............................................................................................................... 10
   5. Meeting Adjourned ............................................................................................................... 10

III. Attachments ........................................................................................................................... 11
   1. 2022 Business Report ............................................................................................................ 12
   2. 2022 Audit Committee’s Review Report ............................................................................... 15
   3. 2022 Execution Status Report on Sound Business Plan ...................................................... 16
   4. Comparison Table of the Rules of Procedure for Board of Directors Meeting of the Company ................................................................. 19
   6. 2021 Fundraising Plan Changes and Adjustments ............................................................... 34
   7. Comparison Table of the amended articles of Association of the Company ...................... 51
   8. Proposal to Release the Prohibition on Non-Competition of Board Directors .................... 59
   9. Comparison Table of the Rules of Procedure for Shareholders’ Meeting of the Company ... 61

IV. Appendices ............................................................................................................................. 64
   1. Rules of Procedure for Board of Director Meetings of the Company (Before Amendment) .... 65
   2. Memorandum and Articles of Association of the Company (Before Amendment) .............. 74
   3. Rules of Procedures for Shareholders’ Meeting (Before Amendment) .................................. 115
   4. Shareholdings of All Directors. ............................................................................................. 132
I. Meeting Procedures
Tanvex BioPharma, Inc.
(The “Company”)

Procedures of 2023 Annual General Shareholders’ Meeting

1. Call the Meeting to Order
2. Chairman’s Address
3. Report Matters
4. Acknowledgment Matters
5. Proposals and Discussion
6. Extemporaneous Motion
7. Meeting Adjourned
II. Meeting Agenda
Tanvex BioPharma, Inc.
Meeting Agenda of 2023 Annual General Shareholders’ Meeting

Meeting Type: Physical shareholders meeting
Time: Wednesday, 9:30 am, June 28, 2023, Taipei Local Time
Venue: CHANG YUNG-FA FOUNDATION International Convention Center, 10F, No.11, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 10048, Taiwan (R.O.C.)
Present: All shareholders or their proxy holders
Chairman: Mr. Yun Yen

1. Chairman’s Address

2. Report Matters
   (3) Report on the Communication between the Audit Committee and the Internal Auditor.

3. Acknowledgment Matters
   (2) To accept proposal of 2022 loss make-up.
   (3) Amendment to Fundraising Plan for 2021.

4. Proposals and Discussion
   (1) To amend the Company’s Memorandum and Articles of Association.
   (2) Proposal for release the prohibition on Directors from participation in competitive business.
   (3) To amend the Rules of Procedure for Shareholders’ Meeting of the Company.

5. Extemorary Motion

6. Meeting Adjourned
1. Report Matters

Item 1: The 2022 Business Report.

Explanation: The Audit Committee’s review report is attached as Attachment 2. Please refer to page 15.

Item 3: Report on the Communication between the Audit Committee and the Internal Auditor.
Explanation: The communications between the Company’s Audit Committee and the internal audit. Please refer to page 31 of the 2022 annual report of the Company.


Item 5: The Amendment of the Rules of Procedure for Board of Directors Meeting.
Explanation: In accordance with the Letter number 1110383263 issued by the Financial Supervisory Commission, regarding amendments to the “Regulations Governing Procedure for Board of Directors Meetings of Public Companies”, the Company hereby proposes to amend the Rules of Procedure for Board Meeting of the Company. For the comparison table of Rules of Procedure for Board of Directors Meeting is attached as Attachment 4. Please refer to page 19.

Explanation:
1. The Company’s 2022 Business Report and Consolidated Financial Report have been approved by the Board of Directors and reviewed by the Audit Committee of the Company. The 2022 Consolidated Financial Report, including Balance Sheet, Income Statements, Statement of Changes in Equity and Statement of Cash Flows were audited by Ms. Shu-Fen Yu and Hua-Ling Liang of PricewaterhouseCoopers Taiwan who issued the unqualified opinion of the auditor’s report.


3. It is proposed to approve the proposal.

Resolution:

Item 2: Proposal to accept the loss make-up of 2022. [Proposed by the Board of Directors]

Explanation:
1. After auditing by the CPA, in Year 2022 the Company’s net loss after tax is NT$1,641,130,425. After adding accumulated deficit of NT$11,327,436,762 at the beginning of 2022, the aggregated accumulated deficit is NT$12,968,567,187.

2. The annual loss make-up for 2022 is as follows:

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Losses to be covered in the beginning of the year</td>
<td>(11,327,436,762)</td>
</tr>
<tr>
<td>Plus: 2022 Net loss after tax</td>
<td>(1,641,130,425)</td>
</tr>
<tr>
<td><strong>Losses to be covered at the end of the year</strong></td>
<td><strong>(12,968,567,187)</strong></td>
</tr>
</tbody>
</table>

3. As the Company does not have earnings available for distribution in Year 2022, the Company will not distribute any dividends to shareholders.
4. It is proposed to approve the proposal.

Resolution:

Item 3: Amendment to Fundraising Plan for 2021.[Proposed by the Board of Directors]

Explanation:

1. Due to the unsatisfactory progress and results of the drug certification review for the main product lines TX01 and TX05, and the impact of the COVID-19 pandemic, the progress of the original drug development plans was postponed. As a result, no major products are currently available on the market for sale to stabilize working capital. After careful consideration, as we have limited funds and difficult financing, we need to continue to promote drug development projects and support the management and marketing expenses required to maintain the Company’s operations. In order to make good use of the funds, On August 26, 2022, the Board of Directors approved the first adjustment of the fund-raising plan in 2021. The original plan of “replacing R&D equipment” was temporarily suspended, and at the same time, the funds and use of funds required for each drug project were re-adjusted according to the R&D schedule progress. However, the BLA review result of the TX01 development plan in the first quarter of 2023 was not as expected and the Company’s own funds are not sufficient to respond to changes in the R&D progress and operational needs. Therefore, the Company intends to change the details of the use of “working capital” in accordance with the FDA audit schedule, actual operation and progress of each drug development. Accordingly, the Company intends to make changes to the plan due to changes in the objective environment as shown in the table below. For the adjustment, please refer to Attachment 6 on page 34 of this handbook.
<table>
<thead>
<tr>
<th>Item</th>
<th>Original plan amount (A)</th>
<th>August 26, 2022 Adjustment Plan (B)</th>
<th>Plan after change (C)</th>
<th>Cumulative changes (D) = (C) - (A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX01</td>
<td>170,433</td>
<td>170,433</td>
<td>338,317</td>
<td>167,884</td>
</tr>
<tr>
<td>TX05</td>
<td>306,718</td>
<td>504,228</td>
<td>589,098</td>
<td>282,380</td>
</tr>
<tr>
<td>TX04</td>
<td>828,680</td>
<td>602,890</td>
<td>245,335</td>
<td>(583,345)</td>
</tr>
<tr>
<td>TX16</td>
<td>2,910</td>
<td>2,910</td>
<td>3,001</td>
<td>91</td>
</tr>
<tr>
<td>TX52</td>
<td>89,757</td>
<td>80,740</td>
<td>13</td>
<td>(89,744)</td>
</tr>
<tr>
<td>Other R&amp;D projects</td>
<td>100,575</td>
<td>100,575</td>
<td>139,274</td>
<td>38,699</td>
</tr>
<tr>
<td>Administrative and selling expenses</td>
<td>96,927</td>
<td>218,224</td>
<td>364,962</td>
<td>268,035</td>
</tr>
<tr>
<td><strong>Total working capital</strong></td>
<td><strong>1,596,000</strong></td>
<td><strong>1,680,000</strong></td>
<td><strong>1,680,000</strong></td>
<td><strong>84,000</strong></td>
</tr>
<tr>
<td>Replacement of R&amp;D equipment</td>
<td>84,000</td>
<td>0</td>
<td>0</td>
<td>(84,000)</td>
</tr>
<tr>
<td><strong>Total planned fundraising in 2021</strong></td>
<td><strong>1,680,000</strong></td>
<td><strong>1,680,000</strong></td>
<td><strong>1,680,000</strong></td>
<td><strong>0</strong></td>
</tr>
</tbody>
</table>

2. This proposal was approved by the Board of Directors on May 12, 2023, and was submitted to the shareholders’ meeting for ratification after approval according to Article 10 of the “Regulations Governing the Offering and Issuance of Securities by Foreign Issuers”.

3. It is proposed to approve the proposal.

**Resolution:**
3. Proposals and Discussions

Item 1: Proposal to Amendment to Company’s Memorandum and Articles of Association. [Proposed by the Board of Directors]

Explanation:

1. Referencing to the amendments to the Checklist for Protection of Shareholders' Rights and Interests in the Country where the Foreign Issuer is Registered announced by the Ruling No. 1111704301 by the Taiwan Stock Exchange Corporation dated January 9, 2023, it is proposed to amend part of the Company’s Memorandum and Articles of Association. For the comparison table of the Company’s Memorandum and Articles of Association is attached as Attachment 7. Please refer to page 51.

2. The English version of the Memorandum and Articles of Association of the Company shall govern if there is any discrepancy between the Chinese and English versions.

3. The proposal shall be approved by way of special resolution.

4. It is proposed to approve the proposal.

Resolution:

Item 2: Proposal for Release the prohibition on Directors from participation in competitive business. [Proposed by the Board of Directors]

Explanation:

1. Referencing to the provisions of Article 209 of the Company Act of R.O.C, a Director who does anything for himself or on behalf of another person that is within the scope of the company's business, shall explain to the meeting of shareholders the essential contents of such an act and secure its approval.

2. A Director of the Company is under the situation of doing things for himself or on behalf of another person that is within the same of similar business scope the Company, if there is no damage to the Company's interests, it is proposed to release such director from the prohibition of non-competition according to Sections 32 and 97B of the Memorandum and Articles of Association.

3. For details of the proposal to release the non-competition prohibition, are attached as Attachment 8. Please refer to page 59.
4. It is proposed to approve the proposal.

Resolution:

Item 3: Proposal to Amend the Rules of Procedure for Shareholders' Meeting of the Company.

[Proposed by the Board of Directors]

Explanation:
1. Pursuant to the amendment of the Regulations Governing Procedure for Rules of Procedure for Shareholders' Meeting issued in Ruling No. 1120004167 by the Taiwan Stock Exchange Corporation, the Company hereby proposes to amend the Rules of Procedure for Shareholders' Meeting. For the comparison table of the Rules of Procedure for Shareholders' Meeting is attached as Attachment 9. Please refer to page 61.

2. It is proposed to approve the proposal.

Resolution:

4. Extemporary Motion

5. Meeting Adjourned
III. Attachments
2022 Business Report

Expensive biopharmaceuticals have caused financial stress in global medicine; for example, although the USA is the largest single market of biopharmaceuticals worldwide, it is also the country with highest medical expenditure. Therefore, providing effective and affordable biosimilars with excellent quality has become one of the best solutions for reducing medical expenditure in various countries. In view of this, the USA government passed the BPCIA (Biologics Price Competition and Innovation Act) in 2010 to establish clear and simplified path of regulations and market entry for biosimilars. Pursuant to FDA approval of the first biosimilar (Zarxio® from Sandoz) in 2015, the FDA has approved 40 biosimilars up till 2022, and among them, 25 biosimilars have been marketed in USA. Although the speed of FDA approval slowed down significantly over the peak duration of global COVID-19 pandemic, rebound of approval number appeared in 2022, where licenses of 7 new biosimilars in total were granted. All these 7 biosimilars had been approved previously, and there was no any other biosimilars as products of new reference. A total of 4 new biosimilar drugs will be launched in 2022, including 2 Lucentis® (ranibizumab) biosimilar drugs. It could be observed that the potential of developing USA biosimilars continued to increase. Due to the continuing of Covid-19 pandemic in 2022, the macro economy was impacted in general; yet Tanvex BioPharma, Inc. (hereinafter referred to as “Tanvex” or the Company) continued to promote products in efficient manner still, where our TX01 acquired the Canadian license in July 2022 successfully.

Tanvex is a biosimilar developer focusing on the USA market. Through utilization of its development, production, commercialization, and mass production technology for to vertical integration with the industry chain, the Company is able to control cost, maintain flexible operation strategies and ensure product competitiveness for successful entry into the USA market.

Status of business results, financial performance and budget execution in 2022:

I. Outcome of 2022 business plan implementation:
The main product developed by the Company is still at R&D stage and has yet to contribute revenue; however, we have started to undertake CDMO projects from AP Biosciences Inc. since 2022 for generating relevant revenue. Our revenue in 2022 was NT$ 22,404 thousand, which increased by approximately 314% comparing to 2021. The net loss for 2022 was NT$1,641,130 thousand, which slightly increased by approximately 6% comparing to 2021. The 2022 Business status report for the Company is as follows:

<table>
<thead>
<tr>
<th>Item</th>
<th>2022</th>
<th>2021</th>
<th>Difference</th>
<th>Variance percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating revenue</td>
<td>22,404</td>
<td>5,406</td>
<td>16,998</td>
<td>314%</td>
</tr>
<tr>
<td>Operating costs</td>
<td>(41,752)</td>
<td>(1,856)</td>
<td>(39,896)</td>
<td>2150%</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(1,586,169)</td>
<td>(1,602,734)</td>
<td>16,565</td>
<td>-1%</td>
</tr>
<tr>
<td>Non-operating income and expenses</td>
<td>(35,590)</td>
<td>55,995</td>
<td>(91,585)</td>
<td>-164%</td>
</tr>
</tbody>
</table>
The revenue in 2022 mainly came from the Company undertaking CDMO project under AP Biosciences, which was used in developing and producing the latest clinical candidates from development platform of bispecific antibody. Moreover, to cooperate with the progress of product development, the Company continued to invest in R&D activities and commercialization in 2022. This resulted the net loss after tax in 2022 at NT$1,641,130 thousand, which was a slight increase of NT$97,919 thousand comparing to 2021. The R&D expenditures in 2022 were mainly used for relevant items such as the CRL supplementary correction prepared for TX01, inspection preparation for BLA review, and CRL-related supplementary correction data as reply to the FDA for TX05.

II. Budget execution:
The actual net loss after tax in 2022 for the Company was NT$1,641,130 thousand, which was equivalent to the 2022 budget. The current operating expenses were mainly invested in R&D, which amounted to about NT$1,351,425 thousand, accounting for about 85% of the operating expenses.

III. Research and development status:
Tanvex upholds its commitment to shareholders and employees, where the Company actively promotes progress in various product, constructs the foundation for product commercialization and deploys the sales channels. The progress of implementing each plan and operation is described as follows:

- **Product TX01 (Original medicine: Neupogen®)**
  - In August 2022, the supplementary documents for license assessment were submitted to the FDA.
  - The sales and marketing teams are ready to launch the TX01 product.
  - In July 2022, the drug establishment license was approved by Health Canada.

- **Product: TX05 (Brand drug: Herceptin®)**
  - In July 2022, the complete response from the FDA was received, indicating that the current license assessment was completed. The Company intends to communicate with the FDA in US, where the supplementary information is expected to be provided to the FDA in US for completing the subsequent BLA review.
  - Preparation for passing the preliminary assessment of licensing.

- **Product: TX04 (Brand drug: Neulasta®)**
  - The Company is planning to scale up the production process and prepare for the Phase III pivotal trial. Currently, the stability test is being conducted simultaneously.

- **Product TX16 (Original medicine: Avastin®)**
  - The Phase I clinical trial on human subject has been completed. At present, the design for Phase III clinical trial and patent-related procedures are under planning continuously.

- **Product: TX52 (Brand drug: Perjeta®)**
The pre-clinical and manufacturing process are still under development currently.

- **Product: TX54 (Brand drug: Keytruda®)**
  - Cell Line Development Department.

- **CDMO business service**
  - Entrusted by OBI Pharma in Taiwan for composite development, manufacturing and production of cell lines in small batches.
  - Entrusted by AP Biosciences to develop and produce the latest bispecific antibody development platform’s clinical candidate drug.

The development progress for various major products in 2022 is shown as per figure below:

<table>
<thead>
<tr>
<th>Pipeline Product</th>
<th>Molecule</th>
<th>Innovator Product</th>
<th>Pre-clin</th>
<th>Phase I</th>
<th>Phase III</th>
<th>Submission</th>
<th>Approval</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX-01</td>
<td>filgrastim</td>
<td>Neupogen® (Amgen)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BLA resubmission in Q3. FDA site inspection in Q1 2023.</td>
</tr>
<tr>
<td>TX-05</td>
<td>trastuzumab</td>
<td>Herceptin® (Genentech)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CRL received in Q3 2022. Plan for BLA resubmission late 2023.</td>
</tr>
<tr>
<td>TX-04</td>
<td>pegfilgrastim</td>
<td>Neulasta® (Amgen)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-clinical activities; pivotal trial preparation.</td>
</tr>
<tr>
<td>TX-16</td>
<td>bevacizumab</td>
<td>Avastin® (Genentech)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>on hold (delaying initiation of Phase III due to clinical cost).</td>
</tr>
<tr>
<td>TX-52</td>
<td>pertuzumab</td>
<td>Perjeta® (Genentech)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>on hold</td>
</tr>
<tr>
<td>TX-54</td>
<td>pembrolizumab</td>
<td>Keytruda® (Merck)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cell line development in 2022</td>
</tr>
<tr>
<td>CDMO AP-2206</td>
<td>bispecific antibody</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CDMO activity; cell line development in 2022</td>
</tr>
</tbody>
</table>

**Management policy and future prospects for 2023**

Tanvex will continue to strive from R&D towards development in commercialization. The Company's product TX01 (Brand drug: Neupogen®) (Figrastim) has acquired the Canadian license in 2022, and expected to be distributed in the Canadian market by 2023. TX01 is also expected to be licensed by the FDA by 2023 for sales in the US market. In addition, the Company will also continue the R&D for other biosimilar products already planned, and continue to develop towards CDMO refinement.

Chairman：Yun Yen  CEO：Yun Yen  Accounting Officer：Peter Lin
Audit Committee's Audit Report

March 3, 2023

The Company BoD produced the consolidated financial statement, business report and proposal for writing off loss for 2022. Among them, the consolidated financial statements was audited and certified by PwC Taiwan, where the audit report with no reserved comments was issued. The Audit Committee has agreed with the audition comments from above-mentioned CPA firm. The business report and loss off-setting proposal have been review and passed, where the report has been produced as per requirements under Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, please examine accordingly.

To

Shareholders’ Meeting of Tanvex BioPharma Inc.

Tanvex BioPharma Inc

Audit Committee

Convener: Jin-Pau Tsai
Tanvex BioPharma Inc
Report on 2022 Sound Business Plan and Implementation Status

I. Company Profile
Tanvex BioPharma, Inc. was founded on May 8, 2013. It has two wholly-owned subsidiaries, Tanvex BioPharma USA, Inc. (“Tanvex BioPharma USA, Inc.”), located in San Diego, California, USA. Tanvex USA”) and Tanvex BioPharma, Inc. (“Taiwan Tanvex”) of Xizhi District, New Taipei City, Taiwan (collectively, the above companies are referred to as the “Company”). Tanvex USA is mainly responsible for the process development, production and manufacturing of biopharmaceuticals; while Taiwan Tanvex is mainly responsible for the development of front-end cell lines for biological drugs and initial bioprocess research and development. The Company has another office in Taipei to facilitate overall management of related affairs.

II. Current status of the main products developed:
The Company is currently committed to the development, production and sale of biosimilar products. By 2022, the main products developed and their progress are as follows:

- Self-developed products

<table>
<thead>
<tr>
<th>Main products (Brand patented drug)</th>
<th>Product indication</th>
<th>Development progress</th>
</tr>
</thead>
</table>
| TX01 (Neupogen)                     | Cancer Chemotherapy-Induced Neutropenia | USA
  - In August 2022, the supplementary documents for license assessment were submitted to the FDA.  
  - Canada  
  The Canadian licence and relevant sales permit have been acquired; at present, the preparation for market distribution is under progress. |
| TX05 (Herceptin)                    | Breast cancer      | USA
  - In February 2021, the pivotal trial on human was completed and the major test results indicated that the primary efficacy endpoint was achieved.  
  - In July 2022, the complete response from the FDA was received, indicating that the current license assessment was completed. The Company intends to communicate with the FDA in US, where the supplementary information is expected to be provided to the |
<table>
<thead>
<tr>
<th>Main products (Brand patented drug)</th>
<th>Product indication</th>
<th>Development progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX04 (Neulasta)</td>
<td>Cancer Chemotherapy-Induced Neutropenia (long-acting drug)</td>
<td>• In March 2021, the pivotal trial program was communicated with FDA, where the implementation of scale-up procedure and preparation for pivotal trial were planned continuously. At present, the stability test has commenced simultaneously.</td>
</tr>
<tr>
<td>TX16 (Avastin)</td>
<td>Colorectal cancer and lung cancer</td>
<td>• The Phase I clinical trial on human subject has been completed. At present, the design for Phase III clinical trial and patent-related procedures are under planning continuously.</td>
</tr>
<tr>
<td>TX52 (Perjeta)</td>
<td>Breast cancer</td>
<td>• The pre-clinical and manufacturing process are still under development currently.</td>
</tr>
</tbody>
</table>

- **CDMO business service**
  
  Undertake research and development projects for customers to produce new cell lines for producing new antibodies. Currently, the Company is expanding its existing production capacity, and is actively seeking contracted research and production business at home and abroad, and is committed to becoming a cooperative partner of customers.

III. Main business activities in 2022:

For matters related to the implementation of the Company's business plan in 2022, please refer to the business report in the Company's Meeting Handbook.

IV. 2022 financial overview:

The Company's products are still in the research and development stage. In order to keep up with the progress of product development and continue to invest in R&D activities and resources, as audited by CPAs, the net loss after tax in 2022 was NT$1,641,130 thousand, which was a slight increase of NT$97,919 thousand compared to 2021. Among them, the R&D expenses in 2022 were NT$1,351,425 thousand. R&D expenses were flat mainly due to the clinical trials of each product had come to an end and the peak expense period had passed, resulting in a decrease in the R&D expenses in 2022.

IV. Sound business plan implementation report:

According to the letter No. 1110004801 of the Securities Investors and Futures Traders Protection Center dated November 11, 2022 and the Jin-Guan-Zheng-Fa-Zi No. 1110368084 letter dated February 10, 2023, the implementation of the sound business plan will be reported quarterly to the board of directors for control and report to the shareholders meeting.
The financial information and sound business plan declaration information in 2022 are listed as follows.

<table>
<thead>
<tr>
<th>Item/ year</th>
<th>2022</th>
<th>Difference</th>
<th>Difference %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sound business plan declaration</td>
<td>Consolidated FS</td>
<td></td>
</tr>
<tr>
<td>Operating revenue</td>
<td>42,768</td>
<td>22,404</td>
<td>(20,364)</td>
</tr>
<tr>
<td>Operating cost</td>
<td>25,367</td>
<td>41,752</td>
<td>16,385</td>
</tr>
<tr>
<td>Operating profit(loss)</td>
<td>17,401</td>
<td>(19,348)</td>
<td>(36,749)</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>1,638,121</td>
<td>1,586,169</td>
<td>(51,952)</td>
</tr>
<tr>
<td>Operating loss</td>
<td>(1,620,720)</td>
<td>(1,605,517)</td>
<td>15,203</td>
</tr>
<tr>
<td>Non-operating income and (expenses)</td>
<td>(34,225)</td>
<td>(35,590)</td>
<td>(1,365)</td>
</tr>
<tr>
<td>Loss before income tax</td>
<td>(1,654,945)</td>
<td>(1,641,107)</td>
<td>13,838</td>
</tr>
<tr>
<td>Loss for the year</td>
<td>(1,654,968)</td>
<td>(1,641,130)</td>
<td>13,838</td>
</tr>
</tbody>
</table>

In 2022, the project with a relatively large difference ratio between the declared number of the sound business plan and the consolidated financial information is operating income, which is mainly due to the recognition of the difference in revenue and cost according to the progress of the CDMO contract with AP Biosciences. The difference ratio of the remaining items is insignificant.

Overall, the development cycle of biosimilar drugs is long. Any revision to drug approval regulations and circumstances encountered during the drug development process may cause the actual development schedule to be different from the original plan, causing changes in the basis of estimation, resulting in differences. The Company's management will analyze and manage the overall business goals scheduled on a regular or from time to time, and make necessary improvements and adjustments depending on the actual implementation. The actual achievement rate in 2022 does not differ from the original expectation. Therefore, the progress of the implementation of the overall business plan in 2022 is considered appropriate. Tanvex will continue its efforts from R&D to commercialization, accelerate the launch of products, and create interests for shareholders and company value.
## Comparison Table of the “Rules of Procedure for Board of Directors Meeting” before and after amendment

<table>
<thead>
<tr>
<th>Provisions after amendment</th>
<th>Existing clause</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article 3 Convention and notification of board meetings</td>
<td>Article 3 Convention and notification of board meetings</td>
<td>Since the subparagraphs of Paragraph 1 of Article 12 are important matters concerning the operation of the Company, they should be specified in the cause of the meeting, so that the directors have sufficient information and time to evaluate the motions before making a decision. In this case, the requirements in Paragraph 4 are deleted. The matters specified in the Paragraph 1 of Article 12 should be listed in the cause of the meeting and should not be raised by an extraordinary motion.</td>
</tr>
<tr>
<td>The board of directors shall meet at least quarterly. A notice of the reasons for convening a board meeting shall be given to each director and supervisor before 7 days before the meeting is convened. In emergency circumstances, however, a board meeting may be called on shorter notice. The notice to be given under the preceding paragraph may be affected by means of electronic transmission with the prior consent of the recipients. All matters set forth under Article 12, paragraph 1 of these Rules shall be specified in the notice of the reasons for convening a board meeting. None of those matters may be raised by an extraordinary motion.</td>
<td>The board of directors shall meet at least quarterly. A notice of the reasons for convening a board meeting shall be given to each director and supervisor before 7 days before the meeting is convened. In emergency circumstances, however, a board meeting may be called on shorter notice. The notice to be given under the preceding paragraph may be affected by means of electronic transmission with the prior consent of the recipients. All matters set forth under Article 12, paragraph 1 of these Rules shall be specified in the notice of the reasons for convening a board meeting. None of those matters may be raised by an extraordinary motion.</td>
<td></td>
</tr>
</tbody>
</table>
Article 12 Matters requiring discussion at a board meeting

The matters listed below as they relate to this Corporation shall be raised for discussion at a board meeting:

1. The Corporation's business plan.
2. Annual and semi-annual must be audited and attested by a certified public accountant (CPA).
3. Adoption or amendment of an internal control system pursuant to Article 14-1 of the Securities and Exchange Act and assessment of the effectiveness of the internal control system.
4. Adoption or amendment, pursuant to Article 36-1 of the Securities and Exchange Act, of any handling procedures for material financial or business transactions, such as the acquisition or disposal of assets, derivatives trading, loans of funds to others, and endorsements or guarantees for others.
5. The offering, issuance, or private placement of equity-type securities.
6. If the board of directors does not have a managing director, the chairman is to be elected and dismissed.
7. The appointment or discharge of a financial, accounting, or internal audit officer.
8. A donation to a related party or a major donation to a non-related party, provided that a public-interest donation of disaster relief that is made for a major natural disaster may be submitted to the following board of directors meeting for retroactive recognition.

1. In accordance with the provisions of the Company Act, and as explained in the letter of the Ministry of Economic Affairs, and since the dismissal and election of the Chairman are also important matters of the Company, Paragraph 6 is hereby newly added, stating that if the board of directors does not have a managing director, the election or dismissal of the Chairman shall be proposed for discussion of the board of directors. The current subparagraphs 6 to 8 have been renumbered as 7 to 9.
2. In addition, pursuant to Paragraph 2 of Article 208 of the Company Act, the election of the Chairman by the Board of Directors shall be consistent with the procedures for the election and dismissal of the Chairman and the rules of the meeting procedure for the board of directors. The same applies mutatis mutandis to Article 18.
made for a major natural disaster may be submitted to the following board of directors meeting for retroactive recognition.

9. Any matter that, under Article 14-3 of the Securities and Exchange Act or any other law, regulation, or bylaw, must be approved by resolution at a shareholders meeting or board meeting, or any material matter as may be prescribed by the competent authority.

The term "related party" in subparagraph 8 of the preceding paragraph means a related party as defined in the Regulations Governing the Preparation of Financial Reports by Securities Issuers. The term "major donation to a non-related party" means an individual donation, or cumulative donations within a 1-year period to a single recipient, at an amount of NTD100 million or more, or at an amount equal to or greater than 1 percent of net operating revenue or 5 percent of paid-in capital as stated in the CPA-attested financial report for the most recent year. (In the case of a foreign issuer whose shares have no par value or a par value other than NT$10, 2.5 percent of shareholders' equity shall be substituted for the calculation of the amount equal to 5 percent of paid-in capital required under this paragraph.)

The term "within a 1-year period" in the preceding paragraph means a period of 1 year calculated retroactively from the date on which the current board of directors meeting is convened. Amounts already submitted to and passed by a resolution of the board are exempted from inclusion in the calculation.

At least one independent director of this Corporation shall attend the meeting in
and passed by a resolution of the board are exempted from inclusion in the calculation. At least one independent director of this Corporation shall attend the meeting in person. With respect to the matters which must be approved by resolutions at a board meeting as provided in the first paragraph, any and all independent directors shall attend the meeting. Where an independent director is unable to attend the meeting, that independent director shall appoint another independent director to attend the meeting as proxy. If an independent director objects to or expresses reservations about such a matter, it shall be recorded in the board meeting minutes; if an independent director intends to express an objection or reservation but is unable to attend the meeting in person, then unless there is a legitimate reason to do otherwise, that director shall issue a written opinion in advance, which shall be recorded in the board meeting minutes.

<table>
<thead>
<tr>
<th>Article 18 Meetings of board of managing directors</th>
</tr>
</thead>
<tbody>
<tr>
<td>If the Company has established managing directors, the provisions of Article 2, Article 3, paragraph 2, Articles 4 to 6, Articles 8 to 11, and Articles 13 to 16 should apply mutatis mutandis; the election or dismissal of the Chairman of the Board is subject to the provisions of Article 3, Paragraph 4. However, when meetings of the board of managing directors are held at regular intervals of 7 days or less, notices of such meetings may be given to each managing director before 2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Article 18 Meetings of board of managing directors</th>
</tr>
</thead>
<tbody>
<tr>
<td>The provisions of Article 2, Article 3, paragraph 2, Articles 4 to 6, Articles 8 to 11, and Articles 13 to 16 apply, mutatis mutandis, to this Corporation's meetings of the board of managing directors, provided that when meetings of the board of managing directors are held at regular intervals of 7 days or less, notices of such meetings may be given to each managing director before 2 days before the meeting</td>
</tr>
</tbody>
</table>

<p>| Where the Board of Directors includes a managing director, and applicable provisions governing the election or dismissal of the chairman, the reasons are the same as that described in 1 and 2 of Article 12. |</p>
<table>
<thead>
<tr>
<th>days before the meeting</th>
</tr>
</thead>
</table>

**Article 19: Supplementary provisions**

Amendments to these Rules of Procedure shall be adopted by the approval of meeting of the board of directors and shall be reported to the shareholders meeting

---

Revision of text.
INDEPENDENT AUDITORS’ REPORT TRANSLATED FROM CHINESE

To Tanvex Biopharma, Inc.

Opinion

We have audited the accompanying consolidated balance sheets of Tanvex Biopharma, Inc. and its subsidiaries (the “Group”) as at December 31, 2022 and 2021, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2022 and 2021, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Independent auditors’ responsibilities for the audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
**Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group’s 2022 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

The key audit matter for the Group’s 2022 consolidated financial statements are stated as follows:

**Impairment assessment of property, plant and equipment and right-of-use assets**

**Description**

As of December 31, 2022, the Group’s property, plant and equipment and right-of-use assets amounted to NT$2,150,560 thousand, accounting for 63% of the consolidated total assets. Refer to Note 4(14) for the related accounting policy on impairment of non-financial assets, Note 6(6) for the details of property, plant and equipment and Note 6(7) for the details of right-of-use assets.

The Group is currently engaged in conducting research and development of biosimilar products, so the property, plant and equipment and right-of-use assets are mainly used for the purposes of research, development and further manufacturing, the usage is highly relevant to the outcome of biosimilar drugs’ development. In addition, the balance of property, plant and equipment and right-of-use assets at December 31, 2022 was significant. Thus, we considered the impairment assessment of property, plant and equipment and right-of-use assets as a key audit matter.

**How our audit addressed the matter**

Our procedures performed in respect of the above key audit matter included:

Reviewing the reasonableness of the assessment of impairment indicators provided by management and discussing with management and research and development supervisor as to whether:

1. Main research and development technology has not lost competition in the market.
2. There is no major delay in the major research and development projects.
3. The main research and development equipment is in normal use and has not been damaged or outdated.
4. The market value of the Group’s stock is not lower than its book value at the balance sheet date.

Accuracy of recognition of revenue from contract development organization (CDO) services

Description

Refer to Note 4(21) for the accounting policy on revenue from CDO services and Note 6(17) for the details of revenue from CDO services.

The Group derives revenue mainly from the CDO services for biopharmaceuticals. Revenue from related transactions is recognized based on the actual service provided to the end of the reporting period as a proportion of the total services to be provided. This is determined based on the actual costs incurred relative to the total expected costs. Given that the calculation basis, record and maintenance of the stage of completion all involve manual work and is subject to management’s determination as to whether the actual costs incurred are appropriate, these could give rise to estimation uncertainty. Thus, we considered the accuracy of recognition of revenue from CDO services for biopharmaceuticals as a key audit matter.

How our audit addressed the matter

Our procedures performed in respect of the above key audit matter included:

1. Obtaining an understanding and ascertaining the reasonableness of revenue-related transaction procedures and the policy and basis for revenue recognition.
2. Testing the operating effectiveness of internal controls over the revenue and collection cycles.
3. Inspecting all types of information and assessing the reasonableness of methods and each assumption used to measure the stage of completion of performance obligations.
4. Recalculating and evaluating the accuracy of the amount and timing of revenue recognition.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial
the preparation of consolidated financial statements that are free from material misstatement, whether
due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group’s
ability to continue as a going concern, disclosing, as applicable, matters related to going concern and
using the going concern basis of accounting unless management either intends to liquidate the Group or
to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the
Group’s financial reporting process.

**Independent auditors’ responsibilities for the audit of the consolidated financial statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements
as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’
report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee
that an audit conducted in accordance with the Standards on Auditing of the Republic of China will
always detect a material misstatement when it exists. Misstatements can arise from fraud or error and
are considered material if, individually or in the aggregate, they could reasonably be expected to
influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise
professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements,
   whether due to fraud or error, design and perform audit procedures responsive to those risks, and
   obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk
   of not detecting a material misstatement resulting from fraud is higher than for one resulting from
   error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the
   override of internal controls.

2. Obtain an understanding of internal controls relevant to the audit in order to design audit procedures
   that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
   effectiveness of the Group’s internal controls.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors’ report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors’ report. However, future events or conditions may cause the Group to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors’ report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Yu, Shu-Fen  
Liang, Hua-Ling

For and on behalf of PricewaterhouseCoopers, Taiwan
March 3, 2023

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or Standards on Auditing of the Republic of China, and their applications in practice.

As the consolidated financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.
The accompanying notes are an integral part of these consolidated financial statements.
TANVEX BIOPHARMA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
(Expressed in thousands of New Taiwan dollars, except for loss per share amount)

The accompanying notes are an integral part of these consolidated financial statements.

<table>
<thead>
<tr>
<th>Items</th>
<th>Notes</th>
<th>2022</th>
<th>%</th>
<th>2021</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>4000 Operating revenue</td>
<td>6(17) and 7</td>
<td>$22,404</td>
<td>100</td>
<td>$5,406</td>
<td>100</td>
</tr>
<tr>
<td>5000 Operating costs</td>
<td>6(4)(12)</td>
<td>($41,752)</td>
<td>(186)</td>
<td>($1,856)</td>
<td>(34)</td>
</tr>
<tr>
<td>5900 Net operating margin</td>
<td></td>
<td>($19,348)</td>
<td>(86)</td>
<td>$3,550</td>
<td>66</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>6(6)(7)(8)(10) (11)(22)(23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6100 Selling expenses</td>
<td></td>
<td>($25,990)</td>
<td>(116)</td>
<td>($42,429)</td>
<td>(785)</td>
</tr>
<tr>
<td>6200 General and administrative expenses</td>
<td></td>
<td>($208,754)</td>
<td>(932)</td>
<td>($176,784)</td>
<td>(3270)</td>
</tr>
<tr>
<td>6300 Research and development expenses</td>
<td></td>
<td>($1,351,425)</td>
<td>(6032)</td>
<td>($1,383,521)</td>
<td>(25592)</td>
</tr>
<tr>
<td>6000 Total operating expenses</td>
<td></td>
<td>($1,586,169)</td>
<td>(7080)</td>
<td>($1,602,734)</td>
<td>(29647)</td>
</tr>
<tr>
<td>6900 Operating loss</td>
<td></td>
<td>($1,605,517)</td>
<td>(7166)</td>
<td>($1,599,184)</td>
<td>(29581)</td>
</tr>
<tr>
<td>Non-operating income and expenses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7100 Interest income</td>
<td>6(2)(18)</td>
<td>9,597</td>
<td>43</td>
<td>3,144</td>
<td>58</td>
</tr>
<tr>
<td>7010 Other income</td>
<td>6(19)</td>
<td>4,254</td>
<td>19</td>
<td>92,853</td>
<td>1718</td>
</tr>
<tr>
<td>7020 Other gains and losses</td>
<td>6(20)</td>
<td>5,279</td>
<td>23</td>
<td>6,220</td>
<td>115</td>
</tr>
<tr>
<td>7050 Finance costs</td>
<td>6(7)(21)</td>
<td>($54,720)</td>
<td>(244)</td>
<td>($46,222)</td>
<td>(855)</td>
</tr>
<tr>
<td>7000 Total non-operating income and expenses</td>
<td></td>
<td>($35,590)</td>
<td>(159)</td>
<td>$55,995</td>
<td>(1036)</td>
</tr>
<tr>
<td>7900 Loss before income tax</td>
<td></td>
<td>($1,641,107)</td>
<td>(7325)</td>
<td>($1,543,189)</td>
<td>(28545)</td>
</tr>
<tr>
<td>7950 Income tax expense</td>
<td>6(24)</td>
<td>($23)</td>
<td>-</td>
<td>($22)</td>
<td>-</td>
</tr>
<tr>
<td>8200 Loss for the year</td>
<td></td>
<td>($1,641,130)</td>
<td>(7325)</td>
<td>($1,543,211)</td>
<td>(28545)</td>
</tr>
<tr>
<td>Other comprehensive loss</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Components of other comprehensive loss that will be reclassified to profit or loss</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8361 Financial statements translation differences of foreign operations</td>
<td>6(16)</td>
<td>$163,033</td>
<td>728</td>
<td>($26,084)</td>
<td>(483)</td>
</tr>
<tr>
<td>8300 Other comprehensive income (loss) for the year</td>
<td></td>
<td>$163,033</td>
<td>728</td>
<td>($26,084)</td>
<td>(483)</td>
</tr>
<tr>
<td>8500 Total comprehensive loss for the year</td>
<td></td>
<td>($1,478,097)</td>
<td>(6597)</td>
<td>($1,569,295)</td>
<td>(29028)</td>
</tr>
<tr>
<td>Loss attributable to:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8610 Shareholders of the parent</td>
<td></td>
<td>($1,641,130)</td>
<td>(7325)</td>
<td>($1,543,211)</td>
<td>(28545)</td>
</tr>
<tr>
<td>Comprehensive loss attributable to:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8710 Shareholders of the parent</td>
<td></td>
<td>($1,478,097)</td>
<td>(6597)</td>
<td>($1,569,295)</td>
<td>(29028)</td>
</tr>
<tr>
<td>Loss per share (in dollars)</td>
<td>6(25)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9750 Basic loss per share</td>
<td></td>
<td>($4.65)</td>
<td>-</td>
<td>$4.74</td>
<td></td>
</tr>
<tr>
<td>9850 Diluted loss per share</td>
<td></td>
<td>($4.65)</td>
<td>-</td>
<td>$4.74</td>
<td></td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
TANVEX BIOPHARMA, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021  
(Expressed in thousands of New Taiwan dollars)

<table>
<thead>
<tr>
<th>Notes</th>
<th>Common shares</th>
<th>Share premium</th>
<th>Employee stock options</th>
<th>Others</th>
<th>Deficit yet to be compensated</th>
<th>Financial statements translation differences of foreign operations</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For the year ended December 31, 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at January 1, 2021</td>
<td>$ 3,116,067</td>
<td>$ 8,944,259</td>
<td>$ 538,112</td>
<td>$ 170,540</td>
<td>($ 9,784,225)</td>
<td>($ 364,038)</td>
<td>$ 2,620,715</td>
</tr>
<tr>
<td>Loss for the year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other comprehensive loss for the year</td>
<td>6(16)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total comprehensive loss for the year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Issuance of shares for cash</td>
<td>6(13)</td>
<td>400,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compensation cost of issuance of shares for cash</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compensation cost of employee stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise of employee stock options</td>
<td>6(11)(23)</td>
<td>8,480</td>
<td>14,188</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forfeiture of employee stock options</td>
<td>6(11)(13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at December 31, 2021</td>
<td>$ 3,524,547</td>
<td>$10,233,726</td>
<td>$ 509,409</td>
<td>$ 244,671</td>
<td>($11,327,436)</td>
<td>($ 390,122)</td>
<td>$ 2,794,795</td>
</tr>
<tr>
<td>For the year ended December 31, 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at January 1, 2022</td>
<td>$ 3,524,547</td>
<td>$10,233,726</td>
<td>$ 509,409</td>
<td>$ 244,671</td>
<td>($11,327,436)</td>
<td>($ 390,122)</td>
<td>$ 2,794,795</td>
</tr>
<tr>
<td>Loss for the year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other comprehensive income for the year</td>
<td>6(16)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total comprehensive income (loss) for the year</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compensation cost of employee stock options</td>
<td>6(11)(23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise of employee stock options</td>
<td>6(11)(13)</td>
<td>2,059</td>
<td>7,261</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forfeiture of employee stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at December 31, 2022</td>
<td>$ 3,526,606</td>
<td>$10,240,987</td>
<td>$ 488,632</td>
<td>$ 330,910</td>
<td>($12,968,566)</td>
<td>($ 227,089)</td>
<td>$ 1,391,480</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
## TANVEX BIOPHARMA, INC. AND SUBSIDIARIES
### CONSOLIDATED STATEMENTS OF CASH FLOWS
#### FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
(Expressed in thousands of New Taiwan dollars)

<table>
<thead>
<tr>
<th>Notes</th>
<th>For the years ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
</tr>
<tr>
<td>Loss before income tax</td>
<td>($1,641,107)</td>
</tr>
<tr>
<td>Adjustments items</td>
<td></td>
</tr>
<tr>
<td>Adjustments to reconcile profit (loss)</td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>280,014</td>
</tr>
<tr>
<td>Amortization</td>
<td>1,545</td>
</tr>
<tr>
<td>Compensation cost of employees stock options</td>
<td>67,547</td>
</tr>
<tr>
<td>Interest income</td>
<td>9,597</td>
</tr>
<tr>
<td>Interest expense</td>
<td>54,720</td>
</tr>
<tr>
<td>Loss on disposal of property, plant and equipment</td>
<td>7,205</td>
</tr>
<tr>
<td>Government grants - project grant borrowings transferred to other income</td>
<td>-</td>
</tr>
<tr>
<td>Changes in assets and liabilities relating to operating activities</td>
<td></td>
</tr>
<tr>
<td>Changes in assets relating to operating activities</td>
<td></td>
</tr>
<tr>
<td>Contract assets - current</td>
<td>2,523</td>
</tr>
<tr>
<td>Accounts receivable - related parties</td>
<td>333</td>
</tr>
<tr>
<td>Other receivables</td>
<td>2,065</td>
</tr>
<tr>
<td>Inventory</td>
<td>80,510</td>
</tr>
<tr>
<td>Prepayments</td>
<td>1,910</td>
</tr>
<tr>
<td>Changes in liabilities relating to operating activities</td>
<td></td>
</tr>
<tr>
<td>Contract liabilities - current</td>
<td>28,069</td>
</tr>
<tr>
<td>Other payables</td>
<td>15,593</td>
</tr>
<tr>
<td>Provisions for liabilities - current</td>
<td>6,502</td>
</tr>
<tr>
<td>Provisions for liabilities - non-current</td>
<td>10,469</td>
</tr>
<tr>
<td>Cash outflow generated from operations</td>
<td>1,288,701</td>
</tr>
<tr>
<td>Receipt of interest</td>
<td>9,597</td>
</tr>
<tr>
<td>Payment of interest</td>
<td>54,720</td>
</tr>
<tr>
<td>Income tax paid</td>
<td>22</td>
</tr>
<tr>
<td>Net cash flows used in operating activities</td>
<td>1,333,842</td>
</tr>
<tr>
<td>CASH FLOWS FROM INVESTING ACTIVITIES</td>
<td></td>
</tr>
<tr>
<td>Acquisition of financial assets at amortized cost</td>
<td>203,564</td>
</tr>
<tr>
<td>Proceeds from disposal of financial assets at amortized cost</td>
<td>203,564</td>
</tr>
<tr>
<td>Acquisition of property, plant and equipment</td>
<td>93,504</td>
</tr>
<tr>
<td>Proceeds from disposal of property, plant and equipment</td>
<td>1,815</td>
</tr>
<tr>
<td>Acquisition of intangible assets</td>
<td>2,575</td>
</tr>
<tr>
<td>(Increase) decrease in refundable deposits</td>
<td>1,184</td>
</tr>
<tr>
<td>Increase in other non-current assets</td>
<td>1,904</td>
</tr>
<tr>
<td>Net cash flows (used in) from investing activities</td>
<td>97,352</td>
</tr>
<tr>
<td>CASH FLOWS FROM FINANCING ACTIVITIES</td>
<td></td>
</tr>
<tr>
<td>Redemption of lease liabilities</td>
<td>130,525</td>
</tr>
<tr>
<td>Issuance of shares for cash</td>
<td>1,675,000</td>
</tr>
<tr>
<td>Exercise of employee share options</td>
<td>7,235</td>
</tr>
<tr>
<td>Net cash flows (used in) from financing activities</td>
<td>123,290</td>
</tr>
<tr>
<td>Effect of exchange rate changes on cash and cash equivalents</td>
<td>117,745</td>
</tr>
<tr>
<td>Net (decrease) increase in cash and cash equivalents</td>
<td>1,436,744</td>
</tr>
<tr>
<td>Cash at beginning of year</td>
<td>2,222,977</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of year</td>
<td>$786,233</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these consolidated financial statements.
I. Reason for change

Due to the unsatisfactory progress and results of the drug certification review for the main product lines TX01 and TX05, and the impact of the COVID-19 pandemic, the progress of the original drug development projects was postponed. As a result, no major products are currently available on the market for sale to stabilize working capital.

After careful consideration, as we have limited funds and difficult financing, we need to continue to promote drug development projects and support the management and marketing expenses required to maintain the Company's operations. In order to make good use of the funds, on August 26, 2022, the Board of Directors approved the first adjustment. The original plan of “replacing R&D equipment” was temporarily suspended, and at the same time, the funds and use of funds required for each drug project were re-adjusted according to the R&D schedule progress. However, the BLA review result of the TX01 development plan in the first quarter of 2023 was not as expected and the Company's own funds are not sufficient to respond to changes in the R&D progress and operational needs. Therefore, the Company intends to change the details of the use of “working capital” in accordance with the FDA audit schedule, actual operation and progress of each drug development. The changes to the Company's projects are as follows:

<table>
<thead>
<tr>
<th>Item</th>
<th>Original plan amount (A)</th>
<th>August 26, 2022 Adjustment Plan (B)</th>
<th>Plan after change (C)</th>
<th>Cumulative changes (D) = (C) - (A)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX01</td>
<td>170,433</td>
<td>170,433</td>
<td>338,317</td>
<td>167,884</td>
<td>Adjusted according to the actual development progress. As plant inspection preparations and results of the first quarter of 2023 were not as expected, the actual investment amount was higher than the original expectation, and a supplementary BLA review was required. The available funds and the discretionary funds on the account were insufficient to meet the needs, resulting in an increase in the funding demand for the project.</td>
</tr>
<tr>
<td>TX05</td>
<td>306,718</td>
<td>504,228</td>
<td>589,098</td>
<td>282,380</td>
<td>Adjusted according to the actual development progress. The third-party verification was required to prepare and supplement the cost required for BLA review, and the remaining available funds of the plan and discretionary funds on the account were not sufficient to meet the needs, resulting in an increase in</td>
</tr>
<tr>
<td>Item</td>
<td>Original plan amount (A)</td>
<td>August 26, 2022 Adjustment Plan (B)</td>
<td>Plan after change (C)</td>
<td>Cumulative changes (D) = (C) - (A)</td>
<td>Notes</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
<td>--------------------------------------</td>
<td>-----------------------</td>
<td>-----------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>TX04</td>
<td>828,680</td>
<td>602,890</td>
<td>245,335</td>
<td>(583,345)</td>
<td>According to the development progress adjustment, due to the delay in the R&amp;D schedule and the urgent need for funds for the TX01 and TX05 drug development plans, as well as for sales and management expenses of other projects, we plan to allocate a portion of the funds from these projects to support other projects in a more efficient manner. The insufficient funds of the plan will be paid off from the fundraising plan in 2022.</td>
</tr>
<tr>
<td>TX16</td>
<td>2,910</td>
<td>2,910</td>
<td>3,001</td>
<td>91</td>
<td>The available funds were not sufficient for the TX16 drug development project, so it will be adjusted according to the actual use.</td>
</tr>
<tr>
<td>TX52</td>
<td>89,757</td>
<td>80,740</td>
<td>13</td>
<td>(89,744)</td>
<td>Adjusted based on the progress, due to the delay in the R&amp;D schedule and the urgent funding needs for the TX01 and TX05 drug development projects, as well as sales and management expenses, in order to utilize the funds more effectively, it is proposed to allocate a portion of the funds from these projects to support other projects. The insufficient funds of the project will be paid off from the fundraising plans in subsequent years.</td>
</tr>
<tr>
<td>Other R&amp;D projects</td>
<td>100,575</td>
<td>100,575</td>
<td>139,274</td>
<td>38,699</td>
<td>The available funds were not sufficient for other R&amp;D projects. Therefore, the amounts of the TX04 and TX52 projects were adjusted according to the actual situation to support other R&amp;D projects, so that the fund requirements for these projects would increase.</td>
</tr>
<tr>
<td>Administrative and selling expenses</td>
<td>96,927</td>
<td>218,224</td>
<td>364,962</td>
<td>268,035</td>
<td>The current available funds were not sufficient to maintain the operation of the sales management department. Therefore, other plans were adjusted according to the actual situation to cover the sales and marketing expenses, resulting in an increase in capital demand for such projects.</td>
</tr>
<tr>
<td>Total working capital</td>
<td>1,596,000</td>
<td>1,680,000</td>
<td>1,680,000</td>
<td>84,000</td>
<td></td>
</tr>
<tr>
<td>Replacement of R&amp;D equipment</td>
<td>84,000</td>
<td>0</td>
<td>0</td>
<td>(84,000)</td>
<td>As there was no stable revenue to inject funds, the suspension of the use of funds for more efficient use of funds was proposed.</td>
</tr>
<tr>
<td>Total planned fundraising in 2021</td>
<td>1,680,000</td>
<td>1,680,000</td>
<td>1,680,000</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

In addition, after the change of the plan, the total cumulative decrease or increase in the amount of funds required for individual projects has reached 20% of the total amount of funds raised. Therefore, this was submitted to the latest shareholders' meeting for ratification in
accordance with Article 10 of the “Regulations Governing the Offering and Issuance of Securities by Foreign Issuers”.

II. Plan items and expected benefits before the change

1. Projects originally planned and progress of fund utilization

(1) Original plan of fundraising in 2021

<table>
<thead>
<tr>
<th>Plan items</th>
<th>Total funds required</th>
<th>Utilization progress of planned funds</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q4</td>
</tr>
<tr>
<td>TX01</td>
<td>170,433</td>
<td>64,603</td>
<td>59,386</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>24,475</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>21,969</td>
</tr>
<tr>
<td>TX05</td>
<td>306,718</td>
<td>128,866</td>
<td>106,925</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>44,359</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>26,568</td>
</tr>
<tr>
<td>TX16</td>
<td>2,910</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2,910</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>TX04</td>
<td>828,680</td>
<td>112,012</td>
<td>121,044</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>224,088</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>371,536</td>
</tr>
<tr>
<td>TX52</td>
<td>89,757</td>
<td>12,921</td>
<td>16,496</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>27,386</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>32,954</td>
</tr>
<tr>
<td>Other R&amp;D projects</td>
<td>100,575</td>
<td>21,964</td>
<td>27,995</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>26,382</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>24,234</td>
</tr>
<tr>
<td>Sales and management expenses</td>
<td>96,927</td>
<td>22,895</td>
<td>27,012</td>
</tr>
<tr>
<td><strong>Total working capital</strong></td>
<td><strong>1,596,000</strong></td>
<td><strong>363,261</strong></td>
<td><strong>358,858</strong></td>
</tr>
<tr>
<td>Replacement of R&amp;D equipment</td>
<td>84,000</td>
<td>21,000</td>
<td>21,000</td>
</tr>
<tr>
<td><strong>Total planned fundraising in 2021</strong></td>
<td><strong>1,680,000</strong></td>
<td><strong>384,261</strong></td>
<td><strong>379,858</strong></td>
</tr>
</tbody>
</table>

Note: This working capital enhancement plan was mainly used for the R&D expenses required for TX01, TX04, TX05, TX16 and TX52 projects and other early R&D projects. In addition to the R&D expenses, the working capital also covered the administrative expenses required for the operation. and marketing expenses. Moreover, the update, replacement, calibration of R&D equipment were carried out in a timely manner according to the R&D needs of each project.
(2) The adjustment plan was approved by the board of directors on August 26, 2022

<table>
<thead>
<tr>
<th>Item</th>
<th>Plan completion date</th>
<th>Total funds required</th>
<th>Utilization progress of planned funds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>2022</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q1</td>
</tr>
<tr>
<td>TX01</td>
<td>Q2 2023</td>
<td>170,433</td>
<td>0</td>
</tr>
<tr>
<td>TX05</td>
<td>Q4 2022</td>
<td>504,228</td>
<td>0</td>
</tr>
<tr>
<td>TX04</td>
<td>Q2 2023</td>
<td>602,890</td>
<td>0</td>
</tr>
<tr>
<td>TX16</td>
<td>Q4 2022</td>
<td>2,910</td>
<td>0</td>
</tr>
<tr>
<td>TX52</td>
<td>Q1 2023</td>
<td>80,740</td>
<td>0</td>
</tr>
<tr>
<td>Other R&amp;D projects</td>
<td>Q4 2022</td>
<td>100,575</td>
<td>0</td>
</tr>
<tr>
<td>Sales and management expenses</td>
<td>Q4 2022</td>
<td>218,224</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total working capital</strong></td>
<td><strong>Q2 2023</strong></td>
<td><strong>1,680,000</strong></td>
<td>0</td>
</tr>
</tbody>
</table>

Unit: NT$ thousand
2. Expected benefits of the original plan

(1) Projected development progress

<table>
<thead>
<tr>
<th>Main products (Brand patented drug)</th>
<th>Product indication</th>
<th>Projected development progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX01 (Neupogen)</td>
<td>Neutropenia caused by chemotherapy against cancer</td>
<td>• In May 2021, we received a notice from the U.S. FDA that drug permit review for TX01 was completed. Due to the impact of COVID-19, TX01 is currently unable to come forward. The Company will supplement and provide the information required for FDA review according to the schedule and requirements. • It is expected to be launched in the U.S. market in 2022.</td>
</tr>
<tr>
<td>TX05 (Herceptin)</td>
<td>Breast cancer</td>
<td>• In February 2021, the pivotal trial on human was completed and the major test results indicated that the primary efficacy endpoint was achieved. • An application was submitted to the U.S. Food and Drug Administration (FDA) in August 2021 for review of drug marketing registration.</td>
</tr>
<tr>
<td>TX04 (Neulasta)</td>
<td>Neutropenia induced by chemotherapy (long-acting drug)</td>
<td>• A meeting with the FDA was held in March 2021 to discuss the Phase III clinical trial plan. • Currently, the Company is preparing for the scale-up process and preparing for the Phase III clinical project.</td>
</tr>
<tr>
<td>TX16 (Avastin)</td>
<td>Colorectal cancer and lung cancer</td>
<td>• The Phase I clinical trials on human subject have been completed. At present, the design for Phase III clinical trials and patent-related procedures are under planning.</td>
</tr>
<tr>
<td>TX52 (Perjeta)</td>
<td>Breast cancer</td>
<td>• The pre-clinical and manufacturing process are continued to be developed.</td>
</tr>
</tbody>
</table>

The adjustment plan was approved by the board of directors on August 26, 2022.

<table>
<thead>
<tr>
<th>Main products (Brand patented drug)</th>
<th>Indications</th>
<th>Projected R&amp;D progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX01 (Neupogen)</td>
<td>Neutropenia caused by chemotherapy against cancer</td>
<td>• A supplemental submission to the FDA for a drug certificate was made in August 2022. The BLA review and marketing is expected to be completed and launched in the U.S. market in 2023. • The “drug establishment license” from Health Canada was obtained in July 2022, and is expected to sell TX01 in Canada in 2023.</td>
</tr>
<tr>
<td>Main products (Brand patented drug)</td>
<td>Indications</td>
<td>Projected R&amp;D progress</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| **TX05** (Herceptin) | Breast cancer | • In July 2022, the Company received a Complete Response Letter (CRL) from the FDA. The result of the U.S. FDA marketing review was that no major defects were raised in the plant inspection or clinical trials. However, some of the similarities between TX05 and the brand product required to be further clarified. Therefore, specific information must be supplemented prior to marketing approval in order to comply with the principle of biosimilar drugs. Currently, the Company plans to collect and analyze the original clinical data to verify the similarities between TX05 and Herceptin, the original brand drug. The Company is expected to submit the relevant data to the FDA for a supplemental submission for drug certification in Q3 2023.  
• It is expected to be launched in the U.S. market in 2024. |
| **TX04** (Neulasta) | Neutropenia (long-acting drug) | • The Company will continue to scale up its production process and prepare for Phase III clinical trials (pivotal trials). Currently, stability studies are being conducted. Phase III clinical trials (pivotal trial) is expected to take place in 2024. |
| **TX16** (Avastin) | Colorectal cancer and lung cancer | • The Phase I of human clinical trial has been completed, and the Phase III of clinical design and patent confirmation related procedures are currently under planning. The pre-clinical and manufacturing process are continued to be developed.  
• Expected to enter the Phase III of clinical trials (pivotal trials) in 2024 |
| **TX52** (Perjeta) | Breast cancer | • The pre-clinical and manufacturing process are continued to be developed.  
• Expected to enter the Phase I of human clinical trial in Q4 2023 |
(2) Expected benefits

①Original plan of fundraising in 2021

A. Estimated benefits and loss

The biosimilar drug product developed this time was expected to be launched on the market in 2022 and start to generate operating revenue in that year.

B. Financial structure

<table>
<thead>
<tr>
<th>Item</th>
<th>Year</th>
<th>Q1 2021 (Before capital increase)</th>
<th>Q3 2021 (After capital increase)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1,802,376</td>
<td>3,602,376</td>
</tr>
<tr>
<td>Basic Financial information</td>
<td>Current assets</td>
<td>1,802,376</td>
<td>3,602,376</td>
</tr>
<tr>
<td></td>
<td>Total assets</td>
<td>3,885,768</td>
<td>5,685,768</td>
</tr>
<tr>
<td></td>
<td>Current liabilities</td>
<td>228,407</td>
<td>228,407</td>
</tr>
<tr>
<td></td>
<td>Total liabilities</td>
<td>1,637,287</td>
<td>1,637,287</td>
</tr>
<tr>
<td></td>
<td>Debt ratio (%)</td>
<td>42.14</td>
<td>28.80</td>
</tr>
<tr>
<td></td>
<td>Ratio of long-term funds to property, plant and equipment</td>
<td>676.98</td>
<td>1,010.16</td>
</tr>
<tr>
<td>Financial structure</td>
<td>Current ratio (%)</td>
<td>789.11</td>
<td>1,577.17</td>
</tr>
<tr>
<td>Solvency</td>
<td>Quick ratio (%)</td>
<td>723.53</td>
<td>1,533.92</td>
</tr>
</tbody>
</table>

②The adjustment plan was approved by the board of directors on August 26, 2022

A. Product R&D benefits

The biosimilar drug product developed this time is expected to be launched on the market in 2023 and start to generate operating revenue in that year.

B. Financial structure

The effect of improving the financial structure remains unchanged and remains the same as the original plan.
3. Implementation of original plans and use of funds as of the end of Q1 2023

(1) Progress of capital utilization

<table>
<thead>
<tr>
<th>Item</th>
<th>Execution status</th>
<th>As of the end of Q1 2023</th>
<th>Reasons for being ahead or behind schedule and improvement plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrichment of working capital</td>
<td>Expected</td>
<td>1,508,440</td>
<td>Cash capital increase for the Company was completed on September 29, 2021, and the plan adjustment was approved under BoD resolution on August 26, 2022 to postpone the replacement of R&amp;D equipment originally planned, as well as accommodating with the schedule of FDA review by readjusting the capital needed and progress of capital utilization for each drug plan.</td>
</tr>
<tr>
<td></td>
<td>Actual</td>
<td>1,567,522</td>
<td></td>
</tr>
<tr>
<td>Execution progress</td>
<td>Expected</td>
<td>89.79%</td>
<td>Up till Q1 of 2023, the accumulated amount of actual expenditure is NT$1,567,522 thousand, which is under consecutive implementation according to the plan after adjustment.</td>
</tr>
<tr>
<td></td>
<td>Actual</td>
<td>93.31%</td>
<td></td>
</tr>
</tbody>
</table>

(2) Explanation on progress difference of capital utilization

<table>
<thead>
<tr>
<th>Item</th>
<th>2022</th>
<th>2023</th>
<th>As of Q1 2023</th>
<th>Explanation of the difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX01</td>
<td>Originally Expected (Note 1)</td>
<td>Adjustment (Note 2)</td>
<td>Originally Expected (Note 1)</td>
<td>Adjustment (Note 2)</td>
</tr>
<tr>
<td></td>
<td>Year-round</td>
<td>Q1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>170,433</td>
<td>132,939</td>
<td>0</td>
<td>27,036</td>
</tr>
</tbody>
</table>

The Company originally expected to complete the drug certification review by the end of Q2 2022. However, after repeated communication with the FDA, the Company decided to conduct third-party data validation and analysis of the drug data to complete the drug certification review data. The Company obtained validation information and prepare the analysis data in the Q1 2022. Later, as the FDA notified the TX05 plant for inspection. Taking into account that two drugs (TX01 and TX05) could not be inspected at the same time, after consulting the FDA, the Company agreed to postpone the supplemental submission in August 2022 and complete the inspection of the San Diego plant in Q1 2023. Salaries of R&D personnel and research expenses incurred due to the delay in the R&D progress, as well as the production costs of batches of APIs for FDA inspection, annual FDA fees, replacement costs and raw material costs for stocking were still required. Therefore, although the progress of the R&D was not as good as expected, the related R&D expenses...
In July 2022, the Company received a Complete Response Letter (CRL) from the FDA. The result of the marketing review was that no major defects were raised in the plant inspection or clinical trials. However, some of the similarities between TX05 and the brand name drug required to be further clarified. Therefore, specific information must be supplemented prior to marketing approval in order to comply with the principle of biosimilar drugs. The Company has planned to work with a third-party validation consulting company to collect and analyze more information and scientific evidence for the R&D data to verify the similarities between TX05 and the brand name drug. In addition to the production costs for FDA inspection, annual FDA fees, replacement costs for stocking, salaries of R&D personnel and research expenses incurred due to the delay in the R&D progress, as well as the commissioned certification service of a third-party validation consulting company, were also added to the expenses. Therefore, although the progress of the R&D was not as good as expected, the related R&D expenses continued to be incurred, making the actual amount spent on the progress higher than the original plan.

### TX04

TX04 is the long-acting drug of TX01. The Company's brand product development strategy for TX04 is to advance TX04 to Phase III clinical trials after TX01 is successfully certified and launched on the market in Q4 2022. However, a drug certification was not obtained for TX01 as scheduled, leading to a suspension of the development of TX04. This made the originally expected FDA annual fee, Phase III clinical design fee, and R&D expenses such as process scale-up to be deferred.”

### TX05

The Company originally planned to continue the preclinical development of TX52 in 2022, and the development strategy of TX52 was to develop TX52 when there is excess capacity available after the commercial mass production of TX05. However, the progress of the FDA's drug certification review for TX01 and TX05 products was not as expected. Due to this, the Company still has to continue to invest a lot of manpower and resources to complete the FDA review and supplementary documents and other related verification tests for TX01 and TX05. After considering the overall effective use of resources, we have slightly slowed down the progress of the development of TX52, resulting in a delay in the actual expenditure and progress of TX52 compared to the original plan.

### TX16

It is mainly due to the expert consultation fees incurred due to the delay in the R&D progress.

### Other projects

This project is mainly for candidate drug search and cell line development. As the R&D project continued, the related investment in R&D personnel salaries and R&D expenses continued to be incurred, resulting in the actual amount spent higher than the original plan.

### Sales and management expenses

It is mainly due to the fact that the actual amount raised in the 2021 fundraising plan was lower than the original expectation. Due to this, the funds available for marketing expenses were lower than the actual expenditures. As a result, the funds available to the Company were not sufficient to maintain the operations of the marketing department. Other plans were adjusted according to the actual situation to cover the expenses, resulting in an increase in the actual expenditures for the project.

### Total working capital

Overall, due to the impact of the COVID-19 pandemic on the progress of research and development and the drug certification review progress of TX01 and TX05, the Company was not able to maintain the planned progress and actual expenditure on R&D activities. As a result, the Company experienced delays in various research and development schedules and expenses incurred due to the delay in the actual progress compared to the original plan.
<table>
<thead>
<tr>
<th>Item</th>
<th>2022 Year-round</th>
<th>Year-round</th>
<th>2023 Q1</th>
<th>As of Q1 2023</th>
<th>Explanation of the difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Originally Expected</td>
<td>Adjustment</td>
<td>Originally Expected</td>
<td>Adjustment</td>
<td>Original Expected</td>
</tr>
<tr>
<td>Replacement of R&amp;D equipment</td>
<td>84,000</td>
<td>0</td>
<td>0</td>
<td>84,000</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>1,680,000</td>
<td>1,239,566</td>
<td>0</td>
<td>268,874</td>
<td>1,680,000</td>
</tr>
</tbody>
</table>

Note 1: Original fundraising plan in 2021
Note 2: The adjustment passed by the Board of Directors on August 26, 2022
4. Execution of the original plans, use of funds, and achievement of benefits as of the end of Q1 2023

(1) Execution of expected development progress

<table>
<thead>
<tr>
<th>Main products</th>
<th>Indications</th>
<th>Results from Q3 2021 up till now</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX01 Brand patented drug (Neupogen)</td>
<td>Neutropenia caused by chemotherapy against cancer</td>
<td>Sales: The Company obtained the “drug establishment license” from Health Canada in July 2022, and TX01 is now available for sale in Canada. USA: After repeated communication with the FDA, third-party data verification such as Biacore assays (binding) study is still pending to complete the review data. We obtained validation information and prepared data analysis in Q1 2022, and submitted additional information required for drug certification review to the FDA in August 2022. In January 2023, we completed the inspection of San Diego plant with no major defects. However, we received a Complete Response Letter (CRL) from FDA in February 2023 that there were still matters for downstream needle manufacturers to improve. Given this, we must wait for the downstream needle manufacturers to pass the review before obtaining the drug certification. Furthermore, the Company has worked closely with downstream needle manufacturers for the improvement of matters, while also communicating with FDA. The Company expects to complete the supplementary submission information and BLA review in 2023. Canada: In October 2021, the marketing authorization was obtained from Health Canada (drug certification).</td>
</tr>
<tr>
<td>TX05 Brand patented drug (Herceptin)</td>
<td>Breast cancer</td>
<td>Research and development: In July 2022, the Company received a Complete Response Letter (CRL) from the FDA. The result of the marketing review was that no major defects were raised in the factory inspection or clinical trials. However, some of the similarities between TX05 and the brand product Herceptin required to be further clarified. Therefore, specific information must be supplemented prior to marketing approval in order to comply with the principle of biosimilar drugs. Therefore, the Company has planned to cooperate with a third-party validation consulting company to collect and analyze more information and scientific basis for the R&amp;D data in order to verify the similarity between TX05 and the brand drug. In Q4 2023, the relevant information will be submitted to the FDA to supplement the information required for the drug certification review.</td>
</tr>
<tr>
<td>TX04 Brand patented drug (Neulasta)</td>
<td>Neutropenia (long-acting drug)</td>
<td>In March 2021, we preliminary discussed and prepared a Phase III clinical trial plan with the FDA, and will continue to scale up the process and prepare for Phase III clinical trials. Currently, stability studies are being conducted simultaneously. As TX04 is a long-acting form of TX01, the development strategy is to enter clinical trials in Q4 2022 after the launch of TX01. However, as the drug certificate for TX01 has not yet been obtained according to the original schedule, the development progress of TX04 is suspended and is expected to be postponed until 2024 to enter the Phase III clinical trials (pivotal trial).</td>
</tr>
<tr>
<td>TX16 - Brand patented drug (Avastin)</td>
<td>Colorectal cancer and lung cancer</td>
<td>At present, the preparation of Phase III clinical trial and related procedures for patent confirmation are underway. However, due to the limited funds, the R&amp;D progress has been slowed down slightly, and the Phase III human clinical trial will be postponed until 2025.</td>
</tr>
<tr>
<td>TX52 Brand patented drug (Perjeta)</td>
<td>Breast cancer</td>
<td>The preclinical and manufacturing process is currently under development, but considering the development progress of TX05, Phase I of human clinical trial is expected to take place in Q3 2025.</td>
</tr>
</tbody>
</table>
(2) Actual benefits achieved

A. Estimated benefits and loss

The Company's biosimilar products were expected to be available on the market in 2022 and to generate operating revenue in that year. However, due to the impact of COVID-19, the factory investigation of TX01 was postponed. After repeated communication with the FDA, third-party data verification such as Biacore assays (binding) study is still pending to complete the review data. We obtained validation information and prepared data analysis in Q1 2022, and submitted additional information required for drug certification review to the FDA in August 2022. In January 2023, we completed the inspection of San Diego plant with no major defects. However, we received a Complete Response Letter (CRL) from FDA in February 2023 that there were matters for downstream needle manufacturers to improve. Given this, we must wait for the downstream needle manufacturers to pass the review before obtaining the drug certification. Therefore, the Company has worked closely with downstream needle manufacturers for improvement while also communicating with FDA. The Company expects to complete the supplementary submission information and BLA review in 2023, which is to be available for sale in the United States by 2024. In July 2022, the Company received a Complete Response Letter (CRL) from the FDA regarding further clarification of similarities. Therefore, we have planned to cooperate with a third-party validation consulting company to collect and analyze more data and scientific evidence to verify the similarity of TX05 with the brand drug. We have communicated with the FDA on related matters, and it is expected that the relevant information will be submitted to the FDA in Q4 2023 to supplement the information required for the drug certification review, and the listing schedule will be postponed until 2024. The launch of TX04 has also been postponed to 2025 due to the pandemic and the R&D progress. For estimated benefits and loss after adjustment, please refer to projected benefits after the change.
B. Financial structure

<table>
<thead>
<tr>
<th>Item</th>
<th>Year</th>
<th>Q1 2021 (Before capital increase)</th>
<th>Projected amount</th>
<th>Actual amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2021 Q3 (after capital increase)</td>
<td>2021 Q3 (after capital increase)</td>
<td></td>
</tr>
<tr>
<td>Current assets</td>
<td>1,802,376</td>
<td>3,602,376</td>
<td>2,707,053</td>
<td></td>
</tr>
<tr>
<td>Total assets</td>
<td>3,885,768</td>
<td>5,685,768</td>
<td>5,080,708</td>
<td></td>
</tr>
<tr>
<td>Current liabilities</td>
<td>228,407</td>
<td>228,407</td>
<td>237,070</td>
<td></td>
</tr>
<tr>
<td>Total liabilities</td>
<td>1,637,287</td>
<td>1,637,287</td>
<td>1,947,532</td>
<td></td>
</tr>
</tbody>
</table>

**Basic Financial information**

| Debt ratio (%)                      | 42.14                 | 28.80                             | 38.33            |
| Ratio of long-term funds to property, plant and equipment | 676.98 | 1,010.16 | 983.03 |

**Financial structure**

| Current ratio (%)                   | 789.11                | 1,577.17                          | 1,141.88         |
| Quick ratio (%)                     | 723.53                | 1,533.92                          | 1,084.95         |

The issuance of new shares for cash is used to enrich the working capital. After the completion of the capital raising and working capital injection in Q3 2021, the debt ratio decreased from 42.14% before fundraising to 38.33%, and the long-term capital to property, plant, and equipment ratio increased from 676.98 % to 983.03%; the current ratio and quick ratio increased from 789.11% and 723.53% before the capital increase to 1,141.88% and 1,084.95%, respectively. As the financial ratios are sound compared to those before the capital raising, the benefits of the fundraising to strengthen the financial structure and reduce operational risks should be visible.
### III. Items and expected benefits after the change

1. Progress of capital utilization after change

<table>
<thead>
<tr>
<th>Item</th>
<th>Plan completion date</th>
<th>Total funds required</th>
<th>Utilization progress of planned funds</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
<tr>
<td>TX01</td>
<td>Q2 2023</td>
<td>338,317</td>
<td>0</td>
<td>28,048</td>
<td>41,810</td>
</tr>
<tr>
<td>TX05</td>
<td>Q2 2023</td>
<td>589,098</td>
<td>0</td>
<td>245,794</td>
<td>174,131</td>
</tr>
<tr>
<td>TX04</td>
<td>Q1 2023</td>
<td>245,335</td>
<td>0</td>
<td>47,667</td>
<td>85,980</td>
</tr>
<tr>
<td>TX16</td>
<td>Q1 2023</td>
<td>3,001</td>
<td>0</td>
<td>1,276</td>
<td>1,634</td>
</tr>
<tr>
<td>TX52</td>
<td>Q1 2023</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other R&amp;D projects</td>
<td>Q2 2023</td>
<td>139,274</td>
<td>0</td>
<td>27,675</td>
<td>22,561</td>
</tr>
<tr>
<td>Sales and management expenses</td>
<td>Q2 2023</td>
<td>364,962</td>
<td>0</td>
<td>110,005</td>
<td>88,546</td>
</tr>
<tr>
<td>Total working capital</td>
<td>Q2 2023</td>
<td>1,680,000</td>
<td>0</td>
<td>460,465</td>
<td>414,662</td>
</tr>
</tbody>
</table>

Unit: NTD thousands
2. Projected benefits after the change
   (1) Projected development progress

<table>
<thead>
<tr>
<th>Main products</th>
<th>Indications</th>
<th>Projected R&amp;D progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX01 Brand patented drug (Neupogen)</td>
<td>Neutropenia caused by chemotherapy against cancer</td>
<td>• BLA review expected to be completed in the United States in 2023, with the product launched in the United States in 2024. • The “drug establishment license” from Health Canada was obtained in July 2022, and is expected to sell TX01 in Canada in 2023.</td>
</tr>
<tr>
<td>TX05 Brand patented drug (Herceptin)</td>
<td>Breast cancer</td>
<td>• It is expected that the relevant information will be submitted to the FDA for drug certification in Q4 2023. • It is expected to be launched in the U.S. market in 2024.</td>
</tr>
<tr>
<td>TX04 Brand patented drug (Neulasta)</td>
<td>Neutropenia (long-acting drug)</td>
<td>• The Company will continue to scale up its production process and prepare for Phase III clinical trials (pivotal trials). Currently, stability studies are being conducted. Phase III clinical trials (pivotal trial) is expected to take place in 2024.</td>
</tr>
<tr>
<td>TX16 - Brand patented drug (Avastin)</td>
<td>Colorectal cancer and lung cancer</td>
<td>• The Phase I of human clinical trial has been completed, and the Phase III of clinical design and patent confirmation related procedures are currently under planning. The pre-clinical and manufacturing process are continued to be developed. • It is expected to enter the Phase III human clinical trial in 2025.</td>
</tr>
<tr>
<td>TX52 Brand patented drug (Perjeta)</td>
<td>Breast cancer</td>
<td>• The pre-clinical and manufacturing process are continued to be developed. • It is expected to enter the Phase I human clinical trial in 2025.</td>
</tr>
</tbody>
</table>

Expected benefits

A. Product R&D benefits
   The biosimilar drug product developed this time is expected to be launched on the market in 2023 and start to generate operating revenue in that year.

B. Financial structure
   The effect of improving the financial structure remains unchanged and remains the same as the original plan.
IV. The reasonableness and necessity of the planned change

Due to the COVID-19 pandemic, the FDA review results of TX01 and TX05 were not as expected, leading to a delay of the development project progress of TX04 and TX52. Therefore, in response to the changes in the progress of the Company's drug development and in line with the operational needs, the Board of Directors of the Company resolved and approved on August 26, 2022 to adjust the unspent funds totaling NT$84,000 thousand originally planned for the replacement of research and development equipment to be used to enrich the working capital, and to appropriately adjust the utilization and execution progress of the replenishment of working capital. In addition, for TX01 product, although the plant inspection of the U.S. production site was completed in January 2023, and the inspection results of the U.S. production site showed no major defects, but received a Complete Response Letter (CRL) from the FDA in February 2023, that there were matters for downstream needle manufacturers to improve. Given this, we must wait for the downstream needle manufacturers to pass the review before obtaining the drug certification. As a result, drug certificates were not yet obtained for TX01 products according to the original schedule, which also affected the drug development progress and the use of funds, resulting in the Company's available funds insufficient to respond to changes in the R&D plan. In order to make good use of the funds, the Company intends to adjust the use of working capital and the implementation period in a timely manner according to the actual operational needs, the progress of drug certification review and the progress of research and development.

In conclusion, due to the impact of uncontrollable changes in objective factors, such as the COVID-19 pandemic and the unsatisfactory review results of the FDA, and the lack of freely available funds, the Company still needs to continue to promote the drug development plan and support the maintenance of the Company. For the management and sales expenses required for operation, it was reasonable and necessary to re-adjust the use of funds for each project and the progress of implementation according to the development schedule in order to make the use of funds more efficient.
V. The impact of the planned change on shareholders' equity.

Due to the COVID-19 pandemic and the unsatisfactory FDA review schedule and results of TX01 and TX05, all drug development plans have been postponed at the same time. However, the Company must continue its drug development programs and meet its marketing expenses to maintain its operations. Therefore, given the insufficient balance of available funds, timely adjustment of the capital utilization plan based on the efficiency of capital utilization and the actual R&D progress will ensure the normal operation of the Company and the promotion of the drug development plan, and increase the flexibility and advantage of capital allocation. In addition, the content of the plan is mainly a detailed adjustment of the working capital and does not exceed the scope of the original fundraising plan; therefore, the change in the plan should not have a material adverse impact on shareholders' equity.
<table>
<thead>
<tr>
<th>Article No.</th>
<th>Current Memorandum and Articles of Association (adopted by special resolution passed on June 17, 2022)</th>
<th>Proposed Amendments to Provisions of Memorandum and Articles of Association (as underlined) (anticipated to be adopted by special resolution passed on June 28, 2023)</th>
<th>Explanations</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Subject to the Law, in the event any of the resolutions with respect to the paragraph (a), (b), or (c) of Article 32 is adopted by general meeting, any Shareholder who has notified the Company in writing of his objection to such proposal prior to such meeting and subsequently raised his objection at the meeting may request the Company to purchase all of his Shares at the then prevailing fair price within twenty (20) days after the date of the resolution. In the event the Company fails to reach such agreement with the Shareholder within sixty (60) days after the date of the resolution, the Shareholder may, within thirty (30) days after such sixty (60)-day period, file a petition to any competent court of Taiwan for a ruling on the appraisal price, and, to the extent that the ruling is capable of enforcement and recognition outside Taiwan, such ruling by such Taiwan court shall be binding and conclusive as between the Company and requested</td>
<td>Subject to the Law, in the event any of the resolutions with respect to the paragraph (a), (b), or (c) of Article 32 or Spin-off, Merger, Acquisition or share swap of the Company is adopted by general meeting, any Shareholder who has voted against such matter or forfeited his right to vote on such matter and expressed his dissent therefor, in writing or verbally (with a record) before or during the general meeting may request in writing the Company to purchase all of his Shares at the then prevailing fair price and specify the purchase price within twenty (20) days after the date of the resolution. In the event the Company fails to reach such agreement with the Shareholder within sixty (60) days after the date of the resolution, the Company shall apply to any competent court of Taiwan for a ruling on the fair price against all the dissenting shareholders as the opposing party within thirty (30) days</td>
<td>To revise according to the &quot;Checking List of Protecting Rights of Foreign Issuer's Shareholders in the Country of Registration&quot; promulgated by a TWSE announcement Tai-Zheng-Shan-Second-No. 1111704301 dated January 9, 2023 and to consolidate the original paragraphs 2 and 4 into paragraph 1.</td>
</tr>
</tbody>
</table>
between the Company and requested Shareholder solely with respect to the appraisal price.

Subject to the Law, in the event any of the resolutions with respect to the Company’s Spin-off, Merger, Acquisition or share swap, the Shareholder, who has forfeited his right to vote on such matter and expressed his dissent therefor, in writing or verbally (with a record) before or during the general meeting, may request the Company to purchase all of his Shares in writing within twenty (20) days after the date of the resolution and specifies the price of the Shares to be repurchased.

For the purpose of this Article 34, if the Company and any Shareholder reach an agreement about the price of the Shares to be repurchased by the Company, the Company shall pay for such agreed purchase price of Shares to be repurchased within ninety (90) days from the date of passing of the resolution by general meeting. In case no agreement as to the purchase price is reached, the Company shall pay the fair price as determined by the Company to such Shareholder within ninety (90) days from the date on which the resolution was adopted. If the Company fails to pay the agreed purchase price, the Company shall be deemed to agree to the price as requested by the Shareholder.

For the Shareholder who requests the Company to purchase all of his Shares in accordance with the second paragraph, in the event the Company fails to reach such opposing party within thirty (30) days after such sixty (60)-day period, and Taiwan Taipei District Court may have the jurisdiction of first instance. To the extent that the ruling is capable of enforcement and recognition outside Taiwan, such ruling by such Taiwan court shall be binding and conclusive as between the Company and requested Shareholder solely with respect to the appraisal price.

The number of shares held by the shareholders who forfeited his right to vote shall not be counted toward the number of votes represented by the Shareholders present at a general meeting.

For the purpose of this Article 34, if the Company and any Shareholder reach an agreement about the price of the Shares to be repurchased by the Company, the Company shall pay for such agreed purchase price of Shares to be repurchased within ninety (90) days from the date of passing of the resolution by general meeting. In case no agreement as to the purchase price is reached, the Company shall pay the fair price as determined by the Company to such Shareholder within ninety (90) days from the date on which the resolution was adopted. If the Company fails to pay the agreed purchase price, the Company shall be deemed to agree to the price as requested by the Shareholder.

新增第2項，並將本條原第2項及第4項規定併於第1項條文中。
agreement with the Shareholder within sixty (60) days after the date on which the resolution was adopted, the Company shall apply to the court for a ruling on the price of the Shares to be repurchased against all the dissenting shareholders as the opposing party within thirty (30) days after such sixty-day period, and Taiwan Taipei District Court has the jurisdiction.

In accordance with the provisions of Paragraph 32 of the Act, if any party objects to the resolution as adopted, the Company shall, within sixty (60) days from the date on which the resolution was adopted, apply to the court for a ruling on the price of the Shares to be repurchased against all the dissenting Shareholders as the opposing party within thirty (30) days after such sixty-day period, and Taiwan Taipei District Court has the jurisdiction.

The Company shall apply to the court for a ruling on the price of the Shares to be repurchased against all the dissenting Shareholders as the opposing party within thirty (30) days after such sixty-day period, and Taiwan Taipei District Court has the jurisdiction.

In this case, the Company shall apply to the court for a ruling on the price of the Shares to be repurchased against all the dissenting Shareholders as the opposing party within thirty (30) days after such sixty-day period, and Taiwan Taipei District Court has the jurisdiction.

The Company shall apply to the court for a ruling on the price of the Shares to be repurchased against all the dissenting Shareholders as the opposing party within thirty (30) days after such sixty-day period, and Taiwan Taipei District Court has the jurisdiction.
A Director who directly or indirectly has personal interest in the matter proposed at the meeting of the Board, including but not limited to a contract or proposed contract or arrangement with the Company shall disclose the nature of his or her personal interest at the meeting of the Board, if he or she knows his or her personal interest then exists, or in any other case at the first meeting of the Board after he or she knows that he or she is or has become so interested. For the purposes of this Article, a general notice to the Board by a Director to the effect that:

(a) he is a member or officer of a specified company or firm and is to be regarded as interested in any contract or arrangement which may after the date of the notice be made with that company or firm; or

(b) he is to be regarded as interested in any contract or arrangement which may after the date of the notice be made with a specified person who is connected with him;

To revise according to the "Checking List of Protecting Rights of Foreign Issuer's Shareholders in the Country of Registration" promulgated by a TSE announcement Tai-Zheng-Shan-Second-No. 1111704301 dated 9 January 2023.
shall be deemed to be a sufficient disclosure of personal interest under this Article in relation to any such contract or arrangement, provided that no such notice shall be effective unless it is given at a meeting of the Board or the Director takes reasonable steps to secure that it is brought up and read at the next Board meeting after it is given.

To the extent required by Applicable Listing Rules, a Director may not vote for himself or on behalf of another Director in respect to any matter, including but not limited to any contract or proposed contract or arrangement or contemplated transaction of the Company, in which such Director bears a personal interest (whether directly or indirectly) which may conflict with and impair the interest of the Company.

Any votes cast by or on behalf of such Director in contravention of the foregoing shall not be counted by the Company, but such Director shall be counted in the quorum for purposes of convening such meeting.

Notwithstanding the first paragraph of this Article, if any Director has personal interest (whether directly or indirectly) in matters on agenda for the Board meeting, a Director who has a personal interest in the resolution of Merger, Acquisition, Spin-off or share swap, a Director who has a personal interest in the transaction of Merger, Acquisition, Spin-off or share swap, a Director who has a personal interest in the
swap shall declare such interest to the Board at the Board meeting and to the shareholders at the general meeting the essential contents of such personal interest and the reasons that the relevant resolution shall be approved or dissented.

In the case that a Director's spouse, a blood relative within second degree of kinship or a company which has parent-subsidiary relationship with the Director has personal interest in a matter on agenda for the Board meeting, such Director shall be deemed to have personal interest in that matter.

The Company shall also elaborate the essential contents of the Director's personal interest and the reason for approving or dissenting the resolution of the Acquisition in the reasons for convening this general meeting; such content shall be published on a website designated by the Taiwan securities competent authorities or the Company, and the URL of such website shall be specified on the general meeting notice.

In the case that a Director's spouse, a blood relative within second degree of kinship or a company which has parent-subsidiary relationship with the Director has personal interest in a matter on agenda for the Board meeting, such Director shall be deemed to have personal interest in that matter.

The Company shall also elaborate the essential contents of the Director's personal interest and the reason for approving or dissenting the resolution of the Acquisition in the reasons for convening this general meeting; such content shall be published on a website designated by the Taiwan securities competent authorities or the Company, and the URL of such website shall be specified on the general meeting notice.

In the case that a Director's spouse, a blood relative within second degree of kinship or a company which has parent-subsidiary relationship with the Director has personal interest in a matter on agenda for the Board meeting, such Director shall be deemed to have personal interest in that matter.

The Company shall also elaborate the essential contents of the Director's personal interest and the reason for approving or dissenting the resolution of the Acquisition in the reasons for convening this general meeting; such content shall be published on a website designated by the Taiwan securities competent authorities or the Company, and the URL of such website shall be specified on the general meeting notice.

In the case that a Director's spouse, a blood relative within second degree of kinship or a company which has parent-subsidiary relationship with the Director has personal interest in a matter on agenda for the Board meeting, such Director shall be deemed to have personal interest in that matter.

The Company shall also elaborate the essential contents of the Director's personal interest and the reason for approving or dissenting the resolution of the Acquisition in the reasons for convening this general meeting; such content shall be published on a website designated by the Taiwan securities competent authorities or the Company, and the URL of such website shall be specified on the general meeting notice.

In the case that a Director's spouse, a blood relative within second degree of kinship or a company which has parent-subsidiary relationship with the Director has personal interest in a matter on agenda for the Board meeting, such Director shall be deemed to have personal interest in that matter.

The Company shall also elaborate the essential contents of the Director's personal interest and the reason for approving or dissenting the resolution of the Acquisition in the reasons for convening this general meeting; such content shall be published on a website designated by the Taiwan securities competent authorities or the Company, and the URL of such website shall be specified on the general meeting notice.
送後之董事會議中被提出並審閱。
如上市(欄)法令有所要求，董事對於董事會議之事項，包括但不限於契約或契約之提案或協議或本公司擬進行之交易，有自身利害關係(無論直接或間接)致有害於本公司利益之處時，不得加入表決，並不得代理他董事行使表決權。董事違反前述規定親自或由代理人行使之表決權，本公司應不予計算，但該董事仍應計入該次會議之法定出席數。

不論本條第一項內容如何，如任何董事對於董事會議之事項，有自身利害關係(論述直接或間接)時，該董事應於當次董事會揭露並說明其自身利害關係之重要內容；於公司決議進行合併、收購、分割或股份轉換時，董事應向董事會及股東會說明其與合併、收購、分割或股份轉換交易自身利害關係之重要內容及贊成或反對併購決議之理由。

董事之配偶、二親等內血親，或與董事具有控制從屬關係之公司，就董事會之議事事項有利害關係者，視為董事就該事項有自身利害關係。

知發後送後可能與該公司或附屬簽署之契約或協議應認為有利害關係；或

(b) 其就該通知發後送後可能與和其具有關係之特定人簽署之契約或協議應認為有利害關係；

應視為已依本條關於該等契約或協議之自身利害關係為適當之揭露，但此等通知僅有於董事會會議中為之或該董事採取合理步驟以確保該通知能於其發送後立刻董事會會議中被提出並審閱。

如上市(欄)法令有所要求，董事對於董事會議之事項，包括但不限於契約或契約之提案或協議或本公司擬進行之交易，有自身利害關係(無論直接或間接)致有害於本公司利益之處時，不得加入表決，並不得代理他董事行使表決權。董事違反前述規定親自或由代理人行使之表決權，本公司應不予計算，但該董事仍應計入該次會議之法定出席數。

不論本條第一項內容如何，如任何董事對於董事會之事項，有自身利害關係(論述直接或間接)時，該董事應於當次董事會揭露並說明其自身利害關係之重要內容；於公司決議進行合併、收購、分割或股份轉換時，董事應向董事會及股東會說明其與合併、收購、分割或股份轉換交易自身利害關係之重要內容及贊成或反對併購決議之理由，公司並應於股東會召集書中敘明董事利害關係之重要內容及贊成或反對併購決議之理由，其內容得置於中華民國證券主管機關或公司指定之網站，並應將其網址
<table>
<thead>
<tr>
<th>截明於股東會開會通知。</th>
</tr>
</thead>
<tbody>
<tr>
<td>董事之配偶、二親等內血親，或與董事具有控制從屬關係之公司，就董事會之會議事項有利害關係者，視為董事就該事項有自身利害關係。</td>
</tr>
</tbody>
</table>
# Tanvex BioPharma Inc

List of removal of non-compete agreement for directors.

<table>
<thead>
<tr>
<th>Director's name</th>
<th>Concurrent positions in other companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Yun Yen</td>
<td>• Chair Professor for doctorate curriculum of cancer biology and drug research in Taipei Medical University</td>
</tr>
<tr>
<td></td>
<td>• Distinguished Professor in Tzu-Chi University</td>
</tr>
<tr>
<td></td>
<td>• Consultant of Cell Therapy Center in Tzu-Chi Hospital (Hualian)</td>
</tr>
<tr>
<td></td>
<td>• Voluntary Chairman of Sino American Cancer Foundation</td>
</tr>
<tr>
<td></td>
<td>• Chief Scientific Adviser of Stembios</td>
</tr>
<tr>
<td></td>
<td>• Director of Calgent Biotechnology Co. Ltd.</td>
</tr>
<tr>
<td></td>
<td>• Director of Lixte Biotech USA</td>
</tr>
<tr>
<td></td>
<td>• Part-time Professor of California Institute of Technology</td>
</tr>
<tr>
<td></td>
<td>• Part-time Research Fellow in Institute of Biological Chemistry, Academia Sinica</td>
</tr>
<tr>
<td></td>
<td>• Director of Theragent Inc.</td>
</tr>
<tr>
<td></td>
<td>• Director of Nano Targeting &amp; Therapy Biopharma Inc.</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director Representative of Obigen Pharma Inc.</td>
</tr>
<tr>
<td></td>
<td>• Director of the National Institutes of Health</td>
</tr>
<tr>
<td></td>
<td>• Director and Chairman of Tanvex BioPharma Inc. (Taiwan)</td>
</tr>
<tr>
<td></td>
<td>• Director and Chairman of Tanvex BioPharma USA, Inc.</td>
</tr>
<tr>
<td></td>
<td>• Director and CEO concurrently of OBI Pharma, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mr. Chen, Chi-Chuan (Representative of Peng-Lin Investment Limited)</th>
<th>Corporate Director Representative of Nan Shan Life Insurance Co., Ltd.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Corporate Director Representative of Mirror Vision Inc.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of Miho International Cosmetic Co., Ltd.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of Mega Growth Venture Capital Co., Ltd.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of Brogent Technologies Inc.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of Theragent Inc.</td>
</tr>
<tr>
<td></td>
<td>GP Partner and Director of Delos Capital Holdings Limited</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of RenBio, Inc.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of RenBio Holding Ltd. (Cayman Island)</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of Cotton Field Organic Co., Ltd.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative (Chairman) of Obigen Pharma Inc.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of Amaran Biotechnology Inc.</td>
</tr>
<tr>
<td></td>
<td>Corporate Director Representative of Mithra Chemical Analysis Laboratory Inc.</td>
</tr>
<tr>
<td>Director’s name</td>
<td>Concurrent positions in other companies</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director Representative of Do-Intelligent Consulting Inc.</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director Representative of Mass Solutions Technology Co., Ltd.</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director Representative of Mithra Biotechnology Inc.</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director representative (Chairman) AP Biosciences Inc.</td>
</tr>
<tr>
<td></td>
<td>• CFO of OBI Pharma Inc.</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director Representative of OBI Pharma Inc.</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director Representative of TaiMed Biologics Inc.</td>
</tr>
<tr>
<td></td>
<td>• Corporate Director Representative of Tanvex Biologics Inc.</td>
</tr>
<tr>
<td>Provisions after amendment</td>
<td>Existing clause</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Article 3</td>
<td>Article 3</td>
</tr>
<tr>
<td><strong>Omitted below.</strong></td>
<td>Omitted below.</td>
</tr>
<tr>
<td>Article 6-1</td>
<td>Article 6-1</td>
</tr>
<tr>
<td><strong>To convene a virtual shareholders meeting,</strong></td>
<td><strong>To convene a virtual shareholders meeting,</strong></td>
</tr>
<tr>
<td><strong>this Corporation shall include the follow particulars in the shareholders meeting notice:</strong></td>
<td><strong>this Corporation shall include the follow particulars in the shareholders meeting notice:</strong></td>
</tr>
<tr>
<td>Paragraphs 1 and 2 omitted. 3. To convene a virtual-only shareholders meeting, appropriate alternative measures available to shareholders with difficulties in attending a virtual shareholders meeting online shall be specified.</td>
<td>Paragraphs 1 and 2 omitted. 3. To convene a virtual-only shareholders meeting, appropriate alternative measures available to shareholders with difficulties in attending a virtual shareholders meeting online shall be specified.</td>
</tr>
</tbody>
</table>
In addition to the circumstances specified in Paragraph 6, Article 44-9 of the Regulations Governing Shareholder Affairs of Public Companies, the Company shall at least provide shareholders with connection equipment and necessary assistance, and shall specify the period during which shareholders may apply to the Company and other relevant matters needing attention.

| II. In the event of a special circumstance as set forth in Article 44-9, Paragraph 6 of the Regulations Governing Shareholder Affairs of Public Companies, where a shareholders’ meeting is held via video conference within a period of time without meeting the provisions of the Articles of Incorporation due to a natural disaster, event or other force majeure, as announced by the Ministry of Economic Affairs, new exclusion to Subparagraph 3, specifying that the end part of Subparagraph 3 shall not apply in the event of a circumstance as set forth in Paragraph 6 of Article 44-9. |

the use of the connection equipment, an end part was added to Subparagraph 3, specifying that the Company shall convene a shareholders’ meeting via video conference by at least providing shareholders with connection equipment, venue and assigning relevant personnel to provide assistance necessary for shareholders to participate in the meeting, and shall specify in the notice of the shareholders’ meeting the period during which shareholders may apply to the Company and other relevant matters to note.
<table>
<thead>
<tr>
<th>Article 22</th>
<th>Article 22</th>
<th>The reason for the amendment is the same as Article 6-1.</th>
</tr>
</thead>
<tbody>
<tr>
<td>When convening a virtual-only shareholders meeting, this Corporation shall provide appropriate alternative measures available to shareholders with difficulties in attending a virtual shareholders meeting online. In addition to the circumstances specified in Paragraph 6, Article 44-9 of the Regulations Governing Shareholder Affairs of Public Companies, the Company shall at least provide shareholders with connection equipment and necessary assistance, and shall specify the period during which shareholders may apply to the Company and other relevant matters needing attention.</td>
<td>When convening a virtual-only shareholders meeting, this Corporation shall provide appropriate alternative measures available to shareholders with difficulties in attending a virtual shareholders meeting online.</td>
<td></td>
</tr>
</tbody>
</table>
IV. Appendices
Article 1 Basis for the adoption of these Rules
To establish a strong governance system and sound supervisory capabilities for this Corporation's board of directors and to strengthen management capabilities, these Rules are adopted pursuant to Article 2 of the Regulations Governing Procedure for Board of Directors Meetings of Public Companies.

Article 2 Scope of these Rules
With respect to the board of director meetings ("board meetings") of this Corporation, the main agenda items, working procedures, required content of meeting minutes, public announcements, and other compliance requirements shall be handled in accordance with the provisions of these Rules.

Article 3 Convening and notice of board meetings
The board of directors shall meet at least quarterly.
A notice of the reasons for convening a board meeting shall be given to each director and supervisor before 7 days before the meeting is convened. In emergency circumstances, however, a board meeting may be called on shorter notice.
The notice to be given under the preceding paragraph may be affected by means of electronic transmission with the prior consent of the recipients.
All matters set forth under Article 12, paragraph 1 of these Rules shall be specified in the notice of the reasons for convening a board meeting. None of those matters may be raised by an extraordinary motion except in the case of an emergency or for other legitimate reason.

Article 4 Meeting notification and meeting materials
The designated unit responsible for the board meetings of this Corporation shall be Administrative department.
The unit responsible for board meetings shall draft agenda items and prepare sufficient meeting materials, and shall deliver them together with the notice of the meeting.
A director who is of the opinion that the meeting materials provided are insufficient may request their supplementation by the unit responsible for board meetings. If a director is of the opinion that materials concerning any proposal are insufficient, the deliberation of such proposal may be postponed by a resolution of the board of directors.

**Article 5 Preparation of attendance book and other documents; attendance by proxy**

When a board meeting is held, an attendance book shall be provided for signing-in by attending directors, which shall be made available for future reference.

Directors shall attend board meetings in person. A director unable to attend in person may appoint another director to attend the meeting in his or her place in accordance with this Corporation's articles of incorporation. Attendance by videoconference will be deemed attendance in person.

A director who appoints another director to attend a board meeting shall in each instance issue a proxy form stating the scope of authorization with respect to the reasons for convening the meeting.

The proxy referred to in paragraph 2 may be the appointed proxy of only one person.

**Article 6 Principles for determining the place and time of a board meeting**

A board meeting shall be held at the premises and during the business hours of this Corporation, or at a place and time convenient for all directors to attend and suitable for holding board meetings.

**Article 7 Chair and acting chair of a board meeting**

Board meetings shall be convened and chaired by the chairperson of the board. However, with respect to the first meeting of each newly elected board of directors, it shall be called and chaired by the director that received votes representing the largest portion of voting rights at the shareholders meeting in which the directors were elected; if two or more directors are so entitled to convene the meeting, they shall select from among themselves one director to serve as chair.

When the chairperson of the board is on leave or for any reason unable to exercise the powers of chairperson, the vice chairperson shall act in place of the chairperson; if there is no vice chairperson or the vice chairperson is also on leave or for any reason unable to exercise the powers of vice chairperson, the chairperson shall appoint one of the managing directors to act, or, if there are no managing directors, one of the directors shall be appointed to act as chair. If no such designation is made by the
chairperson, the managing directors or directors shall select one person from among themselves to serve as chair.

**Article 8 Reference materials, non-voting participants, and holding board meetings**

When a board meeting is held, the management (or the designated unit responsible for the board meetings) shall furnish the attending directors with relevant materials for ready reference.

As merited by the content of a proposal to be put forward at a board meeting, personnel from a relevant department or a subsidiary may be notified to attend the meeting as non-voting participants.

When necessary, certified public accountants, attorneys, or other professionals retained by this Corporation may also be invited to attend the meeting as non-voting participants and to make explanatory statements, provided that they shall leave the meeting when deliberation or voting takes place.

The chair shall call the board meeting to order at the appointed meeting time and when more than one-half of all the directors are in attendance.

If one-half of all the directors are not in attendance at the appointed meeting time, the chair may announce postponement of the meeting time, provided that no more than two such postponements may be made. If the quorum is still not met after two postponements, the chair shall reconvene the meeting in accordance with the procedures in Article 3, paragraph 2.

The number of "all directors," as used in the preceding paragraph and in Article 16, paragraph 2, subparagraph 2, shall be counted as the number of directors then actually in office.

**Article 9 Documentation of a board meeting by audio or video**

Proceedings of a board meeting shall be recorded in their entirety in audio or video, and the recording shall be retained for a minimum of 5 years. The record may be retained in electronic form.

If any litigation arises with respect to a resolution of a board meeting before the end of the retention period of the preceding paragraph, the relevant audio or video record shall be retained until the conclusion of the litigation.

Where a board meeting is held by videoconference, the audio or video documentation of the meeting constitutes part of the meeting minutes and shall be retained for the duration of the existence of this Corporation.
Article 10 Agenda items
Agenda items for regular board meetings of this Corporation shall include at least the following:

1. Matters to be reported:
   (1) Minutes of the last meeting and action taken.
   (2) Important financial and business matters.
   (3) Internal audit activities.
   (4) Other important matters to be reported.

2. Matters for discussion:
   (1) Items for continued discussion from the last meeting.
   (2) Items for discussion at this meeting.

3. Extraordinary motions.

Article 11 Discussion of proposals
A board meeting shall follow the agenda given in the meeting notice. However, the agenda may be changed with the approval of a majority of directors in attendance at the board meeting.

The chair may not declare the meeting closed without the approval of a majority of the directors in attendance at the meeting.

At any time during the course of a board meeting, if the number of directors sitting at the meeting does not constitute a majority of the attending directors, then upon the motion by a director sitting at the meeting, the chair shall declare a suspension of the meeting, in which case Article 8, paragraph 5 shall apply mutatis mutandis.

Article 12 Matters requiring discussion at a board meeting
The matters listed below as they relate to this Corporation shall be raised for discussion at a board meeting:

1. The Corporation's business plan.

2. Annual and semi-annual must be audited and attested by a certified public accountant (CPA).

3. Adoption or amendment of an internal control system pursuant to Article 14-1 of the Securities and Exchange Act and assessment of the effectiveness of the internal control system.

4. Adoption or amendment, pursuant to Article 36-1 of the Securities and Exchange
Act, of any handling procedures for material financial or business transactions, such as the acquisition or disposal of assets, derivatives trading, loans of funds to others, and endorsements or guarantees for others.

5. The offering, issuance, or private placement of equity-type securities.

6. The appointment or discharge of a financial, accounting, or internal audit officer.

7. A donation to a related party or a major donation to a non-related party, provided that a public-interest donation of disaster relief that is made for a major natural disaster may be submitted to the following board of directors meeting for retroactive recognition.

8. Any matter that, under Article 14-3 of the Securities and Exchange Act or any other law, regulation, or bylaw, must be approved by resolution at a shareholders meeting or board meeting, or any material matter as may be prescribed by the competent authority.

The term "related party" in subparagraph 7 of the preceding paragraph means a related party as defined in the Regulations Governing the Preparation of Financial Reports by Securities Issuers. The term "major donation to a non-related party" means an individual donation, or cumulative donations within a 1-year period to a single recipient, at an amount of NTD100 million or more, or at an amount equal to or greater than 1 percent of net operating revenue or 5 percent of paid-in capital as stated in the CPA-attested financial report for the most recent year. (In the case of a foreign issuer whose shares have no par value or a par value other than NT$10, 2.5 percent of shareholders' equity shall be substituted for the calculation of the amount equal to 5 percent of paid-in capital required under this paragraph.)

The term "within a 1-year period" in the preceding paragraph means a period of 1 year calculated retroactively from the date on which the current board of directors meeting is convened. Amounts already submitted to and passed by a resolution of the board are exempted from inclusion in the calculation.

At least one independent director of this Corporation shall attend the meeting in person. With respect to the matters which must be approved by resolutions at a board meeting as provided in the first paragraph, any and all independent directors shall
attend the meeting. Where an independent director is unable to attend the meeting, that independent director shall appoint another independent director to attend the meeting as proxy. If an independent director objects to or expresses reservations about such a matter, it shall be recorded in the board meeting minutes; if an independent director intends to express an objection or reservation but is unable to attend the meeting in person, then unless there is a legitimate reason to do otherwise, that director shall issue a written opinion in advance, which shall be recorded in the board meeting minutes.

Article 13 Voting-I
When the chair at a board meeting is of the opinion that a proposal has been discussed sufficiently to put it to a vote, the chair may announce the discussion closed and call a vote.
When a proposal comes to a vote at a board meeting, if no attending director voices an objection following an inquiry by the chair, the proposal will be deemed approved. If there is an objection following an inquiry by the chair, the proposal shall be brought to a vote.
One voting method for proposals at a board meeting shall be selected by the chair from among those below, provided that when an attending director has an objection, the chair shall seek the opinion of the majority to make a decision:
1. A show of hands or a vote by voting machine.
2. A roll call vote.
3. A vote by ballot.
4. A vote by a method selected at this Corporation's discretion.

"Attending directors," as used in the preceding two paragraphs, does not include directors that may not exercise voting rights pursuant to Article 15, paragraph 1.

Article 14 Voting-II and methods for vote monitoring and counting
Except where otherwise provided by the Securities and Exchange Act and the Company Act, the passage of a proposal at a board meeting shall require the approval of a majority of the directors in attendance at a board of directors meeting attended by a majority of all directors.
When there is an amendment or alternative to a proposal, the chair shall present the amended or alternative proposal together with the original proposal and decide the
order in which they will be put to a vote. If anyone among them is passed, the other proposals shall then be deemed rejected, and no further voting on them shall be required. If a vote on a proposal requires monitoring and counting personnel, the chair shall appoint such personnel, providing that all monitoring personnel shall be directors. Voting results shall be made known on-site immediately and recorded in writing.

**Article 15 Recusal system for directors**

If a director or a juristic person that the director represents is an interested party in relation to an agenda item, the director shall state the important aspects of the interested party relationship at the respective meeting. When the relationship is likely to prejudice the interest of this Corporation, that director may not participate in discussion or voting on that agenda item and shall recuse himself or herself from the discussion or the voting on the item, and may not exercise voting rights as proxy for another director.

Where a director is prohibited by the preceding paragraph from exercising voting rights with respect to a resolution at a board meeting, the provisions of Article 180, paragraph 2 of the Company Act apply mutatis mutandis in accordance with Article 206, paragraph 3 of the same Act.

**Article 16 Meeting minutes and sign-in matters**

Discussions at a board meeting shall be recorded in the meeting minutes, and the minutes shall fully and accurately state the matters listed below:

1. The meeting session (or year) and the time and place of the meeting.
2. The name of the chair.
3. The directors' attendance at the meeting, including the names and the number of directors in attendance, excused, and absent.
4. The names and titles of those attending the meeting as non-voting participants.
5. The name of the minute taker.
6. The matters reported at the meeting.
7. Agenda items: the method of resolution and the result for each proposal; a summary of the comments made by directors, supervisors, experts, or other persons; the name of any director that is an interested party as referred to in paragraph 1 of the preceding article, an explanation of the important aspects of the relationship of interest, the reasons why the director was required or not required
to enter recusal, and the status of their recusal; opinions expressing objections or reservations at the meeting that were included in records or stated in writing; and any opinion issued in writing by an independent director pursuant to Article 12, paragraph 4.

8. Extraordinary motions: The name of the mover, the method of resolution and the result, a summary of the comments of any director, supervisor, expert, or other person; the name of any director that is an interested party as referred to in paragraph 1 of the preceding article, an explanation of the important aspects of their relationship of interest, the reasons why the director was required or not required to enter recusal, and the status of their recusal; and their objections or reservations and any recorded or written statements.

9. Other matters required to be recorded.

The occurrence of any of the following circumstances, with respect to a resolution passed at a board meeting, shall be stated in the meeting minutes and shall be publicly announced and filed on the website of the Market Observation Post System designated by the Financial Supervisory Commission, within 2 days from the date of the meeting:

1. Any objection or expression of reservations by an independent director expresses of which there is a record or written statement.

2. A resolution is adopted with the approval of two-thirds or more of all directors, without having been passed by the audit committee of this Corporation.

The attendance book constitutes part of the minutes for each board meeting and shall be retained for the duration of the existence of this Corporation.

The minutes of a board meeting shall bear the signature or seal of both the chair and the minute taker, and a copy of the minutes shall be distributed to each director and supervisor within 20 days after the meeting. The minutes shall be deemed important corporate records and appropriately preserved during the existence of this Corporation.

The meeting minutes of paragraph 1 may produce and distributed in electronic form.

**Article 17 Principles with respect to the delegation of powers by the board**

With the exception of matters required to be discussed at a board meeting under Article 12, paragraph 1, when the board of directors appoints a party to exercise the powers of the board in accordance with applicable laws and regulations or this
Corporation's articles of incorporation, the levels of such delegation and the content or matters it covers shall be definite and specific, and carried out in accordance with the principles below:

1. The acquisition and disposal of assets, extension of monetary loans to others, and endorsements or guarantees for others of the Company.

2. Investment by the Company.

3. Matters of fund utilization (including but not limited to establishing and utilizing credit line granted by banks).

4. Representing the Company to enter into any agreement, memorandum and letter of intent. If the agreement has substantial effect to the Company's operation, it shall be submitted to the following board of directors meeting for ratification.

5. Application and protection of intellectual properties of the Company.

6. Material personnel appointment and discharge, including designation and arrangement of directors, supervisors, representatives of legal persons and managerial officers for investee companies (including foreign branch), except for Article 17 of the Company's Memorandum and Articles of Association and Article 12 of the Rules.

7. Authorization for date of capital increase or capital reduction, date of declaring cash dividend of the Company.


9. Other matters approved respectively by shareholders meetings or board of directors to authorize the Chairman of the board of directors to conduct such matters in accordance with applicable laws or at his/her discretion.

**Article 18 Meetings of board of managing directors**
The provisions of Article 2, Article 3, paragraph 2, Articles 4 to 6, Articles 8 to 11, and Articles 13 to 16 apply, mutatis mutandis, to this Corporation's meetings of the board of managing directors, provided that when meetings of the board of managing directors are held at regular intervals of 7 days or less, notices of such meetings may be given to each managing director before 2 days before the meeting.

**Article 19 Supplementary provisions**
These Rules of Procedure shall be adopted by the approval of meeting of the board of directors and shall be reported to the shareholders meeting.
THE COMPANIES ACT (AS REVISED)
COMPANY LIMITED BY SHARES
NINTH AMENDED AND RESTATED

MEMORANDUM AND ARTICLES OF ASSOCIATION
OF
Tanvex BioPharma, Inc.

INCORPORATED ON THE 8TH DAY OF MAY, 2013
(Adopted by Special Resolution passed on June 17, 2022)

INCORPORATED IN THE CAYMAN ISLANDS
THE COMPANIES ACT (AS REVISED)
COMPANY LIMITED BY SHARES
NINTH AMENDED AND RESTATE
MEMORANDUM OF ASSOCIATION
OF
Tanvex BioPharma, Inc. 丹福生技股份有限公司
(Adopted by Special Resolution passed on June 17, 2022)

1. The name of the Company is Tanvex BioPharma, Inc. 丹福生技股份有限公司(“Company”).

2. The registered office of the Company will be situated at the offices of Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands or at such other location as the Directors may from time to time determine.

3. The objects for which the Company is established are unrestricted.

The Company have full power and authority to carry out any object not prohibited by any law as provided by Section 7(4) of the Companies Act of the Cayman Islands (as revised) (the “Law”).

4. The Company shall have and be capable of exercising all the functions of a natural person of full capacity irrespective of any question of corporate benefit as provided by Section 27(2) of the Law.

5. The Company will not trade in the Cayman Islands with any person, firm or corporation except in furtherance of the business of the Company carried on outside the Cayman Islands; provided that nothing in this section shall be construed as to prevent the Company effecting and concluding contracts in the Cayman Islands, and exercising in the Cayman Islands all of its powers necessary for the carrying on of its business outside the Cayman Islands.

6. The liability of the Shareholders of the Company is limited to the amount, if any, unpaid on the share respectively held by them.

7. The capital of the Company is NT$5,000,000,000 divided into 500,000,000 shares of a nominal or par value of NT$10 each provided always that subject to the Law and the Articles of Association the Company shall have power to redeem or purchase any of its shares and to sub-divide or consolidate the said shares or any of them and to issue all or any part of its capital whether original, redeemed, increased or reduced with or without any preference, priority, special privilege or other rights or subject to any postponement of rights or to any conditions or restrictions whatsoever and so that unless the conditions of issue shall otherwise expressly provide every issue of shares whether stated to be ordinary, preference or otherwise shall be subject to the powers on the part of the Company hereinbefore provided.

8. The Company may exercise the power contained in Section 206 of the Law to deregister in the Cayman Islands and be registered by way of continuation in some other jurisdiction.
THE COMPANIES ACT (AS REVISED)
COMPANY LIMITED BY SHARES
NINTH AMENDED AND RESTATED
ARTICLES OF ASSOCIATION

OF
Tanvex BioPharma, Inc. 泰福生技股份有限公司
(Adopted by Special Resolution passed on June 17, 2022)

TABLE A

The Regulations contained or incorporated in Table 'A' in the First Schedule of the Law shall not apply to Tanvex BioPharma, Inc. 泰福生技股份有限公司 (the "Company") and the following Articles shall comprise the Articles of Association of the Company.

INTERPRETATION

1. In these Articles the following defined terms will have the meanings ascribed to them, if not inconsistent with the subject or context:

"Acquisition" refers to an act wherein a company acquiring shares, business or assets of another company in exchange for shares, cash or other assets;

"Affiliated Company" means with respect to any affiliated company as defined in the Applicable Listing Rules;

"Applicable Listing Rules" means the relevant laws, regulations, rules and code as amended, from time to time, applicable as a result of the original and continued trading or listing of any Shares on any Taiwan stock exchange or securities market, including, without limitation the relevant provisions of Taiwan Company Act, Securities and Exchange Act, the Acts Governing Relations Between Peoples of the Taiwan Area and the Mainland Area, or any similar statute and the rules and regulations of the Taiwan authorities thereunder, and the rules and regulations promulgated by the Financial Supervisory Commission, the TPEx or the Taiwan Stock Exchange;

"Articles" means these articles of association of the Company, as amended or substituted from time to time;

"Audit Committee" means the audit committee of the Company formed by the Board pursuant to Article 118 hereof, or any successor audit committee;

"Book-Entry Transfer" means a method whereby the issue, transfer or delivery of Shares is effected electronically by debit and credit to accounts opened with securities firms by Shareholders, without delivering physical share certificates. If the Shareholder has not opened an account with a securities firm, the Shares delivered by Book-Entry Transfer shall be recorded in the entry sub-account under the Company's account with the securities central depositary in Taiwan;

"Capital Reserves" means the share premium account, income from endowments received by the Company, capital redemption reserve, profit and loss account and other reserves generated...
in accordance with generally accepted accounting principles.

“Chairman” has the meaning given thereto in Article 82;

“Class” or “Classes” means any class or classes of Shares as may from time to time be issued by the Company;

“Commission” means Financial Supervisory Commission of Taiwan or any other authority for the time being administering the Securities and Exchange Act of Taiwan;

“Common Share” means a common share in the capital of the Company of NT$10 nominal or par value issued subject to and in accordance with the provisions of the Law and these Articles, and having the rights and being subject to restrictions as provided for under these Articles with respect to such Share;

“Constituent Company” means an existing company that is participating in a Merger with one (1) or more other existing companies within the meaning of the Law;

“Directors” and “Board of Directors” and “Board” means the directors of the Company for the time being, or as the case may be, the directors assembled as a board or as a committee thereof;

“Delisting” means (a) the delisting of the Shares registered or listed on any Taiwan stock exchange or securities market as a result of a Merger in which the Company will dissolve, general assumption (as defined in the Applicable Listing Rules), share swap (as defined in the Applicable Listing Rules) or Spin-off; and (b) the shares of the surviving company in the Merger, the transferee company in the general assumption or the existing company or newly-incorporated company in the share swap or Spin-off will not be registered or listed on any Taiwan stock exchange or securities market;

“electronic” shall have the meaning given to it in the Electronic Transactions Act (as amended) of the Cayman Islands and any amendment thereto or re-enactments thereof for the time being in force and includes every other law incorporated therewith or substituted therefore;

“electronic communication” means transmission to any number, address or internet website or other electronic delivery methods as otherwise decided and approved by not less than two-thirds (2/3) of the vote of the Board;

“Emerging Market” means the emerging market board of TPEx in Taiwan;

“Family Relationship within Second Degree of Kinship” in respect of a natural person, means another natural person who is related to the first person either by blood or by marriage of a member of the family and within the second degree to include but not limited to the parents, siblings, grandparents, children and grandchildren of the first person as well as the first person’s spouse’s parents, siblings and grandparents;

“Guidelines Governing Election of Directors” means guidelines governing election of Directors of the Company, as amended or substituted from time to time as prescribed in the Applicable Listing Rules;

“Hybrid General Meeting” means a general meeting held at a physical location and electronically, providing the Shareholders with the option to attend either in person or by visual communication network, as defined in the Applicable Listing Rules;

“Indemnified Person” has the meaning given thereto in Article 152;
"Independent Director" means a director who is an independent director as defined in the Applicable Listing Rules;

"Law" means the Companies Act of the Cayman Islands (as revised);

"Legal Reserves" the legal reserve allocated in accordance with the Applicable Listing Rules;

"Memorandum of Association" means the memorandum of association of the Company, as amended or substituted from time to time;

"Merger" means the merging of two (2) or more Constituent Companies and the vesting of their undertaking, property and liabilities in one (1) of such companies as the Surviving Company within the meaning of the Law;

"MOEA" means Ministry of Economic Affairs of Taiwan being administering the Company Act of Taiwan and relevant corporate matters in Taiwan;

"Office" means the registered office of the Company as required by the Law;

"Ordinary Resolution" means a resolution passed by a simple majority of such Shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the Company and where a poll is taken regard shall be had in computing a majority to the number of votes to which each Shareholder is entitled;

"paid up" means paid up as to the par value and any premium payable in respect of the issue of any Shares and includes credited as paid up;

"Person" means any natural person, firm, company, joint venture, partnership, corporation, association or other entity (whether or not having a separate legal personality) or any of them as the context so requires;

"preferred Shares" has the meaning given thereto in Article 10;

"Procedural Rules of Board Meetings" means procedural rules of the Board meetings of the Company, as amended or substituted from time to time as prescribed in the Applicable Listing Rules;

"Procedural Rules of General Meetings" means procedural rules of the general meetings of the Company, as amended or substituted from time to time as prescribed in the Applicable Listing Rules;

"Register" or "Register of Members" means the register of Members of the Company required to be kept pursuant to the Law;

"Republic of China" or "Taiwan" means the Republic of China, its territories, its possessions and all areas subject to its jurisdiction;

"Retained Earnings" means the sums including but not limited to the Legal Reserves, Special Reserves, and unappropriated earnings;

"Rules of Audit Committee" means rules of Audit Committee of the Company, as amended or substituted from time to time as prescribed in the Applicable Listing Rules;

"Seal" means the common seal of the Company (if adopted) including any facsimile thereof;
"Secretary" means any Person appointed by the Directors to perform any of the duties of the secretary of the Company;

"Share" means a share in the capital of the Company. All references to "Shares" herein shall be deemed to be Shares of any or all Classes as the context may require. For the avoidance of doubt in these Articles the expression "Share" shall include a fraction of a Share;

"Shareholder" or "Member" means a Person who is registered as the holder of Shares in the Register;

"Share Premium Account" means the share premium account established in accordance with these Articles and the Law;

"Shareholders’ Service Agent" means the agent licensed by Taiwan authorities to provide certain shareholders services in accordance with the Applicable Listing Rules to the Company;

"signed" means bearing a signature or representation of a signature affixed by mechanical means or an electronic symbol or process attached to or logically associated with an electronic communication and executed or adopted by a person with the intent to sign the electronic communication;

"Special Reserves" means the reserve allocated from Retained Earnings in accordance with the Applicable Listing Rules, or resolutions of shareholders meetings;

"Special Resolution" means a special resolution of the Company passed in accordance with the Law, being a resolution passed by a majority of not less than two-thirds (2/3) of such Shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the Company of which notice specifying the intention to propose the resolution as a special resolution has been duly given and where a poll is taken regard shall be had in computing a majority to the number of votes to which each Shareholder is entitled;

"Spin-off" refers to an act wherein a transferor company transfers all of its independently operated business or any single independently operated business to an existing or a newly incorporated company as consideration for that existing transferee company or newly incorporated transferee company to issue new shares to the transferor company or to shareholders of the transferor company;

"Supermajority Resolution Type A" means a resolution passed by Shareholders, as being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting, such Shareholders holding not less than half of the Shares held by all Shareholders attending that meeting, and such meeting attended by Shareholders holding not less than two-thirds (2/3) of all issued Shares of the Company;

"Supermajority Resolution Type B" means where the Shareholders attending the general meeting are holding less than two-thirds (2/3) of all issued Shares of the Company entitled to vote thereon as required under the Supermajority Resolution Type A, a resolution passed by Shareholders, as being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting, such Shareholders holding not less than two-thirds (2/3) of the Shares held by all Shareholders attending that meeting, and such meeting attended by Shareholders holding not less than half of all issued Shares of the Company;

"Supermajority Special Resolution" means a Special Resolution approved by the Shareholders holding at least two-thirds (2/3) of the Shares in issue at the time of the general meeting;
“Surviving Company” means the sole remaining Constituent Company into which one (1) or more other Constituent Companies are merged within the meaning of the Law;

“Treasury Shares” means Shares that were previously issued but were purchased, redeemed or otherwise acquired by the Company and not cancelled, in accordance with these Articles, the Law and the Applicable Listing Rules;

“TPEx” means Taipei Exchange;

“TSE” means the Taiwan Stock Exchange; and

“Virtual General Meeting” means a general meeting held electronically without physical presence which the Shareholders may only attend by means of visual communication network, as defined in the Applicable Listing Rules.

2. In these Articles, save where the context requires otherwise:

(a) words importing the singular number shall include the plural number and vice versa;

(b) words importing the masculine gender only shall include the feminine gender and any Person as the context may require;

(c) the word "may" shall be construed as permissive and the word "shall" shall be construed as imperative;

(d) reference to a statutory enactment shall include reference to any amendment or re-enactment thereof for the time being in force;

(e) reference to any determination by the Directors shall be construed as a determination by the Directors in their absolute discretion and shall be applicable either generally or in any particular case; and

(f) reference to "in writing" shall be construed as written or represented by any means reproducible in writing, including any form of print, lithograph, email, facsimile, photograph or telex or represented by any other substitute or format for storage or transmission for writing or partly one (1) and partly another.

3. Subject to the last two preceding Articles, any words defined in the Law shall, if not inconsistent with the subject or context, bear the same meaning in these Articles.

PRELIMINARY

4. The business of the Company may be commenced at any time after incorporation.

5. The Office shall be at such address in the Cayman Islands as the Directors may from time to time determine. The Company may in addition establish and maintain such other offices and places of business and agencies in such places as the Directors may from time to time determine.

6. The preliminary expenses incurred in the formation of the Company and in connection with the issue of Shares shall be paid by the Company. Such expenses may be amortised over such period as the Directors may determine and the amount so paid shall be charged against income and/or capital in the accounts of the Company as the Directors shall determine.

7. The Board of Directors shall keep, or cause to be kept, the Register which may be kept in or outside the Cayman Islands at such place as the Board of Directors may from time to time determine and, in the absence of any such determination, the Register shall be kept at the Office.
SHARES

8. Subject to these Articles, all Shares for the time being unissued shall be under the control of the Directors who may:

(a) issue, allot and dispose of the same to such Persons, in such manner, on such terms and having such rights and being subject to such restrictions as they may from time to time determine; and

(b) grant options with respect to such Shares and issue warrants or similar instruments with respect thereto;

and, for such purposes, the Directors may reserve an appropriate number of Shares for the time being unissued.

9. The Directors may authorise the division of Shares into any number of Classes and the different Classes shall be authorised, established and designated (or re-designated as the case may be) and the variations in the relative rights (including, without limitation, voting, dividend and redemption rights), restrictions, preferences, privileges and payment obligations as between the different Classes (if any) shall be fixed and determined by the Directors.

10. The Company may issue Shares with rights which are preferential to those of ordinary Shares issued by the Company ("preferred Shares") with the approval of a majority of the Directors present at a meeting attended by two-thirds (2/3) or more of the total number of the Directors and with the approval of a Special Resolution. Prior to the issuance of any preferred Shares approved pursuant to this Article 10, these Articles shall be amended to set forth the rights and obligations of the preferred Shares, including but not limited to the following terms, and the same shall apply to any variation of rights of preferred Shares:

(a) number of preferred Shares issued by the Company and the number of preferred Shares the Company is authorized to issue;

(b) order, fixed amount or fixed ratio of allocation of dividends and bonus on preferred Shares;

(c) order, fixed amount or fixed ratio of allocation of surplus assets of the Company;

(d) order of or restriction on the voting right(s) (including declaring no voting rights whatsoever) of preferred Shareholders;

(e) other matters concerning rights and obligations incidental to preferred Shares; and

(f) the method by which the Company is authorized or compelled to redeem the preferred Shares, or a statement that redemption rights shall not apply.

11. Subject to these Articles and the Applicable Listing Rules, the issue of new Shares of the Company shall be approved by a majority of the Directors present at a meeting attended by two-thirds (2/3) or more of the total number of the Directors. The issue of new Shares shall at all times be subject to the sufficiency of the authorised capital of the Company.

12. Subject to Article 12A, the Company shall not issue any unpaid Shares or partly paid-up Shares. The Company shall not issue shares in bearer form.

12A. If a subscriber fails to pay any call or instalment of call with respect of any Shares on the day appointment for payment, the Directors may, at any time thereafter during such time as any part of such call or instalment remains unpaid, serve a notice on him requiring payment of so much of
the call or instalment as is unpaid, together with any interest which may have accrued, within a period of not less than 1 month from the date of the notice given by the Directors. The notice shall name a further day (not earlier than the expiration of aforesaid one month or longer period from the date of the notice) on or before which the payment required by the notice is to be made, and shall state that in the event of non-payment at or before the time appointed the Shares in respect of which the call was made will be liable to be forfeited. If the requirements of any such notice as aforesaid are not complied with, any Share in respect of which the notice has been given may at any time thereafter, before the payment required by notice has been made, be forfeited by a determination of the Directors to that effect. A forfeited Share may be sold or otherwise disposed of on such terms and in such manner as the Directors think fit, and at any time before a sale or disposition the forfeiture may be cancelled on such terms as the Directors think fit. A Person whose Shares have been forfeited shall cease to be a Shareholder in respect of the forfeited Shares, but shall, notwithstanding, remain liable to pay to the Company all moneys which at the date of forfeiture were payable by him to the Company in respect of the Shares forfeited, but his liability shall cease if and when the Company receives payment in full of the amount unpaid on the Shares forfeited. The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which by the terms of issue of a Share becomes due and payable, whether on account of the amount of the Share, or by way of premium, as if the same had been payable by virtue of a call duly made and notified. Under the aforesaid circumstances, compensation for loss or damage, if any, may still be claimed against such defaulting Shareholder.

13. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, upon each issuance of new Shares, the Directors may reserve not more than fifteen percent (15%) of the new shares for subscription by the employees of the Company and/or any Subsidiaries of the Company who are determined by the Board in its reasonable discretion. The term “Subsidiaries” above refers to the companies defined under No. 10 and No. 11 of the IFRS (i.e., International Financial Reporting Standards) and No. 28 of the IAS (i.e., International Accounting Standards).

14. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, unless otherwise provided herein, in the Applicable Listing Rules or resolved by the Shareholders in general meeting by Ordinary Resolution, if at anytime the Board resolves to issue any new Shares, the Company shall, after reserving the portion of Shares for subscription by its employees and for public offering in Taiwan pursuant to Article 13 (if any) and Article 16 respectively, first offer such remaining new Shares by public announcement and a written notice to each then Shareholder for their subscriptions in proportion to the number of Shares held by them respectively. The public announcement and written notice shall state that if any Shareholder fails to subscribe for new Shares, his right shall be forfeited. In no event shall the subscription right in this Article be transferred to any other third parties. Where a fractional percentage of the original Shares being held by a Shareholder is insufficient to subscribe for one new Share, the fractional percentages of the original Shares being held by several Shareholders may be combined for joint subscription of one (1) or more integral new Shares or for subscription of new Shares in the name of a single Shareholder. New Shares left unsubscribed by original Shareholders may be open for public offering or for subscription by specific person or persons through negotiation.

15. The Shareholders’ pre-emptive right prescribed under Article 14 shall not apply in the event that new Shares are issued due to the following reasons or for the following purpose:
(a) in connection with a Merger with another company, or the Spin-off of the Company, or pursuant to any reorganization of the Company;

(b) in connection with meeting the Company's obligation under Share subscription warrants and/or options;

(c) in connection with meeting the Company's obligation under corporate bonds which are convertible bonds or vested with rights to acquire Shares; or

(d) in connection with meeting the Company's obligation under preferred Shares vested with rights to acquire Shares.

16. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, unless otherwise provided in the Applicable Listing Rules, where the Company increases its capital by issuing new Shares in Taiwan, the Company shall allocate ten percent (10%) of the total amount of the new Shares to be issued, for offering in Taiwan to the public unless it is not deemed necessary or appropriate by the Commission, according to the Applicable Listing Rules, for the Company to conduct the aforementioned public offering. Provided however, if a percentage higher than the aforementioned ten percent (10%) is resolved by an Ordinary Resolution to be offered, the percentage determined by such resolution shall prevail. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, unless otherwise provided in the Applicable Listing Rules, the Company shall obtain a prior approval of the Commission and/or other competent authorities for any capital increase (i.e., issue of new Shares) (whether inside Taiwan or outside Taiwan) in accordance with the Applicable Listing Rules.

17. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, subject to the Applicable Listing Rules, the Company may, upon resolution by a majority votes at a meeting of the Board of Directors attended by two-thirds (2/3) or more of the Directors, adopt one (1) or more employee incentive programmes (such as employee stock option plan) pursuant to which options, warrants, or other similar instruments to acquire Shares may be granted to employees of the Company and/or any Subsidiaries of the Company to subscribe for Shares. However, in no event shall the aggregate number of Shares to be issued pursuant to such employee incentive programmes exceed fifteen percent (15%) of the then total outstanding Shares of the Company. The options, warrants, or other similar instruments to acquire Shares granted to any employee under any employee stock option plan shall be non-transferable, except to the heirs of the employees. The term "Subsidiaries" above refers to the companies defined under No. 10 and No. 11 of the IFRS (i.e., International Financial Reporting Standards) and No. 28 of the IAS (i.e., International Accounting Standards).

17B. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the Company may, with the authority of either a Supermajority Resolution Type A or a Supermajority Resolution Type B, issue restricted shares for employees. In respect of the issuance of restricted shares for employees in the preceding paragraph, the number of shares to be issued, issue price, issue conditions and other matters shall be subject to the Applicable Listing Rules and the requirements of the Commission.

PRIVATE PLACEMENT

17C. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, subject to the Applicable Listing Rules, the Company may by a resolution passed by at least two-thirds (2/3) of votes cast by Shareholders present at the general meeting with a quorum of more than half of the total number of the issued Shares at the general meeting carry out private placement of its securities to the following entities in Taiwan:
(a) banking enterprises, bill enterprises, trust enterprises, insurance enterprises, securities enterprises or any other legal entities or institutions approved by the Commission;

(b) individuals, legal entities or funds meeting the qualifications established by the Commission; and

(c) Directors, supervisors (if any) and managers of the Company or the Affiliated Companies.

For so long as the Shares are registered in the Emerging Market or listed on the TPEX or TSE, subject to the Applicable Listing Rules, a private placement of ordinary corporate bonds may be carried out in instalments within one (1) year of the date of the relevant resolution of the Board of Directors approving such private placement.

MODIFICATION OF RIGHTS

18. Whenever the capital of the Company is divided into different Classes (such as the Common Shares and the preferred Shares), the rights attached to any such Class may (unless otherwise provided by the terms of issue of the Shares of that Class) only be materially adversely varied or abrogated (including but not limited to the circumstances where there is any amendment to these Articles which may be prejudicial to the rights of the holders of any preferred Shares) by: (i) a Special Resolution passed at a general meeting of holders of Common Shares; and (ii) a Special Resolution passed at a separate meeting of the holders of Shares of the relevant Class (such as the preferred Shares).

To every such separate meeting all the provisions of these Articles relating to general meetings of the Company or to the proceedings thereat shall, mutatis mutandis, apply, except that the necessary quorum shall be one (1) or more Persons at least holding or representing by proxy one-half (1/2) in total amount of the issued Shares of the relevant Class (but so that if at any adjourned meeting of such holders a quorum as above defined is not present, those Shareholders who are present shall form a quorum) and that, subject to the terms of issue of the Shares of that Class, every Shareholder of the Class shall on a poll have one (1) vote for each Share of the Class held by him.

19. The rights conferred upon the holders of the Shares of any Class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the Shares of that Class, be deemed to be materially adversely varied or abrogated by, inter alia, the creation, allotment or issue of further Shares ranking pari passu with or subsequent to them or the redemption or purchase of Shares of any Class by the Company.

CERTIFICATES

20. The Company shall deliver Shares to the subscribers of new Shares by Book-Entry Transfer within thirty (30) days from the date the Shares may be issued pursuant to the Applicable Listing Rules and make public announcement prior to the delivery. So long as the Shares are registered in the Emerging Market or listed in the TPEX or TSE, the Company may issue the Shares in scriptless form provided that the Company shall register with the securities central depositary in Taiwan. No Person shall be entitled to a certificate for any or all of his/her Shares, unless the Directors shall determine otherwise.

FRACTIONAL SHARES

21. Subject to these Articles, the Directors may issue fractions of a Share and, if so issued, a fraction of a Share shall be subject to and carry the corresponding fraction of liabilities (whether with respect to nominal or par value, premium, contributions, calls or otherwise), limitations, preferences, privileges, qualifications, restrictions, rights (including, without prejudice to the generality of the foregoing, voting and participation rights) and other attributes of a whole Share.
If more than one (1) fraction of a Share of the same Class is issued to or acquired by the same Shareholder such fractions shall be accumulated.

**TRANSFER OF SHARES**

22. Title to Shares which are registered in the Emerging Market or listed in the TPEX or the TSE may be evidenced and transferred in accordance with the Applicable Listing Rules. Subject to the Applicable Listing Rules, the Law and Article 40E, Shares issued by the Company shall be freely transferable, provided that any Shares reserved for issuance to the employees of the Company may be subject to transfer restrictions for a period of not more than two (2) years as the Directors may agree with such employees.

Subject to the Law and notwithstanding anything to the contrary in these Articles, Shares that are listed or admitted to trading on an approved stock exchange (as defined in the Law, including the TPEX and the TSE), may be evidenced and transferred in accordance with the rules and regulations of such exchange.

23. The instrument of transfer of any Share shall be in any usual or common form or such other form as the Directors may, in their absolute discretion, approve or the form required by the TPEX or TSE (for so long as the Shares are registered in the Emerging Market or listed in the TPEX or TSE) and be executed by or on behalf of the transferor and if so required by the Directors, shall also be executed on behalf of the transferee and shall be accompanied by the certificate (if any) of the Shares to which it relates and such other evidence as the Directors may reasonably require to show the right of the transferee to make the transfer. The transferee shall be deemed to remain a Shareholder until the name of the transferee is entered in the Register in respect of the relevant Shares. The Register of Members maintained by the Company in respect of the Shares which are registered in the Emerging Market or listed in the TPEX or the TSE may be kept in a form otherwise than legible provided such recording otherwise complies with the laws applicable to the Emerging Market, TPEX or TSE and the Applicable Listing Rules. To the extent the Register of Members is kept in a form otherwise than legible it must be capable of being reproduced in a legible form.

24. The Board may decline to register any transfer of any Share unless:

(a) the instrument of transfer is lodged with the Company, accompanied by the certificate (if any) for the Shares to which it relates and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer;

(b) the instrument of transfer is in respect of only one (1) class of Shares;

(c) the instrument of transfer is properly stamped, if required; or

(d) in the case of a transfer to joint holders, the number of joint holders to whom the Share is to be transferred does not exceed four (4).

This Article is not applicable during the period that the Shares are registered in the Emerging Market or listed in TPEX or TSE.

25. The registration of transfers may be suspended when the Register is closed in accordance with Article 41.

26. All instruments of transfer that are registered shall be retained by the Company, but any instrument of transfer that the Directors decline to register shall (except in any case of fraud) be returned to the Person depositing the same.

-85-
TRANSMISSION OF SHARES

27. The legal personal representative of a deceased sole holder of a Share shall be the only Person recognised by the Company as having any title to the Share. In the case of a Share registered in the name of two (2) or more holders, the survivors or survivor, or the legal personal representatives of the deceased, shall be the only Person recognised by the Company as having any title to the Share.

28. Any Person becoming entitled to a Share in consequence of the death or bankruptcy of a Shareholder shall upon such evidence being produced as may from time to time be required by the Directors, have the right either to be registered as a Shareholder in respect of the Share or, instead of being registered himself, to make such transfer of the Share as the deceased or bankrupt Person could have made. If the person so becoming entitled shall elect to be registered himself as holder he shall deliver or send to the Company a notice in writing signed by him stating that he so elects, but the Directors shall, in either case, have the same right to decline or suspend registration, and for so long as the Shares are registered in the Emerging Market or listed on the TPEX or TSE, decline or suspend registration in accordance with the laws applicable to the Emerging Market, TPEX or TSE and the Applicable Listing Rules, as they would have had in the case of a transfer of the Share by the deceased or bankrupt Person before the death or bankruptcy.

29. A Person becoming entitled to a Share by reason of the death or bankruptcy of a Shareholder shall be entitled to the same dividends and other advantages to which he would be entitled if he were the registered Shareholder, except that he shall not, before being registered as a Shareholder in respect of the Share, be entitled in respect of it to exercise any right conferred by membership in relation to meetings of the Company; provided however, that the Directors may at any time give notice requiring any such person to elect either to be registered himself or to transfer the Share, and if the notice is not complied with within ninety (90) days, the Directors may thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the Share until the requirements of the notice have been complied with. Notwithstanding the above, for so long as the Shares are registered in the Emerging Market or listed on the TPEX or TSE, the Directors shall comply with the laws applicable to the Emerging Market, TPEX or TSE and the Applicable Listing Rules.

VOTING ON RESOLUTION

30. The Company may from time to time by Special Resolution increase the share capital by such sum, to be divided into Shares of such Classes and amount, as the resolution shall prescribe.

The Company may from time to time by Ordinary Resolution:

(a) consolidate and divide all or any of its share capital into Shares of a larger amount than its existing Shares;

(b) convert all or any of its paid up Shares into stock and reconvert that stock into paid up Shares of any denomination;

(c) subdivide its existing Shares, or any of them into Shares of a smaller amount; and

(d) cancel any Shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken by any Person and diminish the amount of its share capital by the amount of the Shares so cancelled.

31. The Company may also by Special Resolution:

(a) change its name;
(b) subject to the Law, reduce its share capital and any capital redemption reserve in any manner authorised by law; and

(c) effect a Merger of the Company in accordance with the Applicable Listing Rules and the Law.

For the avoidance of doubt, in case a Merger is a Delisting, Article 33A shall apply.

32. The Company may also by either a Supermajority Resolution Type A or the Supermajority Resolution Type B:

(a) enter into, amend, or terminate any contract for lease of its business in whole, or for entrusting business, or for regular joint operation with others;

(b) transfer the whole or any material part of its business or assets;

(c) take over the transfer of another's whole business or assets, which will have a material effect on the business operation of the Company;

(d) effect any Spin-off of the Company in accordance with the Applicable Listing Rules;

(e) grant waiver to the Director’s engaging in any business within the scope of the Company’s business;

(f) issue restricted shares for employees pursuant to Article 17B;

(g) distribute part or all of its dividends or bonus by way of issuance of new Shares, for the avoidance of doubts, the allotment of bonus shares in connection with the Employees’ Remunerations and the Directors’ Remunerations pursuant to Article 129 shall not require the approval of a Supermajority Resolution Type A or a Supermajority Resolution Type B; and

(h) share swap.

For so long as the Shares are listed on the TPEx or TSE, granting of employee stock options with an exercise price per share that is lower than the closing price of Common Shares of the Company traded on the TPEx or the TSE as of the grant date shall require a resolution passed by Shareholders, as being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting, such Shareholders holding not less than two-thirds (2/3) of the Shares held by all Shareholders attending that meeting, and such meeting attended by Shareholders holding not less than half of all issued Shares of the Company.

33. Subject to the Law, these Articles and the quorum requirement under the Applicable Listing Rules, with regard to the dissolution procedures of the Company, the Company shall pass:

(a) either a Supermajority Resolution Type A or a Supermajority Resolution Type B, if the Company resolves that it be wound up voluntarily because it is unable to pay its debts as they fall due; or

(b) a Special Resolution, if the Company resolves that it be wound up voluntarily for reasons other than the reason stated in Article 33(a) above.

33A. The Company shall pass a Supermajority Special Resolution if the Company effects a Delisting in accordance with the Applicable Listing Rules.
34. Subject to the Law, in the event any of the resolutions with respect to the paragraph (a), (b), or (c) of Article 32 is adopted by general meeting, any Shareholder who has notified the Company in writing of his objection to such proposal prior to such meeting and subsequently raised his objection at the meeting may request the Company to purchase all of his Shares at the then prevailing fair price within twenty (20) days after the date of the resolution. In the event the Company fails to reach such agreement with the Shareholder within sixty (60) days after the date of the resolution, the Shareholder may, within thirty (30) days after such sixty (60)-day period, file a petition to any competent court of Taiwan for a ruling on the appraisal price, and, to the extent that the ruling is capable of enforcement and recognition outside Taiwan, such ruling by such Taiwan court shall be binding and conclusive as between the Company and requested Shareholder solely with respect to the appraisal price.

Subject to the Law, in the event any of the resolutions with respect to the Company’s Spin-off, Merger, Acquisition or share swap, the Shareholder, who has forfeited his right to vote on such matter and expressed his dissent therefor, in writing or verbally (with a record) before or during the general meeting, may request the Company to purchase all of his Shares in writing within twenty (20) days after the date of the resolution and specifies the price of the Shares to be repurchased.

For the purpose of this Article 34, if the Company and any Shareholder reach an agreement about the price of the Shares to be repurchased by the Company, the Company shall pay for such agreed purchase price of Shares to be repurchased within ninety (90) days from the date of passing of the resolution by general meeting. In case no agreement as to the purchase price is reached, the Company shall pay the fair price as determined by the Company to such Shareholder within ninety (90) days from the date on which the resolution was adopted. If the Company fails to pay the agreed purchase price, the Company shall be deemed to agree to the price as requested by the Shareholder.

For the Shareholder who requests the Company to purchase all of his Shares in accordance with the second paragraph, in the event the Company fails to reach such agreement with the Shareholder within sixty (60) days after the date on which the resolution was adopted, the Company shall apply to the court for a ruling on the price of the Shares to be repurchased against all the dissenting shareholders as the opposing party within thirty (30) days after such sixty-day period, and Taiwan Taipei District Court has the jurisdiction.

REDEMPTION AND PURCHASE OF SHARES

35. Subject to the Law, the Applicable Listing Rules and these Articles, the Company is authorized to issue shares which are to be redeemed or are liable to be redeemed at the option of the Company or a Shareholder. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the repurchase of the Shares by the Company shall be subject to the Applicable Listing Rules and the Cayman Islands law.

36. The Company is authorised to make payments in respect of the redemption of its shares out of the funds lawfully available (including out of capital) in accordance with the Law and the Applicable Listing Rules.

37. The redemption price of a redeemable Share, or the method of calculation thereof, shall be fixed by the Directors at or before issue of such Share. Every share certificate representing a redeemable share shall indicate that the share is redeemable.

38. Subject to the Applicable Listing Rules and Articles 38B and 39B, and with the sanction of an Ordinary Resolution authorising the manner and terms of purchase, the Directors may on behalf of the Company purchase any share in the Company (including a redeemable share) by agreement with the Shareholder or pursuant to the terms of the issue of the share and may make
payments in respect of such purchase in accordance with the Law, the Applicable Listing Rules and the Ordinary Resolution authorizing the manner and terms of purchase.

38B. Subject to the Applicable Listing Rules, upon approval of a majority of Directors present at a Board meeting attended by two-thirds (2/3) of all Directors or more, the Company may repurchase its outstanding Shares listed on the TPEx or TSE. The resolutions of Board of Directors in the preceding paragraph and how such resolutions are implemented shall be reported to the Shareholders at the next general meeting. If the Company fails to accomplish the repurchase of its outstanding Shares listed on the TPEx or TSE as approved and anticipated by the resolutions of the Board of Directors, it shall be reported to the Shareholders at the next general meeting.

39. The redemption price or repurchase price may be paid in any manner authorised by the Law and these Articles. A delay in payment of the redemption price or repurchase price shall not affect the redemption or repurchase but, in the case of a delay of more than thirty (30) days, interest shall be paid for the period from the due date until actual payment at a rate which the Directors, after due enquiry, estimate to be representative of the rates being offered by Class A banks in the Cayman Islands for thirty day deposits in the same currency.

39B. The Shares may only be cancelled in connection with a repurchase of Shares out of the share capital of the Company or any account or funds legally available therefor with the sanction of either the Supermajority Resolution Type A or the Supermajority Resolution Type B. The number of Shares to be repurchased and cancelled pursuant to a repurchase of Shares described in the preceding paragraph shall be pro rata among the Shareholders in proportion to the number of Shares held by each such Shareholder.

The amount payable to the Shareholders in connection with a repurchase of Shares out of the share capital of the Company or any account or funds legally available therefor may be paid in cash or by way of delivery of assets in specie (i.e., non-cash). The assets to be delivered and the amount of such substitutive share capital in connection with a repurchase of Shares out of the share capital of the Company or any account or funds legally available therefor shall be approved by either the Supermajority Resolution Type A or the Supermajority Resolution Type B and shall be subject to consent by the Shareholder receiving such assets. Prior to such general meeting, the Board of Directors shall have the value of assets to be delivered and the amount of such substitutive share capital in respect of repurchase of the Shares (as described in the preceding paragraph) be audited and certified by a certified public accountant in Taiwan.

**TREASURY SHARES**

40. No share may be redeemed unless it is fully paid-up. Shares that the Company purchases, redeems or acquires (by way of surrender or otherwise) may, at the option of the Company, be immediately cancelled or held as Treasury Shares in accordance with the Law and Applicable Listing Rules. If the Board of Directors does not specify that the relevant Shares are to be held as Treasury Shares, such Shares shall be cancelled.

40B. No dividend may be declared or paid, and no other distribution (whether in cash or otherwise) of the Company's assets (including any distribution of assets to members on a winding up) may be declared or paid in respect of Treasury Shares.

40C. The Company shall be entered into the Register as the holder of the Treasury Shares provided that:

(a) the Company shall not be treated as a member for any purpose and shall not exercise any right in respect of the Treasury Shares, and any purported exercise of such a right shall be void;
(b) a Treasury Share shall not be voted, directly or indirectly, at any meeting of the Company and shall not be counted in determining the total number of issued Shares at any given time, whether for the purposes of these Articles or the Law, save that, subject to the Applicable Listing Rules and the Law, an allotment of Shares as fully paid bonus shares in respect of a Treasury Shares is permitted and Shares allotted as fully paid bonus shares in respect of a Treasury Shares shall be treated as Treasury Shares.

40D Subject to Article 40E and the Applicable Listing Rules, the Treasury Shares may be disposed of by the Company on such terms and conditions as determined by the Board of Directors. If the Treasury Shares having been repurchased by the Company is for the purpose of the transfer to employees under the Applicable Listing Rules, such employees may undertake to the Company to refrain from transferring such Shares during certain period with a maximum of two (2) years.

40E. Subject to the Applicable Listing Rules, the transfer of Treasury Shares to its employees by the Company at a price lower than the average price at which the Treasury Shares were actually repurchased by the Company shall be approved at the next general meeting by a resolution passed by at least two-thirds (2/3) of votes of Shareholders attending the meeting with a quorum of more than half of the total issued Shares. The following matters shall be listed in the reasons for convening this general meeting and in no event shall such matters be proposed at the general meeting as ad hoc motions:

(a) transfer price determined, discount rate, calculation basis and fairness;

(b) number of Treasury Shares to be transferred, purpose and fairness;

(c) criteria of eligible employees and number of Treasury Shares that may be subscribed for; and

(d) impact on shareholders' rights: (i) the amount to be booked as expense of the Company and dilution of earnings per Share; and (ii) description of the Company's financial burden arising from the transfer of Treasury Shares to employees at a price lower than the average price at which the Treasury Shares were actually repurchased by the Company.

The accumulated number of Treasury Shares that have been transferred to employees as so approved at each general meetings shall not exceed five (5%) of the total issued Shares of the Company, and the accumulated number of Treasury Shares transferred to a single employee shall not exceed zero point five percent (0.5%) of the total issued Shares.

CLOSING REGISTER OR FIXING RECORD DATE

41. For the purpose of determining those Members that are entitled to receive notice of, attend or vote at any meeting of Members or any adjournment thereof, or those Members that are entitled to receive payment of any dividend, or in order to make a determination as to who is a Member for any other purpose, the Directors may provide that the Register shall be closed for transfers for a stated period. For so long as the Shares are registered in the Emerging Market or listed in the TPEx or TSE, the Register shall be closed at least for a period of sixty (60) days, thirty (30) days and five (5) days inclusive of the date of each annual general meeting, each extraordinary general meeting and the record date for a dividend distribution, respectively.

42. Apart from closing the Register, the Directors may fix in advance a date as the record date for any such determination of those Members that are entitled to receive notice of, attend or vote at a general meeting and for the purpose of determining those Members that are entitled to receive payment of any dividend. In the event the Directors designate a record date in accordance with this Article 42 in respect of convening a general meeting, such record date shall be a date prior to the general meeting and the Directors shall immediately make a public announcement on the
website designated by the Commission and the TPEx or TSE pursuant to the Applicable Listing Rules.

GENERAL MEETINGS

43. All general meetings other than annual general meetings shall be called extraordinary general meetings.

44. The Board may, whenever they think fit, convene a general meeting of the Company; provided that the Company shall in each year hold a general meeting as its annual general meeting within six (6) months after close of each financial year and shall specify the meeting as such in the notices calling it.

45. At these meetings the report of the Directors (if any) shall be presented. For so long as the Shares are registered in the Emerging Market or listed in the TPEx or TSE, all physical general meetings shall be held in Taiwan, if a physical general meeting is to be convened outside Taiwan, the Company, an application shall be made with the TPEx or TSE for permission within two (2) days after the Board adopts such resolution, or, in the event of an extraordinary general meeting convened pursuant to Article 46, the relevant Shareholders obtain approval on the convening of such meeting from the Commission.

46. Extraordinary general meetings may also be convened by the Board on the requisition in writing of any Shareholder or Shareholders entitled to attend and vote at general meetings of the Company holding three percent (3%) or more of the total number of issued Shares of the Company for a period of one (1) consecutive year or a longer time deposited at the Office or the Shareholders' Service Agent specifying the objects of the meeting, and if the Board does not duly proceed to convene such meeting for a date not later than 15 days after the date of such deposit, for so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the requisitionists themselves may convene the extraordinary general meeting in the same manner as provided for under Article 48, as nearly as possible, as that in which general meetings may be convened by the Directors, and all reasonable expenses incurred by the requisitionists as a result of the failure of the Directors to convene the general meeting shall be reimbursed to them by the Company.

47. If at any time there are no Directors, any Shareholder or Shareholders holding three percent (3%) or more of the total number of the issued Shares of the Company for a period of one (1) consecutive year or a longer time may, for so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, convene a general meeting in the same manner as nearly as possible as that in which general meetings may be convened by the Directors.

NOTICE OF GENERAL MEETINGS

48. At least thirty (30) and fifteen (15) days' notices in writing shall be given for any annual and extraordinary general meetings, respectively. Every notice shall be exclusive of the day on which it is given or deemed to be given and of the day for which it is given and shall specify the place, the day and the hour of the meeting and the general nature of the business. The notice for a general meeting may be given by means of electronic communication if the Company obtains prior consent by the individual recipients.

48A. Where the general meetings are held by means of visual communication network in accordance with Article 51A, for so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the Company shall, in accordance with the Applicable Listing Rules (including but not limited to the Regulations Governing the Administration of Shareholder Services of Public Companies), specify in the notice the methods for attending the general meeting by visual communication network and for exercising rights, the ways to overcome obstacles to the visual meeting platform or to the visual communication network arising out of calamities, incidents or
force majeure. Where the Company holds a Virtual General Meeting, the notice shall also specify the appropriate alternatives to Shareholders who have difficulties in attending Virtual General Meetings.

48B. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the Company shall make public announcements with regard to notice of general meeting, proxy form, and summary information and details about issues for recognition, discussion, election or dismissal of Directors or supervisors (if any) at least thirty (30) days prior to any annual general meeting or at least fifteen (15) days prior to any extraordinary general meeting.

If the Shareholders exercise the votes and cast the votes in writing, the Company shall also send to the Shareholders the information and documents as described in the preceding paragraph, together with the voting right exercise forms.

49. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the Board shall prepare a manual setting out the agenda of a general meeting (including all the subjects and matters to be resolved at the meeting and other matters) pursuant to the Applicable Listing Rules (including without limitation, the Regulations Governing the Administration of Shareholder Services of Public Companies), shall present such manual together with other information related to the said meeting on the day of such general meeting for Shareholders’ reference in accordance with the Applicable Listing Rules (including without limitation, the Regulations Governing the Administration of Shareholder Services of Public Companies), and shall make public announcement(s) in a manner permitted by the Applicable Listing Rules to disclose the contents of such manual together with other information related to the said meeting at least twenty-one (21) days prior to the date of annual general meetings and at least fifteen (15) days prior to the date of extraordinary general meetings. Nevertheless, the said public announcement(s) shall be made thirty (30) days prior to the date of the annual general meeting, provided that the paid-in capital of the end date of the last financial year reaches NT$10 billion or more, or the sum of the foreign and mainland Chinese shareholdings stated in the shareholder register of its annual general meeting held in the immediately preceding year reaches 30% or more. Such manual shall be distributed to all Shareholders attending the general meeting in person, by proxy or by corporate representative(s) (where the Shareholder is a corporation) at the general meeting.

50. The following matters and the essential contents shall be specified in the notice of a general meeting, and shall not be proposed as ad hoc motions; material contents of such matters may be uploaded onto the website designated by the TWSE, TPEx or the Company with the address of website indicated in the notice:

(a) election or discharge of Directors or supervisors (if any);
(b) amendments to the Memorandum of Association and/or these Articles;
(c) reduction in share capital of the Company;
(d) application for de-registration as a public company;
(e) dissolution, share swap (as defined in the Applicable Listing Rules), Merger or Spin-off of the Company;
(f) entering into, amendment to, or termination of any contract for lease of its business in whole, or for entrusting business, or for regular joint operation with others;
(g) the transfer of the whole or any material part of its business or assets;
(h) the takeover of another’s whole business or assets, which will have a material effect on the business operation of the Company;

(i) the private placement of equity-linked securities;

(j) granting waiver to the Director’s engaging in any business within the scope of business of the Company;

(k) distribution of part or all of its dividends or bonus by way of issuance of new Shares;

(l) capitalization of the Legal Reserves and Capital Reserves arising from the share premium account or endowment income, in whole or in part, by issuing new Shares which shall be distributable as dividend shares to the then Shareholders in proportion to the number of Shares being held by each of them;

(m) subject to the Law, distribution of the Legal Reserves and Capital Reserves arising from the share premium account or endowment income, in whole or in part, by paying cash to the then Shareholders in proportion to the number of Shares being held by each of them;

(n) the transfer of Treasury Shares to its employees by the Company;

(o) for so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, granting of employee stock options with an exercise price per share that is lower than the closing price of shares of the Company traded on the Emerging Market, the TPEx or the TSE as of the grant date;

(p) issue of restricted shares for employees; and

(q) the Delisting.

Subject to the Law and these Articles, the Shareholders may propose matters in a general meeting to the extent of matters as described in the agenda of such meeting.

PROCEEDINGS AT GENERAL MEETINGS

51. No business shall be transacted at any general meeting unless a quorum of Shareholders is present at the time when the meeting proceeds to business. Save as otherwise provided by these Articles, the holders of Shares being more than an aggregate of one-half (1/2) of all Shares in issue present in person or by proxy and entitled to vote shall be a quorum for all purposes.

51A. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the Company may, by a resolution adopted by the Board of Directors, hold the general meetings by means of visual communication network in accordance with the prerequisites, procedures and other compliance matters provided for by the Applicable Listing Rules. A resolution adopted by the Board of Directors is not required where the general meeting is convened by a person who is entitled to convene a general meeting pursuant to the Applicable Listing Rules and these Articles. Such general meetings can be Hybrid General Meetings or Virtual General Meetings. Where a general meeting is proceeded via visual communication network, whether it is a Hybrid General Meeting or a Virtual General Meeting, the Shareholders taking part in such meeting shall be deemed to have attended the meeting in person.

52. One or more Shareholders holding in aggregate one percent (1%) or more of the total number of issued Shares immediately prior to the relevant book close period may propose in writing or by way of electronic transmission to the Company a matter for discussion at an annual general
meeting. The Company shall give a public notice in such manner as permitted by the Applicable Listing Rules at such time deemed appropriate by the Board specifying the place and a period of not less than ten (10) days for Members to submit proposals. Any Shareholder(s) whose proposal has been submitted and accepted by the Board, shall continue to be entitled to attend the annual general meeting in person or by proxy or in the case of a corporation, by its authorised representative(s), and participate in the discussion of such proposal.

The Board shall accept a proposal submitted by a one or more Shareholders and arrange for the proposal to be discussed at the annual general meeting unless (i) the number of Shares held by such one or more Shareholders is less than one percent (1%) in aggregate of the total number of issued Shares in the Register of Members as of the record date determined by the Board or upon commencement of the period for which the Register shall be closed before the general meeting; (ii) the proposal involves matters which cannot be resolved at the annual general meeting in accordance with or under the Law or Applicable Listing Rules; (iii) the proposal submitted concerns more than one matter; (iv) the proposal submitted exceeds three hundred words; or (v) the proposal is not submitted within the specified period determined by the Board; provided, however, that if the proposal submitted is to urge the Company to facilitate the public interest or perform social responsibility, the Board may accept that proposal and arrange for it being discussed at the annual general meeting. The Company shall, prior to the dispatch of a notice of the annual general meeting, inform the Shareholders the result of submission of proposals and list in the notice of annual general meeting the proposals accepted for consideration and approval at the annual general meeting. The Board shall explain at the annual general meeting the reasons for excluding proposals submitted by such Shareholder(s).

53. Subject to the Applicable Listing Rules, the Chairman, if any, of the Board of the Directors shall preside as chairman at every general meeting of the Company convened by the Board of Directors. In case the Chairman is on leave or absent or cannot exercise his/her power and authority for any cause, he/she shall designate one of the other Directors to act on his/her behalf. In the absence of such a designation, the Directors shall elect from among themselves a chairman for such meeting.

53A. Any one or more Shareholders holding in aggregate more than half of the total number of the issued Shares of the Company for at least three (3) consecutive months may convene an extraordinary general meeting. The determination of the afore-mentioned holding period and number of Shares shall be based on the Shares held immediately prior to the relevant book close period.

54. Subject to the Applicable Listing Rules, for a general meeting convened by any other person having the convening right, such person shall act as the chairman of that meeting; provided that if there are two (2) or more persons jointly having the convening right, the chairman of the meeting shall be elected from those persons.

54A. The Board of Directors or any person who is entitled to convene a general meeting pursuant to Article 53A above or under these Articles may demand the Company or its Shareholders' Service Agent to provide the Register of Members.

55. Subject to the Applicable Listing Rules, at any general meeting a resolution put to the vote of the meeting shall be decided on a poll. The number or proportion of the votes in favour of, or against, that resolution shall be recorded in the minutes of the meeting.

56. Unless otherwise expressly required by the Law or these Articles, any matter which has been presented for resolution, approval, confirmation or adoption by the Shareholders at any general meeting shall be passed by an Ordinary Resolution.
57. In the case of an equality of votes, the chairman of the meeting shall not be entitled to a second or casting vote. Subject to these Articles and the Applicable Listing Rules, the Company shall additionally comply with the Procedural Rules of General Meetings.

VOTES OF SHAREHOLDERS

58. Subject to these Articles and any rights and restrictions for the time being attached to any Share, every Shareholder and every Person representing a Shareholder by proxy shall have one (1) vote for each Share of which he or the Person represented by proxy is the holder. Subject to the Law and unless otherwise provided for in these Articles, any resolutions at a general meeting of the Company shall be adopted by an Ordinary Resolution.

For so long as the Shares are registered in the Emerging Market or listed on the TPEX or TSE, any Shareholder holding Shares on behalf of another beneficiary Shareholder(s) may exercise his/her voting rights severally in accordance with the request(s) of the respective beneficial Shareholder(s). The qualifications, scopes, exercises, operational procedures and other matters in relation to the aforesaid separate exercise of voting rights shall be conducted in accordance with the Applicable Listing Rules.

59. No vote may be exercised by any Shareholder with respect to any of the following Shares:

(a) the Treasury Shares held by the Company in accordance with the Law, these Articles and the Applicable Listing Rules;

(b) the Shares held by any subordinate company of the Company as defined in the Applicable Listing Rules, where the total number of voting shares or total shares equity held by the Company in such a subordinated company represents more than one-half (1/2) of the total number of voting shares or the total shares equity of such a subordinated company; or

(c) the Shares held by another company, where the Company and its subordinated company directly or indirectly hold more than one-half (1/2) of the total number of the voting shares or total shares equity of such company.

Any votes cast by or on behalf of such Shareholder in contravention of the foregoing shall not be counted in the total number of issued shares while calculating the quorum for the purpose of Article 51.

60. In the case of joint holders, the joint holders shall select among them a representative for the exercise of their shareholder’s rights and the vote of their representative who tenders a vote whether in person or by proxy shall be accepted to the exclusion of the votes of the other joint holders.

61. A Shareholder of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in lunacy, may vote by his committee, or other Person in the nature of a committee appointed by that court, and any such committee or other Person, guardian or any other Person who is similar to guardian and appointed by any court having jurisdiction, may vote by proxy.

62. A Shareholder may appoint a proxy to attend a general meeting on his behalf by executing an instrument in usual or common form or such other form as the Directors may approve, and such proxy form shall be prepared by the Company stating therein the scope of power authorized to the proxy. A Shareholder may only execute one (1) such proxy form and appoint one (1) proxy for each general meeting, and shall serve such written proxy to the Company no later than five (5) days prior to the meeting date. In case the Company receives two (2) or more written proxies
from one (1) Shareholder, the first one arriving at the Company shall prevail unless an explicit statement to revoke the previous written proxy is made in the proxy which comes later.

62B. After a proxy is delivered to the Company, if the Shareholder issuing the proxy intends to attend the general meeting in person (including by means of visual communication method pursuant to Article 51A) or exercise the voting rights in writing or by way of electronic transmission, the Shareholder shall issue a written notice to the Company to revoke the proxy at least two (2) days prior to the general meeting. If the revocation is not made during the prescribed period, the votes casted by the person as proxy shall prevail.

62C. Where the Company holds the general meetings by means of visual communication method, the Shareholders, proxy solicitation agents (if any) or proxies who wish to participate in the meetings by means of visual communication method shall register with the Company at least two (2) days prior to the general meeting. If the Company holds a Hybrid General Meeting, the Shareholders, proxy solicitation agents (if any) or proxies who wish to participate in the physical meetings in person shall revoke the registration at least two (2) days prior to the meetings in the same manner as previously used in registration. If the revocation is not submitted within the prescribed time limit, such Shareholder, proxy solicitation agent (if any) or proxy may attend the general meetings in person only.

63. The instrument appointing a proxy shall be in the form approved by the Board and be expressed to be for a particular meeting only. The form of proxy shall include at least the following information: (a) instructions on how to complete such proxy, (b) the matters to be voted upon pursuant to such proxy, and (c) basic identification information relating to the relevant Shareholder, proxy recipient and proxy solicitation agent (if any). The form of proxy shall be provided to the Shareholders together with the relevant notice by mail or electronic transmission for the relevant general meeting. Notwithstanding any other provisions of these Articles, the distribution of the notice and proxy materials shall be made to all Shareholders and such distribution, regardless of delivering by email or by electronic transmission, shall be made on the same day.

64. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing or, if the appointor is a corporation, either under Seal or under the hand of an officer or attorney duly authorised. A proxy need not be a Shareholder.

65. Except for Taiwan trust enterprises or Shareholders’ Service Agencies approved by Taiwan competent authorities or the chairman appointed pursuant to Article 68, when a person who acts as the proxy for two (2) or more Shareholders concurrently, the number of votes represented by him shall not exceed three percent (3%) of the total number of votes of the Company and the portion of votes in excess of the said three percent (3%) represented by such proxy shall not be counted.

66. To the extent required by the Applicable Listing Rules, any Shareholder who bears a personal interest that may conflict with and impair the interest of the Company in respect of any matter proposed (the “Proposed Matters”) for consideration and approval at a general meeting shall abstain from voting any of the Shares that such Shareholder should otherwise be entitled to vote in person, as a proxy or corporate representative with respect to the said matter, but all such Shares shall be counted in the quorum for the purpose of Article 51 notwithstanding that such Shareholder should not exercise his voting right. Any votes cast by or on behalf of such Shareholder in contravention of the foregoing shall not be counted in the number of votes of Shareholders present at the general meeting for the resolution relating to the Proposed Matters by the Company.

67. Except otherwise provided in the Cayman Islands law, for so long as the Shares are registered in the Emerging Market or listed on the TPEX or TSE, the Company must allow voting power to be exercised by way of electronic voting as one of the voting methods in the general meeting.
68. Whenever the voting at the general meeting is exercised in writing or by way of electronic transmission, the method for exercising the votes shall be described in the notice of the general meeting. A Shareholder who exercises his votes by way of electronic transmission as set forth in the preceding Article 67 shall be deemed to have appointed the chairman of the general meeting as his or her proxy to exercise his or her voting right at such general meeting in accordance with the instructions stipulated in the electronic document, but shall be deemed to have waived his votes in respective of any ad hoc motions and the amendments to the contents of the original proposals at such general meeting; provided, however, that such appointment shall be deemed not to constitute the appointment of a proxy for the purposes of the Applicable Listing Rules. The chairman, acting as proxy of a Shareholder, shall not exercise the voting right of such Shareholder in any way not stipulated in the electronic document.

A Shareholder who exercises his votes by way of electronic transmission pursuant to Article 67 fails to revoke his declaration of intention and attends the general meeting by means of visual communication method shall be deemed to have waived his right to propose amendments to the original proposal and his votes in respect of any ad hoc motions and the original proposal as well as the amendments thereto.

For so long as the Shares are registered in the Emerging Market or listed in the TPEx or TSE, where a general meeting is to be held outside Taiwan, the Company shall engage a designated institute (i.e., Shareholders’ Service Agent located in Taiwan) approved by the Commission and the TPEx or the TSE to handle the administration of such general meeting (including but not limited to the voting for Shareholders of the Company).

69. A Shareholder shall submit his or her vote by way of electronic transmission pursuant to Article 67 to the Company at least two (2) days prior to the scheduled meeting date of the general meeting; whereas if two (2) or more such electronic transmission are submitted to the Company, the proxy deemed to be given to the chairman of the general meeting pursuant to Article 68 by the first electronic transmission shall prevail unless it is expressly included in the subsequent vote by electronic transmission that the original vote submitted by electronic transmission be revoked.

70. In case a Shareholder who has submitted his votes by written ballot or electronic transmission intends to attend the general meeting in person (including by means of visual communication method pursuant to Article 51A), he shall, at least two (2) days prior to the date of the meeting revoke such vote in the same manner previously used in exercising his voting power and such revocation shall constitute a revocation of the proxy deemed to be given to the chairman of the general meeting pursuant to Article 68. If a Shareholder who has submitted his or her vote by way of electronic transmission pursuant to Article 67 does not submit such a revocation before the prescribed time, his or her vote by electronic transmission and the proxy deemed to be given to the chairman of the general meeting pursuant to Article 68 shall prevail.

If a Shareholder has submitted his or her vote by way of electronic transmission pursuant to Article 67, and has subsequently submitted a proxy appointing a person as his or her proxy to attend the general meeting on his or her behalf, the subsequent appointment of that person as his or her proxy shall be deemed to be a revocation of such Shareholder’s deemed appointment of the chairman of the general meeting as his or her proxy pursuant to Article 68 and the vote casted by that person subsequently appointed as his or her proxy shall prevail.

71. In case the procedure for convening a general meeting or the method of adopting resolutions is in violation of the Law, Applicable Listing Rules or these Articles, a Shareholder may, within thirty (30) days from the date of the resolution, submit a petition to a competent court having proper jurisdiction, including, the Taipei District Court of the Republic of China if applicable, for revocation of such resolution.
PROXY AND PROXY SOLICITATION

72. For so long as the Shares are registered in the Emerging Market or listed in the TPEx or the TSE, the Company shall comply with the Applicable Listing Rules (including but not limited to the "Guidelines Governing the Utilization of Proxy for Shareholders Meetings of Public Companies") in respect of the proxies and proxy solicitation.

CORPORATIONS ACTING BY REPRESENTATIVES AT MEETINGS

73. Any corporation which is a Shareholder or a Director may by resolution of its directors or other governing body authorise such Person as it thinks fit to act as its representative at any meeting of the Company or of any meeting of holders of a Class or of the Board of Directors or of a committee of Directors, and the Person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as that corporation could exercise if it were an individual Shareholder or Director.

DIRECTORS

74. Unless otherwise determined by the Company in general meeting, the number of Directors shall be no less than five (5) Directors with a maximum of nine (9) Directors. Amongst the Board of Directors, the Company shall have at least three (3) Independent Directors, and the Independent Directors shall account for at least one-fifth (1/5) of the total number of Directors. At least one (1) of the Independent Directors must be domiciled in Taiwan. For so long as the Shares are listed on the TPEx or the TSE, the Directors shall include such number of Independent Directors as applicable law, rules or regulations or the Applicable Listing Rules require for a foreign issuer. The qualification, formation, appointment, discharge, exercise of authority and other compliance of Directors and Independent Directors shall be subject to and governed by the Applicable Listing Rules.

Where any Shareholder is a corporate entity, its representative may be elected as Director or supervisor (if any). Where there are several representatives of any corporate Shareholder, such representatives may be elected as either Directors or supervisors (if any) but not as Director and supervisors (if any) concurrently.

75. Independent Directors shall possess professional knowledge and maintain independence within the scope of their directorial duties without having any direct or indirect interest in the Company. The professional qualifications, restrictions on shareholdings and concurrent positions held, assessment of independence of Independent Directors, method of nomination of Independent Directors, and other matters in relation to Independent Directors shall be subject to the Applicable Listing Rules.

When the number of Independent Directors falls below the required number of Independent Directors under these Articles or the Applicable Listing Rules due to the disqualification or resignation of an Independent Director or the Independent Director ceases to be a Director for any reason, the vacancy of such Independent Director shall be filled and elected at the next following general meeting. When all of the Independent Directors have been disqualified, resigned or cease to be Directors for any reason, an extraordinary general meeting shall be convened within sixty (60) days of the occurrence of that fact to elect Independent Directors.

76. Unless otherwise permitted by the Commission and under the Applicable Listing Rules, a spousal relationship and/or a Family Relationship within the Second Degree of Kinship shall not exist among more than half (1/2) of the Directors (the "Threshold").

Where the Directors elected at the general meeting do not meet the Threshold, the election of the Director receiving the lowest number of votes among those not meeting the Threshold shall be
deemed null and void. If any of the existing Directors does not meet the Threshold, such Director in office shall be discharged immediately and automatically.

77. When the number of Directors falls below five (5) due to the disqualification or resignation of a Director or any Director ceases to be a Director of the Company for any reason, the Company shall hold an election to elect substitute director(s) at the next following general meeting. When the number of Directors falls short by one-third (1/3) of total number of Directors elected at the previous general meeting convened to elect Directors and notwithstanding the actual current number of Directors, an extraordinary general meeting shall be convened within sixty (60) days of the occurrence of that fact to hold an election of Directors.

If all Directors are re-elected at a general meeting held prior to the expiration of the term of the current Directors (the “Re-Election”), unless otherwise resolved at such general meeting, the term of the existing Directors shall be deemed to have expired immediately prior to the Re-Election. The aforesaid re-election of all Directors shall be held in the general meeting attended by Shareholders representing more than fifty percent (50%) of total issued Shares of the Company.

78. The general meeting of the Shareholders may appoint any natural person or corporation to be a Director or supervisors (if any). At a general meeting of election of Directors or supervisors (if any), the number of votes exercisable in respect of one (1) Share shall be the same as the number of Directors or supervisors (if any) to be elected, and the total number of votes per Share may be consolidated for election of one (1) candidate or may be split for election of two (2) or more candidates. A candidate to whom the ballots cast represent a prevailing number of votes shall be deemed a Director or supervisor (if any) so elected.

79. For so long as the Shares are registered in Emerging Market or listed on the TPEx or TSE, subject to the Applicable Listing Rules, the Company shall adopt a candidate nomination mechanism for the purpose of the appointment and election of Directors (including the Independent Directors) or supervisors (if any) in accordance with the Applicable Listing Rules and (i) the Directors (excluding the Independent Directors) or supervisors (if any) shall only be elected and approved by the Shareholders from the list of candidates for Directors (excluding the Independent Directors) and supervisors (if any); and (ii) the Independent Directors shall only be elected and approved by the Shareholders from the list of candidates for Independent Directors. Subject to these Articles and the Applicable Listing Rules, the Company shall additionally comply with the Guidelines Governing Election of Directors.

80. Subject to these Articles, the term for which a Director and supervisor (if any) will hold office shall not exceed three (3) years; thereafter he/she may be eligible for re-election. In case no election of new Directors or supervisors (if any) is effected after expiration of the term of office of the existing Directors or supervisors (if any), the term of office of such Directors or supervisors (if any) shall be extended until the time new Directors or supervisors (if any) are elected and assume their office.

81. A Director may be discharged at any time by either a Supermajority Resolution Type A or a Supermajority Resolution Type B adopted at a general meeting. If a Director is discharged during the term of his/her office as a director without good cause, such Director may make a claim against the Company for any and all damages sustained by him/her as a result of such discharge.

82. The Board of Directors shall have a Chairman (the “Chairman”) elected and appointed by a majority of the Directors present at the Board meeting the quorum of which shall be two-thirds of all of the Directors then in office.

82B. For so long as the Shares are registered on the Emerging Market or listed on the TPEx or TSE, subject to the Applicable Listing Rules, any Director (other than the Independent Director) or supervisor (if any), who, during his or her term and in one or more transactions, transfers more than fifty percent (50%) of the total Shares held by such Director or supervisor (as the case may
be) at the time of his or her appointment or election as Director or supervisor (as the case may be) being approved at a general meeting (the "Approval Time"), shall be discharged or vacated from the office of Director or supervisor (as the case may be).

For so long as the Shares are registered in the Emerging Market or listed in the TPEX or TSE, subject to the Applicable Listing Rules, if any person transfers, in one or more transactions, more than fifty percent (50%) of the Shares held by him or her at the Approval Time either (i) during the period from the Approval Time to the commencement date of his or her office as Director or supervisor (if any); or (ii) during the period when the Register is closed for transfer of Shares prior to the general meeting at which the appointment or election of such person as a Director or supervisor (if any) will be proposed, his or her appointment or election as Director (other than as an Independent Director) or supervisor (if any) shall be null and void.

83. The Board may, from time to time, and except as required by the applicable laws and Applicable Listing Rules, adopt, institute, amend, modify or revoke the corporate governance policies or initiatives, which shall be intended to set forth the policies of the Company and the Board on various corporate governance related matters as the Board shall determine by resolution from time to time.

84. A Director shall not be required to hold any Shares in the Company by way of qualification.

84B. For so long as the Shares are registered in the Emerging Market or listed in the TPEX or TSE, subject to the Applicable Listing Rules, where any Director, who is also a Shareholder of the Company, creates or has created a pledge on the Shares held by such Director (the "Pledged Shares") exceeding fifty percent (50%) of total Shares held by such Director at the time of his/her appointment as Director being approved at a general meeting, such Director shall refrain from exercising its voting rights on the Shares representing the difference between the Pledged Shares and fifty percent (50%) of total Shares held by such Director at the time of his/her appointment as Director being approved at a general meeting, and such Shares shall not be counted toward the number of votes represented by the Shareholders present at a general meeting.

DIRECTORS' FEES AND EXPENSES

85. Unless otherwise stipulated in these Articles or the Applicable Listing Rules, the remuneration (if any) of the Directors is subject to resolution by the Board of Directors in accordance with the standard prevalent in the industry. Each Director shall be entitled to be repaid or prepaid all travelling, hotel and incidental expenses reasonably incurred or expected to be incurred by him in attending meetings of the Board or committees of the Board or general meetings or separate meetings of any class of Shares or of debentures of the Company or otherwise in connection with the discharge of his duties as a Director.

86. Subject to Article 85, any Director who, by request, goes or resides abroad for any purpose of the Company or who performs services which in the opinion of the Board go beyond the ordinary duties of a Director may be paid such extra remuneration as the Board may determine and such extra remuneration shall be in addition to or in substitution for any ordinary remuneration provided for by or pursuant to any other Article.

86B. The Company shall establish a salaries and remuneration committee, and the professional qualifications of members, formation, appointment, discharge, how such committee functions and exercises its power and other relevant matters shall be subject to the Applicable Listing Rules. The salaries and remunerations in the preceding paragraph include the salaries and remunerations and stock options and other measures providing substantial incentives for Directors and managers.
87. Subject to the Applicable Listing Rules, any Director may appoint another Director to be his or her alternate and to act in such Director’s place at any Board meeting. Every such alternate Director shall be entitled to attend and vote at the Board meeting as the alternate of the Director appointing him or her and where he or she is a Director to have a separate vote in addition to his or her own vote.

88. Subject to the Applicable Listing Rules, the appointment of the alternate Director referred in the preceding article shall be in writing under the hand of the appointing Director and shall be in any usual or common form or such other form as the Directors may approve, and must be lodged with the chairman of the meeting of the Directors at which such appointment is to be used, or first used, prior to the commencement of the Board meeting.

POWERS AND DUTIES OF DIRECTORS

89. At the close of each financial year, the Board of Directors shall prepare the business report, financial statements and the surplus earning distribution and/or loss offsetting proposals for adoption by the annual general meeting, and upon such adoption by the annual general meeting, distribute or make public announcements to each Shareholder copies of adopted financial statements and the resolutions on the surplus earning distribution and/or loss offsetting in accordance with these Articles and the Applicable Listing Rules. For so long as the Shares are registered in the Emerging Stock Market or listed in the TPEx or the TSE, alternatively, the distribution of the aforesaid adopted financial statements and the resolutions on the surplus earning distribution and/or loss offsetting may be accomplished by way of making public announcements by the Company.

90. Subject to the Law, these Articles, Applicable Listing Rules and to any resolutions passed in a general meeting, the business of the Company shall be managed by the Directors, who may pay all expenses incurred in setting up and registering the Company and may exercise all powers of the Company.

91. The Directors may from time to time appoint any Person (exclusive of any Independent Directors), whether or not a Director to hold such office in the Company as the Directors may think necessary for the administration of the Company, including but not limited to, the office of the chief executive officer, president, one (1) or more vice-presidents or chief financial officer, and for such term and at such remuneration (whether by way of salary or commission or participation in profits or partly in one way and partly in another), and with such powers and duties as the Directors may think fit. Notwithstanding the foregoing, if any Directors hold either of the above positions, the relevant remuneration shall be subject to Article 85. Any Person so appointed by the Directors may be removed by the Directors.

92. The Directors may appoint a Secretary (and if need be an assistant Secretary or assistant Secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such powers as they think fit. Any Secretary or assistant Secretary so appointed by the Directors may be removed by the Directors.

93. The Directors may delegate any of their powers to committees consisting of such member or members of their body as they think fit; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that may be imposed on it by the Directors.

94. The Directors may from time to time and at any time by power of attorney (whether under Seal or under hand) or otherwise appoint any company, firm or Person or body of Persons, whether nominated directly or indirectly by the Directors, to be the attorney or attorneys of the Company for such purposes and with such powers, authorities and discretion (not exceeding those vested in or exercisable by the Directors under these Articles) and for such period and subject to such
conditions as they may think fit, and any such power of attorney or other appointment may contain such provisions for the protection and convenience of Persons dealing with any such attorney as the Directors may think fit, and may also authorise any such attorney to delegate all or any of the powers, authorities and discretion vested in him.

95. The Directors may from time to time provide for the management of the affairs of the Company in such manner as they shall think fit and the provisions contained in the two next following Articles shall not limit the general powers conferred by this Article.

96. The Directors from time to time and at any time may establish any committees for managing any of the affairs of the Company (including but not limited to remuneration committee), and unless otherwise provided in the Applicable Listing Rules, the members of such committees shall be Directors. Where any Director holds above position, the relevant remuneration shall be subject to Article 85.

97. Any such delegates as aforesaid may be authorised by the Directors to sub-delegate all or any of the powers, authorities, and discretion for the time being vested in them.

97B. Subject to the Cayman Islands law and the Applicable Listing Rules, any Director shall owe fiduciary duties to the Company and such fiduciary obligations shall include but not limited to the observance of general standards of loyalty, good faith and the avoidance of a conflict of duty and self-interest. If any Director breaches the aforesaid fiduciary duties, subject to the Cayman Islands law and the Applicable Listing Rules, such Director shall be held liable for any damages therefrom.

Subject to the Cayman Islands law and the Applicable Listing Rules, if any Director violates the aforesaid fiduciary duties for him/herself or another person, it may be resolved at the general meeting to deem any income from such behaviour as the Company’s income.

If any Director breaches any applicable laws or regulations in performing business for the Company, therefore causing any loss or damage to third party, subject to the Cayman Islands law and the Applicable Listing Rules, such Director shall be held jointly and severally liable for the loss or damage to such third party with the Company. In this connection, such Director shall indemnify the Company for any loss or damage incurred by the Company to third party.

Subject to Cayman Islands law and the Applicable Listing Rules, to the extent of the scope of their respective duties, the officers and the supervisors (if any) of the Company shall bear the liability identical to that applicable to Directors pursuant to the preceding paragraphs of this Article.

BORROWING POWERS OF DIRECTORS

98. Subject to these Articles and the Applicable Listing Rules, the Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its undertaking and property, to issue debentures, debenture stock and other securities whenever money is borrowed or as security for any debt, liability or obligation of the Company or of any third party.

THE SEAL

99. The Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of the Seal and if given after may be in general form confirming a number of affixings of the Seal. The Seal shall be affixed in the presence of a Director or a Secretary (or an assistant Secretary) or in the presence of any one (1) or more Persons as the Directors may appoint for the purpose and every Person as aforesaid shall sign every instrument to which the Seal is so affixed in their presence.

100. The Company may maintain a facsimile of the Seal in such countries or places as the Directors may appoint and such facsimile Seal shall not be affixed to any instrument except by the authority
of a resolution of the Directors provided always that such authority may be given prior to or after the affixing of such facsimile Seal and if given after may be in general form confirming a number of affixings of such facsimile Seal.

101. Notwithstanding the foregoing, a Secretary or any assistant Secretary shall have the authority to affix the Seal, or the facsimile Seal, to any instrument for the purposes of attesting authenticity of the matter contained therein but which does not create any obligation binding on the Company.

DISQUALIFICATION OF DIRECTORS

102. A person shall not act as a Director and shall be discharged or vacated from the office of Director, if he or she:

(a) committed an organized crime and has been adjudicated guilty by a final judgment, and has not served the term of the sentence yet, has not served the full term of the sentence, or the time elapsed after he has served the full term of the sentence, his term of probation has expired or he has been pardoned is less than five (5) years;

(b) has been sentenced to imprisonment for a term of more than one (1) year for commitment of fraud, breach of trust or misappropriation, and has not served the term of the sentence yet, has not served the full term of the sentence, or the time elapsed after he has served the full term of such sentence, his term of probation has expired or he has been pardoned is less than two (2) years;

(c) has been adjudicated guilty by a final judgment for violating anti-corruption law, and has not served the term of the sentence yet, has not served the full term of the sentence, or the time elapsed after he has served the full term of such sentence, his term of probation has expired or he has been pardoned is less than two (2) years;

(d) becomes bankrupt or enters into liquidation process by a court order and has not been discharged from bankruptcy or liquidation;

(e) has been dishonored for unlawful use of credit instruments, and the term of such sanction has not expired yet;

(f) has no or only limited legal capacity;

(g) dies or is found to be or becomes of unsound mind;

(h) resigns his office by notice in writing to the Company;

(i) becomes subject to the order of commencement of assistance due to incapacity pursuant to relevant law and the order has not been revoked; or

(j) is removed from office and ceases to be the Director pursuant to these Articles.

103. In case a Director has, in the course of performing his/her duties, committed any act resulting in material damage to the Company or in serious violation of applicable laws and regulations and these Articles, but not been discharged or removed by a resolution of the general meeting, any Shareholder(s) holding three percent (3%) or more of the total number of issued Shares may, within thirty (30) days after that general meeting, submit a petition to a competent court having proper jurisdiction, including, the Taipei District Court of the Republic of China if applicable, in respect of such matter, for the removal of such Director, at the Company’s expense.
104. The Directors may meet together (either within or outside the Cayman Islands) for the dispatch of business, adjourn, and otherwise regulate their meetings and proceedings as they think fit. Questions arising at any meeting shall be decided by a majority of votes present at such meeting. In case of an equality of votes the chairman shall not have a second or casting vote. The notice of the Board meeting shall state the reasons for such meeting and shall be given to each Director at least seven (7) days prior to the meeting via mail or electronic transmission; however the Board meeting may be convened from time to time in case of any emergency in accordance with the Applicable Listing Rules. Subject to these Articles and the Applicable Listing Rules, the Company shall additionally comply with the Procedural Rules of Board Meetings.

105. A Director may participate in any meeting of the Board of Directors, or of any committee appointed by the Board of Directors of which such Director is a member, by means of videoconference or similar communication equipment by way of which all Persons participating in such meeting can communicate with each other and such participation shall be deemed to constitute presence in person at the meeting.

106. Unless otherwise provided in these Articles, the quorum necessary for the transaction of the business of the Directors shall be more than one-half (1/2) of the Directors. A Director represented by alternate Director at any Board meeting shall be deemed to be present for the purposes of determining whether or not a quorum is present.

107. A Director who directly or indirectly has personal interest in the matter proposed at the meeting of the Board, including but not limited to a contract or proposed contract or arrangement with the Company shall disclose the nature of his or her personal interest at the meeting of the Board, if he or she knows his or her personal interest then exists, or in any other case at the first meeting of the Board after he or she knows that he or she is or has become so interested. For the purposes of this Article, a general notice to the Board by a Director to the effect that:

(a) he is a member or officer of a specified company or firm and is to be regarded as interested in any contract or arrangement which may after the date of the notice be made with that company or firm; or

(b) he is to be regarded as interested in any contract or arrangement which may after the date of the notice be made with a specified person who is connected with him;

shall be deemed to be a sufficient disclosure of personal interest under this Article in relation to any such contract or arrangement, provided that no such notice shall be effective unless either it is given at a meeting of the Board or the Director takes reasonable steps to secure that it is brought up and read at the next Board meeting after it is given.

To the extent required by Applicable Listing Rules, a Director may not vote for himself or on behalf of other Director in respect to any matter, including but not limited to any contract or proposed contract or arrangement or contemplated transaction of the Company, in which such Director bears a personal interest (whether directly or indirectly) which may conflict with and impair the interest of the Company. Any votes cast by or on behalf of such Director in contravention of the foregoing shall not be counted by the Company, but such Director shall be counted in the quorum for purposes of convening such meeting.

Notwithstanding the first paragraph of this Article, if any Director has personal interest (whether directly or indirectly) in matters on agenda for the Board meeting, such Director shall disclose and explain the material information or contents on such personal interest at the same Board meeting; before the Company adopts any resolution of Merger, Acquisition, Spin-off or share swap, a Director who has a personal interest in the transaction of Merger, Acquisition, Spin-off or share swap shall declare such interest to the Board at the Board meeting and to the shareholders at the
general meeting the essential contents of such personal interest and the reasons that the relevant resolution shall be approved or dissented.

In the case that a Director's spouse, a blood relative within second degree of kinship or a company which has parent-subsidiary relationship with the Director has personal interest in a matter on agenda for the Board meeting, such Director shall be deemed to have personal interest in that matter.

108. A Director (exclusive of any Independent Directors) who does anything for himself or on behalf of another person that is within the scope of the Company's business shall declare the essential contents of such behaviour to the general meeting of the Shareholders and be approved by either a Supermajority Resolution Type A or a Supermajority Resolution Type B. Failure in obtaining such approval shall cause the Director being so interested be liable to account to the Company for any profit realised by any such behaviour if the general meeting so resolves by an Ordinary Resolution within one (1) year from such behaviour.

109. Notwithstanding the preceding Articles, subject to the Applicable Listing Rules, a Director (exclusive of any Independent Directors) may hold any other office or place of profit under the Company (other than the office of internal auditor) in conjunction with his office of Director for such period and on such terms (as to remuneration and otherwise) as the Directors may determine and no Director or intending Director shall be disqualified by his office from contracting with the Company either with regard to his tenure of any such other office or place of profit nor shall any Director so contracting or being so interested be liable to account to the Company for any profit realised by any such contract or arrangement by reason of such Director holding that office or of the fiduciary relation thereby established.

110. Subject to these Articles and the Applicable Listing Rules, any Director (exclusive of any Independent Directors) may act by himself or his firm in a professional capacity for the Company, and he or his firm shall be entitled to remuneration for professional services as if he were not a Director; provided that nothing herein contained shall authorise a Director or his firm to act as internal auditor to the Company.

111. The Directors shall cause all minutes to be made in books or loose-leaf folders provided for the purpose of recording:

(a) all appointments of officers made by the Directors;

(b) the names of the Directors present at each meeting of the Directors and of any committee of the Directors; and

(c) all resolutions and proceedings at all meetings of the Company, and of the Directors and of committees of Directors.

112. Subject to the Applicable Listing Rules, when the chairman of a meeting of the Directors signs the minutes of such meeting the same shall be deemed to have been duly held.

113. Subject to the Applicable Listing Rules, the continuing Directors may act notwithstanding any vacancy in their body but if and for so long as their number is reduced below the number fixed by or pursuant to these Articles as the necessary quorum of Directors, the continuing Directors may act for summoning a general meeting of the Company, but for no other purpose.

114. Subject to the Applicable Listing Rules and any regulations imposed on it by the Directors, a committee appointed by the Directors may elect a chairman of its meetings. If no such chairman is elected, or if at any meeting the chairman is not present within fifteen minutes after the time appointed for holding the meeting, the committee members present may choose one (1) of their number to be chairman of the meeting.
115. A committee appointed by the Directors may meet and adjourn as it thinks proper. Subject to the Applicable Listing Rules and any regulations imposed on it by the Directors, questions arising at any meeting shall be determined by a majority of votes of the committee members present.

116. Subject to the Applicable Listing Rules and any regulations imposed on it by the Directors, all acts done by any meeting of the Directors or of a committee of Directors, or by any Person acting as a Director, shall notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director or Person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such Person had been duly appointed and was qualified to be a Director.

117. The following actions require the approval of a majority of the votes of the Directors present at a Board meeting attended by at least two-thirds (2/3) of all Directors:

(a) entering into, amendment to, or termination of any contract for lease of its business in whole, or for entrusted business, or for regular joint operation with others;
(b) the sale or transfer of the whole or any material part of its business or assets;
(c) taking over the transfer of another's whole business or assets, which will have a material effect on the business operation of the Company;
(d) the election of Chairman of the Board pursuant to these Articles;
(e) pay dividends and bonuses in whole or in part in cash pursuant to Article 125A;
(f) the allocation of Employees’ Remunerations and Directors’ Remunerations pursuant to Article 129; and
(g) issuance of corporate bonds.

AUDIT COMMITTEE

118. The Company shall set up an Audit Committee, and the professional qualifications of members, formation, appointment, discharge, how such committee functions and exercises its power and other relevant matters shall be subject to the Applicable Listing Rules. The Audit Committee shall comprise solely of all Independent Directors and the number of committee members shall not be less than three (3). One (1) of the Audit Committee members shall be appointed as the convener to convene meetings of the Audit Committee from time to time and at least one (1) of the Audit Committee members shall have accounting or financial expertise. A valid resolution of the Audit Committee requires approval of one-half (1/2) or more of all its members.

119. Notwithstanding anything provided to the contrary contained in these Articles, the following matters require approval of one-half (1/2) or more of all members of the Audit Committee and final approval of the Board:

(a) adoption of or amendment to an internal control system;
(b) assessment of the effectiveness of the internal control system;
(c) adoption of or amendment to the handling procedures for financial or operational actions of material significance, such as acquisition or disposal of assets, derivatives trading, provision or extension of monetary loans to others, or endorsements or guarantees for others;
(d) any matter relating to the personal interest of the Directors;
(e) the entering into of a transaction relating to material assets or derivatives;
(f) a material monetary loan, endorsement, or provision of guarantee;
(g) the offering, issuance, or private placement of the Shares or any equity-linked securities;
(h) the hiring or dismissal of an attesting certified public accountant as the auditor of the
    Company, or the compensation given thereto;
(i) the appointment or discharge of a financial, accounting, or internal auditing officers;
(j) annual financial reports and second quarter financial reports that must be audited and
    attested by a CPA, which are signed or sealed by the Chairman, managerial officer and
    accounting officer; and
(k) any other material matter deemed necessary by the Board of Directors or so required by
    Applicable Listing Rules or the competent authority.

Subject to the Applicable Listing Rules, with the exception of item (j) above, any other matter that
has not been approved with the consent of one-half (1/2) or more of all Audit Committee members
may be undertaken upon the consent of two-thirds (2/3) or more of all Directors, and the resolution
of the Audit Committee shall be recorded in the minutes of the Board meeting.

Subject to the Applicable Listing Rules, where the Audit Committee is unable to convene a
meeting for any proper cause, matters may be approved by consent of two-thirds (2/3) or more of
all Directors, provided that the Independent Director members shall still be required to issue an
opinion as to whether the resolution is approved in respect of a matter under item (j) above.

119A. Before the Company holds a meeting of the Board of Directors to adopt any resolution of Merger,
Acquisition, Spin-off or share swap, the Audit Committee shall seek opinion from an independent
expert in order to review the fairness and reasonableness of the plan and transaction of the
Merger, Acquisition, Spin-off or share swap, including but not limited to the justification of share
swap ratio or a distribution by cash or otherwise, and the review result shall be submitted to the
Board of Directors and Shareholders in the general meeting (provided, however, that if the Law
does not require the Shareholders' approval on the said transactions, the expert opinion and
review result do not have to be submitted to the general meeting); and the review result and the
expert opinion shall be provided to the Shareholders together with the notice of general meeting.
If the Law does not require the Shareholders' approval on the said transactions, the Board of
Directors shall report the transactions in the general meeting following the transactions.

For the documents to be given to the Shareholders in the preceding paragraph, if the Company
announces the same content as in those documents on a website designated by the Taiwan
competent authorities and those documents are prepared at the venue of the general meeting for
Shareholders' review, those documents shall be deemed as having been given to Shareholders.

120. The accounts of the Company shall be audited at least once in every year.

121. The Audit Committee shall at all reasonable times have access to and may make copies of all
books, all accounts and vouchers and documents kept by the Company; and the Audit Committee
may call on the Directors or officers of the Company for any information in their possession
relating to the books or affairs of the Company.

122. The statement of income and expenditure and the balance sheet provided for by these Articles
shall be examined by the Audit Committee and compared with the books, accounts and vouchers
relating thereto; and the Audit Committee shall make a written report thereon stating whether such statement and balance sheet are drawn up so as to present fairly the financial position of the Company and the results of its operations for the period under review and, in case information shall have been called for from Directors or officers of the Company, whether the same has been furnished and has been satisfactory. The Audit Committee may appoint, on behalf of the Company, a practicing lawyer and a certified public accountant to conduct the examination. The financial statements of the Company shall be audited by an auditor appointed by the Board in accordance with generally accepted auditing standards. The auditor shall make a written report thereon in accordance with generally accepted auditing standards and the report of the auditor shall be submitted to the Members in general meeting. The generally accepted auditing standards referred to herein may be those of a country or jurisdiction other than the Cayman Islands. If so, the financial statements and the report of the auditor should disclose this fact and name such country or jurisdiction.

123. Subject to the Cayman Islands law, any Shareholder(s) holding one percent (1%) or more of the total number of the issued Shares of the Company for six (6) consecutive months or longer may request in writing any supervisor (if any) to file a litigation against any Director or Directors on behalf of the Company with a competent court having proper jurisdiction, including Taipei District Court of the Republic of China.

If the supervisor (if any) who has been requested by such Shareholder(s) in accordance with the previous paragraph fails or refuses to file such litigation within thirty (30) days after receiving the request by such Shareholder(s), subject to Cayman Islands law, such Shareholder(s) may file such litigation on behalf of the Company with a competent court having proper jurisdiction, including Taipei District Court of the Republic of China.

123A. Other than that the Board of Directors is unwilling or unable to convene a general meeting, a supervisor (if any) may convene a general meeting for the interest of the Company when necessary.

124. Subject to these Articles and the Applicable Listing Rules, the Company shall additionally comply with the Rules of Audit Committee.

DIVIDENDS

125. Subject to the Law, any rights and restrictions for the time being attached to any Shares and these Articles, the Company by Ordinary Resolution may declare dividends and other distributions on Shares in issue and authorise payment of the same out of the funds of the Company lawfully available therefor.

125A. Notwithstanding the preceding Article (125), the Directors may distribute part or all of the dividends or bonus by way of cash with the approval of a majority of the votes of the Directors present at a Board meeting attended by at least two-thirds (2/3) of all Directors, and report the aforementioned distribution to the Shareholders at the next general meeting.

126. Subject to Article 129, the Directors may, before recommending any dividend, set aside out of the funds legally available for distribution such sums as they think proper as a reserve or reserves which shall, in the discretion of the Directors be applicable for meeting contingencies, or for equalising dividends or for any other purpose to which those funds may be properly applied and pending such application may in the absolute discretion of the Directors, either be employed in the business of the Company or be invested in such investments as the Directors may from time to time think fit.

127. Any dividend may be paid by cheque sent through the post to the registered address of the Shareholder or Person entitled thereto, or in the case of joint holders, to the representative of such joint holders at his registered address or to such Person and such address as the
Shareholder or Person entitled, or such joint holders as the case may be, may direct. Every such cheque shall be made payable to the order of the Person to whom it is sent or to the order of such other Person as the Shareholder or Person entitled, or such joint holders as the case may be, may direct.

128. Subject to any rights and restrictions for the time being attached to any Shares, all dividends shall be declared and paid according to the number of the Shares held by the Shareholders.

129. As the Company continues to grow, the need for capital expenditure, business expansion and a sound financial planning for sustainable development, it is the Company's dividends policy that the dividends may be allocated to the Shareholders in the form of cash dividends and/or bonus shares according to the Company's future expenditure budgets and funding needs.

Unless otherwise provided in the Applicable Listing Rules, where the Company makes profits before tax for the annual financial year, the Company shall allocate (1) at least one percent (1%) of such annual profits before tax for the purpose of employees' remunerations (including employees of the Company and/or any Affiliated Company) (the "Employees' Remunerations"); and (2) at most three percent (3%) of such annual profits before tax for the purpose of Directors' remunerations (the "Directors' Remunerations"). Notwithstanding the foregoing paragraph, if the Company has accumulated losses of the previous years for the annual financial year, the Company shall set aside the amount of such accumulated losses prior to the allocation of Employees' Remunerations and Directors' Remunerations. Subject to Cayman Islands law and notwithstanding Article 139, the Employees' Remunerations may be distributed in the form of cash and/or bonus shares, and the Directors' Remunerations may be distributed in the form of cash, upon resolution by a majority votes at a meeting of the Board of Directors attended by two-thirds (2/3) or more of the Directors. The resolutions of Board of Directors regarding the distribution of the Employees' Remunerations and the Directors' Remunerations in the preceding paragraph shall be reported to the Shareholders at the general meeting after such Board resolutions are passed.

Unless otherwise provided in the Applicable Listing Rules, the net profits of the Company for each annual financial year shall be allocated in the following order and proposed by the Board of Directors to the Shareholders in the general meeting for approval:

(a) to make provision of the applicable amount of income tax pursuant to applicable tax laws and regulations;

(b) to set off cumulative losses of previous years (if any);

(c) to set aside ten percent (10%) as Legal Reserve pursuant to the Applicable Listing Rules unless the accumulated amount of such Legal Reserve equals to the total paid-up capital of the Company;

(d) to set aside an amount as Special Reserve pursuant to the Applicable Listing Rules and requirements of the Commission; and

(e) with respect to the earnings available for distribution (i.e. the net profit after the deduction of the items (a) to (d) above plus any previously undistributed cumulative Retained Earnings), the Board of Directors may present a proposal to distribute to the Shareholders by way of dividends at the annual general meeting for approval pursuant to the Applicable Listing Rules. Dividends may be distributed in the form of cash dividends and/or bonus shares, and, subject to Cayman Islands law, the amount of dividends shall be at least ten percent (10%) of the net profit after the deduction of the items (a) to (d) above. Cash dividends shall comprise a minimum of ten percent (10%) and a maximum of one hundred percent (100%) of the total dividends allocated to Shareholders.
130. If several Persons are registered as joint holders of any Share, any of them may give effectual receipts for any dividend or other moneys payable on or in respect of the Share. No dividend shall bear interest against the Company.

ACCOUNTS, AUDIT AND ANNUAL RETURN AND DECLARATION

131. The books of account relating to the Company's affairs shall be kept in such manner as may be determined from time to time by the Directors.

132. The books of account shall be kept at the Office or at such other place or places as the Directors think fit, and shall always be open to the inspection of the Directors.

133. The Board of Directors shall prepare and submit the business reports, financial statements and records to the annual general meeting of Shareholders for its ratification and after the meeting shall distribute to each Shareholder the copies of ratified financial statements and the resolutions on the surplus earning distribution and/or loss offsetting. For so long as the Shares are registered in the Emerging Stock Market or listed in the TPEx or the TSE, alternatively, the distribution of the aforesaid adopted financial statements and the resolutions on the surplus earning distribution and/or loss offsetting may be accomplished by way of making public announcements by the Company.

134. Subject to the Applicable Listing Rules, the Board shall keep copies of the yearly business report, financial statements and other relevant documents at the office of its Shareholders’ Service Agent in Taiwan ten (10) days before the annual general meeting and any of its Shareholders is entitled to inspect such documents from time to time.

135. Save for the preceding Article 134 and Article 148, the Directors shall from time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of the Company or any of them shall be open to the inspection of Shareholders not being Directors, and no Shareholder (not being a Director) shall have any right of inspecting any account or book or document of the Company except as conferred by law or authorised by the Directors or by Ordinary Resolution.

136. The accounts relating to the Company’s affairs shall only be audited in such manner and with such financial year end as may be determined from time to time by the Directors, or required by the Applicable Listing Rules.

137. The Directors in each year shall prepare, or cause to be prepared, an annual return and declaration setting forth the particulars required by the Law and deliver a copy thereof to the Registrar of Companies in the Cayman Islands.

INTERNAL AUDIT

138. The Company shall set up internal audit unit under the Board of Directors, and hire qualified and adequate staffs as internal auditors. Any matters in relation to the internal audit shall comply with the Applicable Listing Rules.

CAPITALISATION OF RESERVES

139. Subject to the Applicable Listing Rules and the Law, the Company may, with the authority of either a Supermajority Resolution Type A or a Supermajority Resolution Type B:

(a) resolve to capitalise an amount standing to the credit of reserves or other capital reserves (including a share premium account, capital redemption reserve, revenue, profit and loss account, Capital Reserves, Legal Reserves and Special Reserves), whether or not available for distribution;
appropriate the sum resolved to be capitalised to the Shareholders in proportion to the number of Shares held by them respectively and apply that sum on their behalf in or towards paying up in full unissued Shares or debentures of a nominal amount equal to that sum, and allot the Shares or debentures, credited as fully paid, to the Shareholders (or as they may direct) in those proportions, or partly in one way and partly in the other;

make any arrangements it thinks fit to resolve a difficulty arising in the distribution of a capitalised reserve and in particular, without limitation, where Shares or debentures become distributable in fractions the Directors may deal with the fractions as they think fit; and

generally do all acts and things required to give effect to any of the actions contemplated by these Articles.

139B. For the avoidance of doubts, the allotment of bonus shares in connection with the Employees’ Remunerations pursuant to Article 129 shall not require the approval of a Supermajority Resolution Type A or a Supermajority Resolution Type B.

**TENDER OFFER**

140. For so long as the Shares of the Company are registered in the Emerging Market and/or listed in the TPEx or TSE, subject to the Applicable Listing Rules, within fifteen (15) days after the receipt of the copy of a tender offer application form and relevant documents by the Company or its litigation or non-litigation agent appointed pursuant to the Applicable Listing Rules, the Board of the Directors shall resolve to recommend to the Shareholders whether to accept or object to the tender offer and make a public announcement of the following:

(a) The types and amount of the Shares held by the Directors and the Shareholders holding more than ten percent (10%) of the outstanding Shares held in its own name or in the name of other persons.

(b) The recommendation based on investigation into the identify and financial position of the tender offeror, fairness of the tender offer conditions, and validity of funding sources to the Shareholders, where in the opinions and reasons of every consenting and objecting Director(s) shall be indicated;

(c) Whether there is any material change in the financial condition of the Company after the submission of the latest financial report and an explanation of the change, if any.

(d) The types, numbers and amount of the shares of the tender offeror or its affiliates held by the Directors and the Shareholders holding more than ten percent (10%) of the outstanding Shares held in its own name or in the name of other persons.

**SHARE PREMIUM ACCOUNT**

141. The Directors shall in accordance with the Law establish a share premium account and shall carry to the credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share.

142. Subject to the Applicable Listing Rules and the Law, there shall be debited to any share premium account on the redemption or purchase of a Share the difference between the nominal value of such Share and the redemption or purchase price provided always that at the discretion of the Directors such sum may be paid out of the profits of the Company or, if permitted by the Law, out of capital.
NOTICES

143. Except as otherwise provided in these Articles or the Applicable Listing Rules, any notice or document may be served by the Company or by the Person entitled to give notice to any Shareholder either personally, or by facsimile, or by sending it through the post in a prepaid letter or via a recognised courier service, fees prepaid, addressed to such Shareholder at his address as appearing in the Register, or to the extent permitted by all applicable laws and regulations, by electronic means by transmitting it to any electronic mail number or address such Shareholder may have positively confirmed in writing for the purpose of such service of notices. In the case of joint holders of a Share, all notices shall be given to that one of the joint holders whose name stands as their representative in the Register in respect of the joint holding, and notice so given shall be sufficient notice to all the joint holders.

144. Any Shareholder present, either personally or by proxy, at any meeting of the Company shall for all purposes be deemed to have received due notice of such meeting and, where requisite, of the purposes for which such meeting was convened.

145. Except as otherwise provided in these Articles or the Applicable Listing Rules, any notice or other document, if served by:

(a) post or courier, shall be deemed to have been served five (5) days after the time when the letter containing the same is posted or delivered to the courier;

(b) facsimile, shall be deemed to have been served upon production by the transmitting facsimile machine of a report confirming transmission of the facsimile in full to the facsimile number of the recipient;

(c) recognised courier service, shall be deemed to have been served forty-eight (48) hours after the time when the letter containing the same is delivered to the courier service; or

(d) electronic mail, shall be deemed to have been served immediately upon the time of the transmission by electronic mail.

In proving service by post or courier service it shall be sufficient to prove that the letter containing the notice or documents was properly addressed and duly posted or delivered to the courier service.

146. Any notice or document delivered or sent by post to or left at the registered address of any Shareholder in accordance with these Articles shall notwithstanding that such Shareholder be then dead or bankrupt, and whether or not the Company has notice of his death or bankruptcy, be deemed to have been duly served in respect of any Share registered in the name of such Shareholder as sole or joint holder, unless his name shall at the time of the service of the notice or document, have been removed from the Register as the holder of the Share, and such service shall for all purposes be deemed a sufficient service of such notice or document on all Persons interested (whether jointly with or as claiming through or under him) in the Share.

147. Notice of every general meeting of the Company shall be given to:

(a) all Shareholders holding Shares with the right to receive notice and who have supplied to the Company an address for the giving of notices to them; and

(b) every Person entitled to a Share in consequence of the death or bankruptcy of a Shareholder, who but for his death or bankruptcy would be entitled to receive notice of the meeting.

No other Person shall be entitled to receive notices of general meetings.
INFORMATION

148. The Board shall keep at the office of its Shareholders’ Service Agent in Taiwan copies of the Memorandum of Association and Articles of Association, the minutes of every general meeting, the financial statements, the Register of Members and the counterfoil of corporate bonds issued by the Company. Any Shareholder may request, by submitting evidentiary document(s) to show his/her interests involved and indicating the scope of interested matters, an access to inspect and to make copies of the foresaid Memorandum of Association and Articles of Association, the minutes of every general meeting, the financial statements, the Register of Members and the counterfoil of the corporate bonds issued by the Company. The Company shall cause its Shareholders’ Service Agent to provide the aforesaid documents.

149. Without prejudice to the rights set forth in these Articles, no Shareholder shall be entitled to require discovery of any information in respect of any detail of the Company’s trading or any information which is or may be in the nature of a trade secret or secret process which may relate to the conduct of the business of the Company and which in the opinion of the Board would not be in the interests of the members of the Company to communicate to the public.

150. The Board shall be entitled to release or disclose to any regulatory or judicial authority any information in its possession, custody or control regarding the Company or its affairs to any of its Shareholder including, without limitation, information contained in the Register of Members and transfer books of the Company.

INDEMNITY OR INSURANCE

151. The Company may by Ordinary Resolution adopt one (1) of the protection mechanisms as described in Article 152 (a) and (b).

152. (a) Every Director and other officer for the time being and from time to time of the Company (each an “Indemnified Person”) may be indemnified and secured harmless out of the assets and funds of the Company against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such Indemnified Person, other than by reason of such Indemnified Person’s own dishonesty, wilful default or fraud, in or about the conduct of the Company’s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such Indemnified Person in defending (whether successfully or otherwise) any civil proceedings concerning the Company or its affairs in any court whether in the Cayman Islands or elsewhere.

(b) The Company may purchase directors and officers liability insurance (“D&O insurance”) for the benefit of every Director and other officer for the time being and from time to time of the Company. Such D&O insurance shall only cover the liability arising from the duty of such Director or officer in accordance with these Articles, the Law and the Applicable Listing Rules. The Board is hereby authorized to handle all matters in relation to the D&O insurance.

FINANCIAL YEAR

153. Unless the Directors otherwise prescribe, the financial year of the Company shall end on December 31st in each year and shall begin on January 1st in each year.

WINDING-UP

154. If the Company shall be wound up, and the assets available for distribution amongst the Shareholders shall be insufficient to repay the whole of the share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the Shareholders in proportion to the number of the Shares held by them. If in a winding up the assets available for
distribution amongst the Shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst the Shareholders in proportion to the number of the Shares held by them at the commencement of the winding up. This Article is without prejudice to the rights of the holders of Shares issued upon special terms and conditions.

155. If the Company shall be wound up, the liquidator may, with the sanction of a Special Resolution and any other sanction required by the Law and in compliance with the Applicable Listing Rules, divide amongst the Shareholders in specie or kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may, for such purpose set such value as he deems fair upon any property to be divided as aforesaid and may determine how such division shall be carried out as between the Shareholders or different Classes. The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the Shareholders as the liquidator, with the like sanction shall think fit, but so that no Shareholder shall be compelled to accept any asset whereon there is any liability.

156. The Company shall keep all statements, records of account and documents for a period of ten years from the date of the completion of liquidation, and the custodian thereof shall be appointed by the liquidator or the Company by Ordinary Resolution.

AMENDMENT OF ARTICLES OF ASSOCIATION

157. Subject to the Law and the Articles, the Company may at any time and from time to time by Special Resolution alter or amend the Memorandum of Association and/or these Articles in whole or in part.

LITIGIOUS AND NON-LITIGIOUS AGENT

158. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, subject to the Applicable Listing Rules, the Company shall appoint a litigious and non-litigious agent in Taiwan (the "Litigious and Non-Litigious Agent"). The Litigious and Non-Litigious Agent shall be the responsible person of the Company in Taiwan and shall have residence or domicile in Taiwan. The Company shall report to the Commission in respect of the name, residence or domicile and authorization document of the Litigious and Non-Litigious Agent. In case of any change of the name, residence or domicile and authorization document of the Litigious and Non-Litigious Agent, the Company shall report to the Commission in respect of such change.

CORPORATE SOCIAL RESPONSIBILITY

159. For the purpose of performing corporate social responsibility, the Company shall follow the applicable laws, regulations and business ethics in operating its businesses and may conduct practices to facilitate public interests.
Article 1  Basic for the adoption of these Rules
To establish a strong governance system and sound supervisory capabilities for this Corporation’s shareholders meetings, and to strengthen management capabilities, these Rules are adopted pursuant to Article 5 of the Corporate Governance Best-Practice Principles for TWSE/GTSM Listed Companies.

Article 2  Scope of these Rules
The rules of procedures for this Corporation’s shareholders meetings, except as otherwise provided by law, regulation, or the articles of incorporation, shall be as provided in these Rules.

Article 3  Convening shareholders meetings and shareholders meeting notices
Unless otherwise provided by law or regulation, this Corporation’s shareholders meetings shall be convened by the board of directors. Changes to how this Corporation convenes its shareholders meeting shall be resolved by the board of directors, and shall be made no later than mailing of the shareholders meeting notice.

This Corporation shall prepare electronic versions of the shareholders meeting notice and proxy forms, and the origins of and explanatory materials relating to all proposals, including proposals for ratification, matters for deliberation, or the election or dismissal of directors or supervisors, and upload them to the Market Observation Post System (MOPS) before 30 days before the date of a regular shareholders meeting or before 15 days before the date of a special shareholders meeting. This Corporation shall prepare electronic versions of the shareholders meeting agenda and supplemental meeting materials and upload them to the MOPS before 21 days before the date of the regular shareholders meeting or before 15 days before the date of the special shareholders meeting. If, however, this Corporation has the paid-in capital of NT$10 billion or more as of the last day of the most current fiscal year, or total shareholding of foreign
shareholders and PRC shareholders reaches 30% or more as recorded in the register of shareholders of the shareholders meeting held in the immediately preceding year, transmission of these electronic files shall be made by 30 days before the regular shareholders meeting. In addition, before 15 days before the date of the shareholders meeting, this Corporation shall also have prepared the shareholders meeting agenda and supplemental meeting materials and made them available for review by shareholders at any time. The meeting agenda and supplemental materials shall also be displayed at this Corporation and the professional shareholder services agent designated thereby.

This Corporate shall make the meeting agenda and supplemental meeting materials in the preceding paragraph available to shareholders for review in the following manner on the date of the shareholders meeting:
1. For physical shareholders meetings, to be distributed on-site at the meeting.
2. For hybrid shareholders meetings, to be distributed on-site at the meeting and shared on the virtual meeting platform.
3. For virtual-only shareholders meetings, electronic files shall be shared on the virtual meeting platform.

The reasons for convening a shareholders meeting shall be specified in the meeting notice and public announcement. With the consent of the addressee, the meeting notice may be given in electronic form.

Election or dismissal of directors or supervisors, amendments to the articles of incorporation, reduction of capital, application for the approval of ceasing its status as a public company, approval of competing with the company by directors, surplus profit distributed in the form of new shares, reserve distributed in the form of new shares, the dissolution, merger, or demerger of the corporation, or any matter under Article 185, paragraph 1, Securities and Exchange Act Article 26-1 and 43-6, and Regulations Governing the Offering and Issuance of Securities by Securities Issuers Article 56-1 and 60-2 shall be set out and the essential contents explained in the notice of the reasons for convening the shareholders meeting. None of the above matters may be raised by an extraordinary motion.

When re-election of all directors and supervisors as well as their inauguration date is stated in the notice of the reasons for convening the shareholders meeting, after the completion of the re-election in said meeting such inauguration date may not be altered by any extraordinary motion or otherwise in the same meeting.
A shareholder holding 1 percent or more of the total number of issued shares may submit to this Corporation a written proposal for discussion at a regular shareholders meeting. The number of items so proposed, however, is limited to one only, and no proposal containing more than one item will be included in the meeting agenda. In addition, when the circumstances of any subparagraph of Article 172-1, paragraph 4 of the Company Act apply to a proposal put forward by a shareholder, the board of directors may exclude it from the agenda. A shareholder may propose a recommendation for urging the corporation to promote public interests or fulfill its social responsibilities, provided procedurally the number of items so proposed is limited only to one in accordance with Article 172-1 of the Company Act, and no proposal containing more than one item will be included in the meeting agenda.

Prior to the book closure date before a regular shareholders meeting is held, this Corporation shall publicly announce its acceptance of shareholder proposals in writing or electronically, and the location and time period for their submission; the period for submission of shareholder proposals may not be less than 10 days.

Shareholder-submitted proposals are limited to 300 words, and no proposal containing more than 300 words will be included in the meeting agenda. The shareholder making the proposal shall be present in person or by proxy at the regular shareholders meeting and take part in discussion of the proposal.

Prior to the date for issuance of notice of a shareholders meeting, this Corporation shall inform the shareholders who submitted proposals of the proposal screening results, and shall list in the meeting notice the proposals that conform to the provisions of this article. At the shareholders meeting the board of directors shall explain the reasons for exclusion of any shareholder proposals not included in the agenda.

Article 4 Proxy and Authorization
For each shareholders meeting, a shareholder may appoint a proxy to attend the meeting by providing the proxy form issued by this Company and stating the scope of the proxy's authorization.
A shareholder may issue only one proxy form and appoint only one proxy for any given shareholders meeting, and shall deliver the proxy form to this Company before 5 days prior to the date of the shareholders meeting. When duplicate proxy forms are delivered, the one received earliest shall prevail...
unless a declaration is made to cancel the previous proxy appointment. After a proxy form has been delivered to this Corporation, if the shareholder intends to attend the meeting in person or to exercise voting rights by correspondence or electronically, a written notice of proxy cancellation shall be submitted to this Company before 2 business days prior to the meeting date. If the cancellation notice is submitted after that time, votes cast at the meeting by the proxy shall prevail.

If, after a proxy form is delivered to this Corporation, a shareholder wishes to attend the shareholders meeting online, a written notice of proxy cancellation shall be submitted to this Corporation two business days before the meeting date. If the cancellation notice is submitted after that time, votes cast at the meeting by the proxy shall prevail.

**Article 5** Principles determining the time and place of a shareholders meeting

The venue for a shareholders meeting shall be the premises of this Corporation, or a place easily accessible to shareholders and suitable for a shareholders meeting. The meeting may begin no earlier than 9 a.m. and no later than 3 p.m. Full consideration shall be given to the opinions of the independent directors with respect to the place and time of the meeting.

The restrictions on the place of the meeting shall not apply when this Corporation convenes a virtual-only shareholders meeting.

**Article 6** Preparation of documents such as the attendance book

This Corporation shall specify in its shareholders meeting notices the time during which attendance registrations for shareholders, solicitors and proxies (collectively "shareholders") will be accepted, the place to register for attendance, and other matters for attention.

The time during which shareholder attendance registrations will be accepted, as stated in the preceding paragraph, shall be at least 30 minutes prior to the time the meeting commences. The place at which attendance registrations are accepted shall be clearly marked and a sufficient number of suitable personnel assigned to handle the registrations. For virtual shareholders meetings, shareholders may begin to register on the virtual meeting platform 30 minutes before the meeting starts. Shareholders completing registration will be deemed as attend the shareholders meeting in person.

Shareholders shall attend shareholders meetings based on attendance cards, sign-in cards, or other certificates of attendance. This Corporation may not arbitrarily add requirements for other documents beyond those showing eligibility to attend presented by shareholders. Solicitors soliciting proxy
forms shall also bring identification documents for verification.
This Corporation shall furnish the attending shareholders with an
attendance book to sign, or attending shareholders may hand in a sign-in
card in lieu of signing in.
This Corporation shall furnish attending shareholders with the meeting
agenda book, annual report, attendance card, speaker's slips, voting slips,
and other meeting materials. Where there is an election of directors or
supervisors, pre-printed ballots shall also be furnished.
When the government or a juristic person is a shareholder, it may be
represented by more than one representative at a shareholders meeting.
When a juristic person is appointed to attend as proxy, it may designate only
one person to represent it in the meeting.
In the event of a virtual shareholders meeting, shareholders wishing to
attend the meeting online shall register with this Corporation two days
before the meeting date.
In the event of a virtual shareholders meeting, this Corporation shall upload
the meeting agenda book, annual report and other meeting materials to the
virtual meeting platform at least 30 minutes before the meeting starts, and
keep this information disclosed until the end of the meeting.

Article 6-1 Convening virtual shareholders meetings and particulars to be
included in shareholders meeting notice
To convene a virtual shareholders meeting, this Corporation shall include
the follow particulars in the shareholders meeting notice:
1. How shareholders attend the virtual meeting and exercise their rights.
2. Actions to be taken if the virtual meeting platform or participation in the
virtual meeting is obstructed due to natural disasters, accidents or other
force majeure events, at least covering the following particulars:
   A. To what time the meeting is postponed or from what time the meeting
      will resume if the above obstruction continues and cannot be
      removed, and the date to which the meeting is postponed or on which
      the meeting will resume.
   B. Shareholders not having registered to attend the affected virtual
      shareholders meeting shall not attend the postponed or resumed
      session.
   C. In case of a hybrid shareholders meeting, when the virtual meeting
      cannot be continued, if the total number of shares represented at the
      meeting, after deducting those represented by shareholders attending
the virtual shareholders meeting online, meets the minimum legal requirement for a shareholder meeting, then the shareholders meeting shall continue. The shares represented by shareholders attending the virtual meeting online shall be counted towards the total number of shares represented by shareholders present at the meeting, and the shareholders attending the virtual meeting online shall be deemed abstaining from voting on all proposals on meeting agenda of that shareholders meeting.

D. Actions to be taken if the outcome of all proposals have been announced and extraordinary motion has not been carried out.

3. To convene a virtual-only shareholders meeting, appropriate alternative measures available to shareholders with difficulties in attending a virtual shareholders meeting online shall be specified.

Article 7 The chair and non-voting participants of a shareholders meeting

If a shareholders meeting is convened by the board of directors, the meeting shall be chaired by the chairperson of the board. When the chairperson of the board is on leave or for any reason unable to exercise the powers of the chairperson, the vice chairperson shall act in place of the chairperson; if there is no vice chairperson or the vice chairperson also is on leave or for any reason unable to exercise the powers of the vice chairperson, the chairperson shall appoint one of the managing directors to act as chair, or, if there are no managing directors, one of the directors shall be appointed to act as chair. Where the chairperson does not make such a designation, the managing directors or the directors shall select from among themselves one person to serve as the chair.

When a managing director or a director serves as chair, as referred to in the preceding paragraph, the managing director or director shall be one who has held that position for six months or more and who understands the financial and business conditions of the company. The same shall be true for a representative of a juristic person director that serves as the chair.

It is advisable that shareholders meetings convened by the board of directors be chaired by the chairperson of the board in person and attended by a majority of the directors, at least one supervisor in person, and at least one member of each functional committee on behalf of the committee. The attendance shall be recorded in the meeting minutes.

If a shareholders meeting is convened by a party with power to convene but other than the board of directors, the convening party shall chair the
meeting. When there are two or more such convening parties, they shall mutually select a chair from among themselves. This Corporation may appoint its attorneys, certified public accountants, or related persons retained by it to attend a shareholders meeting in a non-voting capacity.

**Article 8 Documentation of a shareholders meeting by audio or video**

This Corporation, beginning from the time it accepts shareholder attendance registrations, shall make an uninterrupted audio and video recording of the registration procedure, the proceedings of the shareholders meeting, and the voting and vote counting procedures. The recorded materials of the preceding paragraph shall be retained for at least 1 year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the recording shall be retained until the conclusion of the litigation.

Where a shareholders meeting is held online, this Corporation shall keep records of shareholder registration, sign-in, check-in, questions raised, votes cast and results of votes counted by this Corporation, and continuously audio and video record, without interruption, the proceedings of the virtual meeting from beginning to end.

The information and audio and video recording in the preceding paragraph shall be properly kept by this Corporation during the entirety of its existence, and copies of the audio and video recording shall be provided to and kept by the party appointed to handle matters of the virtual meeting. In case of a virtual shareholders meeting, this Corporation is advised to audio and video record the back-end operation interface of the virtual meeting platform.

**Article 9 The calculation of the number of shares attending the shareholders meeting and the meeting**

Attendance at shareholders meetings shall be calculated based on numbers of shares. The number of shares in attendance shall be calculated according to the shares indicated by the attendance book and sign-in cards handed in, and the shares checked in on the virtual meeting platform, plus the number of shares whose voting rights are exercised by correspondence or electronically.

The chair shall call the meeting to order at the appointed meeting time. At the same time, relevant information such as the number of non-voting rights and the number of shares present will be announced.
However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement, provided that no more than two such postponements, for a combined total of no more than 1 hour, may be made. If the quorum is not met after two postponements and the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned. In the event of a virtual shareholders meeting, this Corporation shall also declare the meeting adjourned at the virtual meeting platform.

If the quorum is not met after two postponements as referred to in the preceding paragraph, but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Article 175, paragraph 1 of the Company Act; all shareholders shall be notified of the tentative resolution and another shareholders meeting shall be convened within 1 month. In the event of a virtual shareholders meeting, shareholders intending to attend the meeting online shall re-register to this Corporation in accordance with Article 6.

When, prior to conclusion of the meeting, the attending shareholders represent a majority of the total number of issued shares, the chair may resubmit the tentative resolution for a vote by the shareholders meeting pursuant to Article 174 of the Company Act.

Article 10 Discussion of proposals

If a shareholders meeting is convened by the board of directors, the meeting agenda shall be set by the board of directors. Votes shall be cast on each separate proposal in the agenda (including extraordinary motions and amendments to the original proposals set out in the agenda). The meeting shall proceed in the order set by the agenda, which may not be changed without a resolution of the shareholders meeting.

The provisions of the preceding paragraph apply mutatis mutandis to a shareholders meeting convened by a party with the power to convene that is not the board of directors.

The chair may not declare the meeting adjourned prior to completion of deliberation on the meeting agenda of the preceding two paragraphs (including extraordinary motions), except by a resolution of the shareholders meeting. If the chair declares the meeting adjourned in violation of the rules of procedure, the other members of the board of directors shall promptly assist the attending shareholders in electing a new chair in accordance with statutory procedures, by agreement of a majority
of the votes represented by the attending shareholders, and then continue the meeting.

The chair shall allow ample opportunity during the meeting for explanation and discussion of proposals and of amendments or extraordinary motions put forward by the shareholders; when the chair is of the opinion that a proposal has been discussed sufficiently to put it to a vote, the chair may announce the discussion closed, call for a vote, and schedule sufficient time for voting.

**Article 11 Shareholder speech**

Before speaking, an attending shareholder must specify on a speaker's slip the subject of the speech, his/her shareholder account number (or attendance card number), and account name. The order in which shareholders speak will be set by the chair.

A shareholder in attendance who has submitted a speaker's slip but does not actually speak shall be deemed to have not spoken. When the content of the speech does not correspond to the subject given on the speaker's slip, the spoken content shall prevail.

Except with the consent of the chair, a shareholder may not speak more than twice on the same proposal, and a single speech may not exceed 5 minutes. If the shareholder's speech violates the rules or exceeds the scope of the agenda item, the chair may terminate the speech.

When an attending shareholder is speaking, other shareholders may not speak or interrupt unless they have sought and obtained the consent of the chair and the shareholder that has the floor; the chair shall stop any violation.

When a juristic person shareholder appoints two or more representatives to attend a shareholders meeting, only one of the representatives so appointed may speak on the same proposal.

After an attending shareholder has spoken, the chair may respond in person or direct relevant personnel to respond.

Where a virtual shareholders meeting is convened, shareholders attending the virtual meeting online may raise questions in writing at the virtual meeting platform from the chair declaring the meeting open until the chair declaring the meeting adjourned. No more than two questions for the same proposal may be raised. Each question shall contain no more than 200 words. The regulations in paragraphs 1 to 5 do not apply.

As long as questions so raised in accordance with the preceding paragraph
are not in violation of the regulations or beyond the scope of a proposal, it is advisable the questions be disclosed to the public at the virtual meeting platform.

**Article 12 Calculation of voting shares and recusal system**

Voting at a shareholders meeting shall be calculated based the number of shares.

With respect to resolutions of shareholders meetings, the number of shares held by a shareholder with no voting rights shall not be calculated as part of the total number of issued shares.

When a shareholder is an interested party in relation to an agenda item, and there is the likelihood that such a relationship would prejudice the interests of this Corporation, that shareholder may not vote on that item, and may not exercise voting rights as proxy for any other shareholder.

The number of shares for which voting rights may not be exercised under the preceding paragraph shall not be calculated as part of the voting rights represented by attending shareholders.

With the exception of a trust enterprise or a shareholder services agent approved by the competent securities authority, when one person is concurrently appointed as proxy by two or more shareholders, the voting rights represented by that proxy may not exceed 3 percent of the voting rights represented by the total number of issued shares. If that percentage is exceeded, the voting rights in excess of that percentage shall not be included in the calculation.

**Article 13 Proposal voting, scrutiny and counting methods**

A shareholder shall be entitled to one vote for each share held, except when the shares are restricted shares or are deemed non-voting shares under Article 179, paragraph 2 of the Company Act.

When this Corporation holds a Shareholder meeting, it shall adopt exercise of voting rights by electronic means and may adopt exercise of voting rights by correspondence. When voting rights are exercised by correspondence or electronic means, the method of exercise shall be specified in the shareholders meeting notice. A shareholder exercising voting rights by correspondence or electronic means will be deemed to have attended the meeting in person, but to have waived his/her rights with respect to the extraordinary motions and amendments to original proposals of that meeting; it is therefore advisable that this Corporation avoid the submission of extraordinary motions and amendments to original proposals.
A shareholder intending to exercise voting rights by correspondence or electronic means under the preceding paragraph shall deliver a written declaration of intent to this Corporation before 2 days before the date of the shareholders meeting. When duplicate declarations of intent are delivered, the one received earliest shall prevail, except when a declaration is made to cancel the earlier declaration of intent.

After a shareholder has exercised voting rights by correspondence or electronic means, in the event the shareholder intends to attend the shareholders meeting in person or online, a written declaration of intent to retract the voting rights already exercised under the preceding paragraph shall be made known to this Corporation, by the same means by which the voting rights were exercised, before 2 business days before the date of the shareholders meeting. If the notice of retraction is submitted after that time, the voting rights already exercised by correspondence or electronic means shall prevail. When a shareholder has exercised voting rights both by correspondence or electronic means and by appointing a proxy to attend a shareholders meeting, the voting rights exercised by the proxy in the meeting shall prevail.

Except as otherwise provided in the Company Act and in this Corporation’s articles of incorporation, the passage of a proposal shall require an affirmative vote of a majority of the voting rights represented by the attending shareholders. At the time of a vote, for each proposal, the chair or a person designated by the chair shall first announce the total number of voting rights represented by the attending shareholders, followed by a poll of the shareholders. After the conclusion of the meeting, on the same day it is held, the results for each proposal, based on the numbers of votes for and against and the number of abstentions, shall be entered into the MOPS.

When there is an amendment or an alternative to a proposal, the chair shall present the amended or alternative proposal together with the original proposal and decide the order in which they will be put to a vote. When any one among them is passed, the other proposals will then be deemed rejected, and no further voting shall be required.

Vote monitoring and counting personnel for the voting on a proposal shall be appointed by the chair, provided that all monitoring personnel shall be shareholders of this Corporation.

Vote counting for shareholders meeting proposals or elections shall be conducted in public at the place of the shareholders meeting. Immediately after vote counting has been completed, the results of the voting, including
the statistical tallies of the numbers of votes, shall be announced on-site at the meeting, and a record made of the vote.

When this Corporation convenes a virtual shareholders meeting, after the chair declares the meeting open, shareholders attending the meeting online shall cast votes on proposals and elections on the virtual meeting platform before the chair announces the voting session ends or will be deemed abstained from voting.

In the event of a virtual shareholders meeting, votes shall be counted at once after the chair announces the voting session ends, and results of votes and elections shall be announced immediately.

When this Corporation convenes a hybrid shareholders meeting, if shareholders who have registered to attend the meeting online in accordance with Article 6 decide to attend the physical shareholders meeting in person, they shall revoke their registration two days before the shareholders meeting in the same manner as they registered. If their registration is not revoked within the time limit, they may only attend the shareholders meeting online.

When shareholders exercise voting rights by correspondence or electronic means, unless they have withdrawn the declaration of intent and attended the shareholders meeting online, except for extraordinary motions, they will not exercise voting rights on the original proposals or make any amendments to the original proposals or exercise voting rights on amendments to the original proposal.

**Article 14 Election of directors and supervisors**

The election of directors or supervisors at a shareholders meeting shall be held in accordance with the applicable election and appointment rules adopted by this Corporation, and the voting results shall be announced on-site immediately, including the names of those elected as directors, supervisors and the numbers of votes with which they were elected and directors, supervisors and the numbers of votes with which they were fail to be elected.

The ballots for the election referred to in the preceding paragraph shall be sealed with the signatures of the monitoring personnel and kept in proper custody for at least 1 year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the ballots shall be retained until the conclusion of the litigation.
Article 15 Minutes of meetings and signatures

Matters relating to the resolutions of a shareholders meeting shall be recorded in the meeting minutes. The meeting minutes shall be signed or sealed by the chair of the meeting and a copy distributed to each shareholder within 20 days after the conclusion of the meeting. The meeting minutes may be produced and distributed in electronic form.

This Corporation may distribute the meeting minutes of the preceding paragraph by means of a public announcement made through the MOPS. The meeting minutes shall accurately record the year, month, day, and place of the meeting, the chair's full name, the methods by which resolutions were adopted, and a summary of the deliberations and their voting results (including the number of voting rights), and disclose the number of voting rights won by each candidate in the event of an election of directors or supervisors. The minutes shall be retained for the duration of the existence of this Corporation.

Where a virtual shareholders meeting is convened, in addition to the particulars to be included in the meeting minutes as described in the preceding paragraph, the start time and end time of the shareholders meeting, how the meeting is convened, the chair's and secretary's name, and actions to be taken in the event of disruption to the virtual meeting platform or participation in the meeting online due to natural disasters, accidents or other force majeure events, and how issues are dealt with shall also be included in the minutes.

When convening a virtual-only shareholder meeting, other than compliance with the requirements in the preceding paragraph, this Corporation shall specify in the meeting minutes alternative measures available to shareholders with difficulties in attending a virtual-only shareholders meeting online.

Article 16 Public disclosure

On the day of a shareholders meeting, this Corporation shall compile in the prescribed format a statistical statement of the number of shares obtained by solicitors through solicitation, the number of shares represented by proxies and the number of shares represented by shareholders attending the meeting by correspondence or electronic means, and shall make an express disclosure of the same at the place of the shareholders meeting. In the event a virtual shareholders meeting, this Corporation shall upload the above
meeting materials to the virtual meeting platform at least 30 minutes before the meeting starts, and keep this information disclosed until the end of the meeting.

During this Corporation's virtual shareholders meeting, when the meeting is called to order, the total number of shares represented at the meeting shall be disclosed on the virtual meeting platform. The same shall apply whenever the total number of shares represented at the meeting and a new tally of votes is released during the meeting.

If matters put to a resolution at a shareholders meeting constitute material information under applicable laws or regulations or under Taiwan Stock Exchange Corporation (or Taipei Exchange Market) regulations, this Corporation shall upload the content of such resolution to the MOPS within the prescribed time period.

Article 17 Maintaining order at the meeting place

Staff handling administrative affairs of a shareholders meeting shall wear identification cards or arm bands.

The chair may direct the proctors or security personnel to help maintain order at the meeting place. When proctors or security personnel help maintain order at the meeting place, they shall wear an identification card or armband bearing the word "Proctor."

At the place of a shareholders meeting, if a shareholder attempts to speak through any device other than the public address equipment set up by this Corporation, the chair may prevent the shareholder from so doing.

When a shareholder violates the rules of procedure and defies the chair's correction, obstructing the proceedings and refusing to heed calls to stop, the chair may direct the proctors or security personnel to escort the shareholder from the meeting.

Article 18 Recess and resumption of a shareholders meeting

When a meeting is in progress, the chair may announce a break based on time considerations. If a force majeure event occurs, the chair may rule the meeting temporarily suspended and announce a time when, in view of the circumstances, the meeting will be resumed.

If the meeting venue is no longer available for continued use and not all of the items (including extraordinary motions) on the meeting agenda have been addressed, the shareholders meeting may adopt a resolution to resume the meeting at another venue.
A resolution may be adopted at a shareholders meeting to defer or resume the meeting within 5 days in accordance with Article 182 of the Company Act.

**Article 19 Disclosure of information at virtual meetings**

In the event of a virtual shareholders meeting, this Corporation shall disclose real-time results of votes and election immediately after the end of the voting session on the virtual meeting platform according to the regulations, and this disclosure shall continue at least 15 minutes after the chair has announced the meeting adjourned.

**Article 20 Location of the chair and secretary of virtual-only shareholders meeting**

When this Corporation convenes a virtual-only shareholders meeting, both the chair and secretary shall be in the same location, and the chair shall declare the address of their location when the meeting is called to order.

**Article 21 Handling of disconnection**

In the event of a virtual shareholders meeting, this Corporation may offer a simple connection test to shareholders prior to the meeting, and provide relevant real-time services before and during the meeting to help resolve communication technical issues.

In the event of a virtual shareholders meeting, when declaring the meeting open, the chair shall also declare, unless under a circumstance where a meeting is not required to be postponed to or resumed at another time under Article 44-20, paragraph 4 of the Regulations Governing the Administration of Shareholder Services of Public Companies, if the virtual meeting platform or participation in the virtual meeting is obstructed due to natural disasters, accidents or other force majeure events before the chair has announced the meeting adjourned, and the obstruction continues for more than 30 minutes, the meeting shall be postponed to or resumed on another date within five days, in which case Article 182 of the Company Act shall not apply.

For a meeting to be postponed or resumed as described in the preceding paragraph, shareholders who have not registered to participate in the affected shareholders meeting online shall not attend the postponed or resumed session.

For a meeting to be postponed or resumed under the second paragraph, the number of shares represented by, and voting rights and election rights exercised by the shareholders who have registered to participate in the
affected shareholders meeting and have successfully signed in the meeting, but do not attend the postpone or resumed session, at the affected shareholders meeting, shall be counted towards the total number of shares, number of voting rights and number of election rights represented at the postponed or resumed session.

During a postponed or resumed session of a shareholders meeting held under the second paragraph, no further discussion or resolution is required for proposals for which votes have been cast and counted and results have been announced, or list of elected directors and supervisors.

When this Corporation convenes a hybrid shareholders meeting, and the virtual meeting cannot continue as described in second paragraph, if the total number of shares represented at the meeting, after deducting those represented by shareholders attending the virtual shareholders meeting online, still meets the minimum legal requirement for a shareholder meeting, then the shareholders meeting shall continue, and not postponement or resumption thereof under the second paragraph is required.

Under the circumstances where a meeting should continue as in the preceding paragraph, the shares represented by shareholders attending the virtual meeting online shall be counted towards the total number of shares represented by shareholders present at the meeting, provided these shareholders shall be deemed abstaining from voting on all proposals on meeting agenda of that shareholders meeting.

When postponing or resuming a meeting according to the second paragraph, this Corporation shall handle the preparatory work based on the date of the original shareholders meeting in accordance with the requirements listed under Article 44-20, paragraph 7 of the Regulations Governing the Administration of Shareholder Services of Public Companies.

For dates or period set forth under Article 12, second half, and Article 13, paragraph 3 of Regulations Governing the Use of Proxies for Attendance at Shareholder Meetings of Public Companies, and Article 44-5, paragraph 2, Article 44-15, and Article 44-17, paragraph 1 of the Regulations Governing the Administration of Shareholder Services of Public Companies, this Corporation shall handle the matter based on the date of the shareholders meeting that is postponed or resumed under the second paragraph.

**Article 22 Handling of digital divide**

When convening a virtual-only shareholders meeting, this Corporation shall provide appropriate alternative measures available to shareholders
with difficulties in attending a virtual shareholders meeting online.

**Article 23 Implementation and revision**

These Rules shall take effect after having been submitted to and approved by a shareholders meeting. Subsequent amendments thereto shall be affected in the same manner.
Tanvex BioPharma, Inc.
Shareholdings of all Board Directors

As of April 30, 2023, Current 5th term Board Directors shareholdings and shareholdings are as follows:

- Common shares issued: 133,665,367 shares
- Legal minimum holding of all directors in number of shares: 8,019,922 shares

As of April 30, 2023, all Board members’ shareholdings are as follows:

<table>
<thead>
<tr>
<th>Title</th>
<th>Name</th>
<th>Shareholding as of Record Date</th>
<th>Number of Shares</th>
<th>Shareholding %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman</td>
<td>Yen, Yun</td>
<td></td>
<td>122,830</td>
<td>0.09%</td>
</tr>
<tr>
<td>Director</td>
<td>Peng-Lin Investment Limited</td>
<td></td>
<td>23,539,537</td>
<td>17.61%</td>
</tr>
<tr>
<td></td>
<td>Representative: Chen, Chi-Chuan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director</td>
<td>Peng-Lin Investment Limited</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Representative: Tamon Tseng</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director</td>
<td>Allen Chao and Lee Hwa Chao Family Trust</td>
<td></td>
<td>8,498,839</td>
<td>6.36%</td>
</tr>
<tr>
<td></td>
<td>Representative: Allen Chao</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director</td>
<td>Hsia Family Trust</td>
<td></td>
<td>864,054</td>
<td>0.65%</td>
</tr>
<tr>
<td></td>
<td>Representative: David Hsia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Director</td>
<td>Delos Capital Fund, LP</td>
<td></td>
<td>4,803,510</td>
<td>3.59%</td>
</tr>
<tr>
<td></td>
<td>Representative: Ula Xue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Independent</td>
<td>Tsai, Jin-Pau</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Director</td>
<td>Wang, Tay-Chang</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Independent</td>
<td>Chang, Chun-Yen</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Director</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>37,828,770</td>
<td>28.30%</td>
</tr>
</tbody>
</table>

Note 1: Independent directors’ holdings are excluded from total shareholding calculation.
Note 2: The limitation on supervisors’ holdings is not applicable as the Company has setup the Audit Committee.